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Natural Products 
Humans have relied on Nature throughout the ages to cater for their basic needs. 
Nature abounds with a rich potential heritage of therapeutic resource that has been 
exploited for effective and beneficial use against various human diseases. For 
millennia, medicinal plants have been a valuable source of therapeutic agents, and 
used as folk medicines for various human ailments. This brought to the forefront a 
large number of herbs used in Indian indigenous system for their approved efficiency 
and administration in modern medicines. The therapeutic properties of plants have 
attracted considerable attention of chemists to explore the chemical behaviour of these 
plants, which led to the birth of Phytochemistry,
1-4
 deals with extraction, isolation, 
purification and identification of compounds from plants sources. In the last few 
decades medicinal plants and their phytochemical studies became of much interest 
because most of the compounds isolated were found to be disease curing and 
lifesaving. 
Tracing the history of medicinal uses of plants we can go back to the prehistoric 
periods. The earliest records on medicinal applications of plants date back to 2600 
BC, documenting the uses of approximately 1000 plant-derived substances in 
Mesopotamia.
5
 The preserved record of Egyptian medicine “Ebers Papyrus” dates 
from about 1500 BC, documenting over 700 drugs, mainly of plant origin.
6,7
 
Traditional Chinese medicine has been extensively documented over thousands of 
years unfolding thousands of preparations from plants as medicine.
8,9
 Likewise, 
Indian Ayurvedic system (Charaka and Sushruta Samhitas) documented before 1000 
BC have recorded the therapeutic uses of about 700 plant drugs.
10,11
 The therapeutic 
use of plants continued to grow with progress of civilization and technological 
developments.and has resulted in the isolation of a large number of therapeutic active 
ingredients from plants sources.  
Rational drug discovery from plants started at the beginning of the 19
th
 century, 
when the German apothecary assistant Friedrich Serturner succeeded in isolating the 
analgesic and sleep-inducing agent morphium (morphine)
12 
from opium. This 
triggered the examination of other medicinal herbs, which led the isolation of many 
bioactive natural products from natural sources during the following decades of the 
19
th
 century.
13-16
 The discovery of β-lactam antibiotics such as penicillin G from 
Pencillium notatum (filamentous fungus) by Alexander Fleming in 1928 prompted an 
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era of drug discovery from microbial sources.
17
 Taxol isolated from Pacific yew tree 
(Taxus brevifolia) is proving to be a life-saving drug due to its ability to suppress 
ovarian and breast cancer.
18-20 Further notable examples include the cholinesterase 
inhibitor Galanthamine discovered  in Galanthus nivalis has been approved for the 
treatment of Alzheimer's disease,
21
  Artemisinin, the potential anti-cancer and 
antimalarial agent derived from the traditional Chinese herb Artemisia annua
22
 and 
Reserpine, the antihypertensive agent, isolated from Rauwolfia serpentina used in 
Ayurvedic medicine for the treatment of snakebite and other ailments.
23
  Other 
significant drugs developed from traditional medicinal plants can be mentioned as 
Vincristine,
24
 Vinblastine,
25
 Rapamycin,
26
 Aconitine,
27
 Hyoscine,
28
 Atropine,
29
 
Quinine,
30
 Codeine,
31
 Ergotamine,
32
 Ergometrine
33
 etc. 
Recently numerous natural compounds have been documented to have different 
biochemical effects such as anticancer, antimicrobial, antioxidant and antiviral 
activities. Some of the examples have been summarized in Table (1-5). 
Table 1: Biological activity of naturally occurring Flavonoids 
Anticancer 
Name Structure Source 
 
Kurzphenol C 
 
 
Macaranga 
kurzii
34
 
 
Bougainvinone B 
 
 
Bougainvillea 
spectabilis
35
 
 
Antioxidant 
 
Eleocharin B 
 
 
 
Eleocharis 
tuberosa
36
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Isorhamnetin-3-O-β-
D-glucopy- ranoside 
 
 
 
Brassica 
napus
37
 
 
 
Antiviral 
 
Tomentin E 
 
 
Paulownia 
tomentosa
38
 
 
Chamaeflavone A 
 
 
Stellera 
chamaejasme
39
 
Antimicrobial 
 
Tephroapollin-F 
 
 
Tephrosia 
Apollinea
40
 
 
5-Carbomethoxymet- 
hyl-4ʹ,7-dihydroxyfla-
vone 
 
 
 
Selaginella  
moellendorffi
41
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Table 2 Biological activities of naturally occurring Terpenoids 
Anticancer 
 
Lugardstatin 1 
 
 
Monadenium 
Lugardae
42
 
 
 
 
Scapairrin H 
 
 
Scapania 
irrigua
43
 
Antioxidant 
 
Artepestrin A 
 
 
Artemisia 
Rupestris
44
 
 
1α-Plumieride 
 
 
Plumeria 
rubra
45
 
Antiviral 
 
Norperovskatone 
 
 
Perovskia 
atriplicifolia
46
 
 
3α-Hydroxy-12-metho-
xy-13-methyl-ent-podo- 
carpa-8,11,13-triene 
 
 
 
Flueggea 
virosa
47
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Antimicrobial 
 
Argophyllin B, 
 
 
Helianthus 
annuus
48
 
 
Prolifepene C 
 
 
 
Euphorbia 
prolifera
49
 
Table 3 Biological activities of naturally occurring Alkaloids 
Anticancer 
 
Fistulopsines A 
 
 
Ficus 
fistulosa
50
 
 
 
 
Cassiarin H 
 
 
Cassia 
siamea
51
 
Antioxidant 
 
 
Beilschglabrines A 
 
 
 
 
Beilschmiedia 
glabra
52 
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(+)-Norstephasubine 
 
 
Alseodaphne 
Corneri
53
 
Antimicrobial 
 
Clauraila D 
 
 
Clausena 
guillauminii
54
 
 
Miliusacunines A 
 
 
Miliusa 
Cuneata
55
 
Antiviral 
 
Nummularine B 
 
 
Ziziphus 
jujuba
56
 
 
Iinsatindibisindol- 
amides 
 
 
Isatis 
indigotica
57
 
Table 4 Biological activities of naturally occurring Coumarins 
Anticancer 
 
Incrassamarin A 
 
 
Calophyllum 
incrassatum
58
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Chimsalicifoliusins 
A 
 
 
Chimonanthus 
Salicifolius
59
 
 
 
Antimicrobial 
 
Methyl galbanate 
 
 
Ferula 
pseudalliacea
60
 
 
Fnarthexone 
 
 
Ferula narthex
61
 
Antioxidant 
 
Imperatorin 
 
 
Angelica 
dahurica
62
 
 
Xanthotoxol 
 
 
Clausena 
lansium
63
 
Antiviral 
 
Cis-3ʹ-isovaleryl-4ʹ-
acetylkhellactone 
 
 
Saposhnikovia 
divaricata
64
 
 
 
Coumarinlignan 
 
 
 
Kadsura 
heteroclita
65
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Table 5 Biological activities of naturally occurring Steroids 
Anticancer 
 
3,4-Epoxy-(22R,25)-
tetrahydrofuran-
stigmast-5-en 
 
 
Aglaia eximia
66
 
 
 
 
Tenacigenin D 
 
 
Marsdenia 
tenacissima
67
 
Antimicrobial 
 
Antrocarines B 
 
 
Antrocaryon 
klaineanum
68
 
 
Epilupeol acetate 
 
 
Ficus drupacea
69
 
Antioxidant 
 
β-Sitosteryl-3-(2ʹ-n-
eicosanyloxy)-
benzoate 
 
 
Lens culinaris
70
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Taiwacin B 
 
 
Momordica 
charantia
71
 
Antiviral 
 
Obtusifoliol 
 
 
Euphorbia 
denticulata
72
 
 
Subergorgol U 
 
 
Subergorgia 
suberosa
73
 
A large number of naturally occurring novel compounds of therapeutic 
importance are added to literature every year. Although it is not feasible to cover all 
the literature related to the isolation of natural products from plant sources but a few 
important, recent and relevant naturally occurring compounds are as follows: 
Flavonoids 
Zheng et al.
74
 have isolated six novel flavonoids, Dysosmaflavones A-F (1-6) from 
the roots of Dysosma versipellis. 
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Rudrapaul and co-workers
75
 isolated one new β-hydroxychalcone, 4-acetoxy-
5,2ʹ,4ʹ,6ʹ,β-pentahydroxy-3-methoxychalcone (7) and one new flavanone, 7,3ʹ-
dihydroxy-5,4ʹ-dimethoxyflavanone (8) from the methanolic fruit extract of Cornus 
mascula. 
 
Wang et al.
76
 have isolated two new highly-oxygenated flavonoid glycosides, 
gossypetin-5-O-(6″-(E)-caffeoyl)-β-D-glucoside (9) and herbacetin-5-O-(6″-(E)-
caffeoyl)-β-D-glucoside (10) from the leaves of Eupatorium adenophorum. 
 
Zhang et al.
77
 have isolated a new biflavone, 6-C-methyl-7,4ʹ,4ʹʹʹ-tri-O-
methylamento-flavone (11), and the new flavone glycoside, apigenin-6-C-methyl-7-
O-β-D-glucopyranoside (12) from the twigs and leaves of Cephalotaxus lanceolata. 
 
Deyou and co-workers
78
 have isolated two new flavonoids viz. 4′-O-geranyl-7-
hydroxyflavanone (13) and 4′-O-geranyl-7-hydroxydihydroflavanol (14) from the root 
bark of Millettia usaramensis. 
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Alkaloids 
Promchai et al.
55
 have isolated five new oxoprotoberberine alkaloids, Miliusacunines 
A-E (15-19), from an acetone extract of the leaves and twigs of Miliusa cuneata, 
which were characterized as 8-oxo-4,9,10-trihydroxy-2,3-dimethoxy-5,6-
dihydroberberine (15), 8-oxo-9,10-dihydroxy-2,3,4-trimethoxy-5,6-dihydroberberine 
(16), 8-oxo-3,9,10-trihydroxy-2,4-dimethoxy-5,6-dihydroberberine (17), (−)-(S)-8-
oxo-3,9,10-trihydroxy-2,4-dimethoxy-5,6,13,13a-tetrahydroberberine (18) and (−)-
(S)-8-oxo-9,10-dihydroxy-2,3,4-trimethoxy-5,6,13,13a-tetrahydroberberine (19). 
 
Ravanelli and co-workers
79
 have reported the isolation of two alkaloids 
Corydine (20) and Norisoboldine (21), from the leaves of Croton echinocarpus 
showing significant anti-HIV property. 
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Ortiz et al.
80
 have isolated two new alkaloids 4-O-methylnangustine (22) and 7-
hydroxyclivonine (23) from the bulbs of Hippeastrum argentinum. 
 
Pulte and co-workers
81
 have reported the isolation of two novel red 
pyrroloquinoline alkaloids Pelianthinarubins A (24) and B (25), from the fruiting 
bodies of the Mushroom Mycena pelianthina. 
 
Terpenoids 
Xu et al.
82
 have carried out phytochemical investigation of the leaves of Callicarpa 
macrophylla which led to the isolation of five new diterpenoids, Macrophypenes A-E 
(26-30). 
 
Xu et al.
83
 have carried out phytochemical investigation on the stems of 
Picrasma quassioides which led to the isolation of a novel compound, Picraquassin A 
(31), with an unprecedented 21,24-cycloapotirucallane skeleton and characterized as 
3,7,21,23,25-pentahydroxy-21,24-cycloapotirucall-14-ene (31). 
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Luo et al.
84
 have isolated three new diterpenoids (32-34) from the from the 
ethanolic extract of Caryopteris glutinosa. (13E)-15-hydroxyneocleroda-3,13-dien-
18-oic acid (32), 18-hydroxy-14,15-dinor-neocleroda-3-en-13-one (33) and 
(3R,10S,16S)-12,16-epoxy-3,11,14-trihydroxy-17(15→16),18(4→3)-diabeo-abieta-
4(19),5,8,11,13-pentaen-7-one (34). 
 
Coumarins  
Lv et al.
85
 have isolated two new rare 8-methylbenzo[h]coumarins, Muralatins A and 
B (35, 36) with nine new C-8-substituted coumarins, Muralatins C-K (37-45) from the 
leaves of Murraya alata. 
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Karunakaran and co-workers
86
 have isolated novel cytotoxic prenylated 
coumarin (6-hydroxy-5-isobutyryl-7,7-bis-(3-methylbut-2-en-1-yl)-4-phenyl-2H-
chromene-2, 8(7H)-dione) (46) from the stem bark of Malaysian Mesua beccariana. 
 
Xia et al.
87
 have isolated the four new pyranocoumarins, Clauemarmarins A-D 
(47-50) from the stems of Clausena emarginata. 
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Sahakitpichan et al.
88
 have reported a new coumarin glucoside, 
Micromelumoside D (51) from the aerial portions of Micromelum minutum which 
was assigned as (1ʹR, 2ʹR)-1ʹ-hydroxy-peucedanol-7-O-β-D-glucopyranoside (55). 
 
 
Heterocyclic Compounds 
Heterocyclic chemistry is an integral part of organic chemistry. It is the most 
challenging and rewarding field of research, since it always attracts the attention of 
scientists working in the area of synthetic organic chemistry and natural products. 
Heterocyclic compounds are important class of compounds, making up more than half 
of all known organic compounds. These are organic compounds that contain at least 
one heteroatom besides carbon in the framework of the ring structure that can show 
both aromatic and aliphatic properties. The most commonly found hetero atoms in 
these rings are oxygen, nitrogen and sulphur. Heterocyclic chemistry is an 
inexhaustible resource of novel compounds and almost unlimited combinations of 
carbon, hydrogen and heteroatoms can be designed. These make compounds with the 
most diverse physical, chemical and biological properties available, so is very easy to 
guess the huge diffusion and importance of heterocyclic compounds.
89
 Heterocyclic 
compounds are widely distributed in nature. Chlorophyll, haemoglobin, 
carbohydrates, tannins and amino acids are derived from heterocyclic origin. Various 
physiologically and metabolically active substances like co-enzymes, heteroauxin, 
histamines and vitamins, energy storage units like ATP and ADP, and electron 
transport system like cytochrome a and b are made of heterocyclic rings. 
Heterocyclic compounds hold a special place among pharmaceutically 
significant natural products and synthetic compounds as almost 80% of drugs in 
clinical uses are based on heterocyclic constituents. Heterocyclic compounds possess 
various biological properties like antitumor, antibiotic, anti-inflammatory, 
antidepressant, antimalarial, diuretic, anticonvulsant, muscle relaxant, 
antihypertensive, antineoplastic, antiulcer,  anti-HIV, antibacterial, antifungal, 
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antiviral, antioxidant, anticholinesterase, anti-diabetic etc.
90-100
 The remarkable ability 
of heterocyclic nuclei to serve as both biomimetic and reactive pharmacophores has 
largely contributed to their unique value as traditional key elements of numerous 
drugs. Beside these, heterocyclic compounds have also found a wide range of 
applications in materials as dyestuff, fluorescent sensor, brightening agents, 
information storage, plastics, and analytical reagents. 
The important and challenging area of contemporary synthetic organic 
chemistry is to synthesize heterocyclic compounds under environmentally benign 
conditions. In recent years, various synthetic routes, catalysts and reagents have been 
developed for the synthesis of heterocyclic compounds. Although, all of these 
reported protocols have certain merits, still numbers of them suffer from various 
shortcomings such as use of toxic reagents, prolonged reaction times, lesser yields and 
low selectivity. The synthetic chemistry community has been under increased 
pressure to produce the myriad of heterocyclic systems required by the society in an 
environmentally benign fashion within a short span of time. Therefore, a number of 
research programs are going on in search of eco-friendly procedure which can be used 
to synthesize new heterocyclic systems with great specificity, higher reactivity and 
greater efficiency. Thus, in order to design new reaction systems satisfying the green 
chemistry principles, we have carried out the synthesis of heterocyclic compounds viz. 
coumarin esters, tetrazoles and azlactones by employing silica supported catalysts 
(SiO2-H2SO4 and SiO2-H3BO3) and ionic liquids, respectively. 
 
Methods of Chemical Analysis 
In recent years, immense development in the field of natural products chemistry and 
synthetic organic chemistry has taken place due to the availability of powerful 
analytical techniques. The spectral techniques provide substantial information 
regarding the structure of individual compounds. The spectroscopic techniques like 
infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (
1
H NMR and 
13
C NMR) and mass spectrometry (MS) have been used for the structure elucidation 
and identification of the synthesized and natural compounds.
101-105
 Here a brief review 
of these technique has been presented in light of the characterization of isoflavones. 
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Ultraviolet Spectroscopy 
Ultraviolet spectroscopy has become a major technique for the structure analysis of 
natural compounds especially flavonoids.
106
 The UV spectra of isoflavones typically 
exhibit an intense absorption band at around 245-270 nm (Band II) due to benzoyl 
moiety, with a shoulder or low intensity band at around 310-330 nm (Band I). The 
Band II absorption of isoflavones is relatively unaffected by increased hydroxylation 
of B-ring, however, shifted bathochromically by increased oxygenation in the A-
ring.
107
  
 
The structural information obtained from the UV spectrum is considerably 
enhanced by the use of specific shift reagents such as sodium methoxide (NaOMe), 
sodium acetate (NaOAc), sodium acetate/ boric acid (NaOAc/H3BO3), aluminium 
chloride (AlCl3) and aluminium chloride/ hydrochloric acid (AlCl3/HCl).
108
 The 
addition of these shift reagents separately to an alcoholic solution of the isoflavones 
induces significant shifts in the UV absorption and hence provides sufficient 
information about the orientation of the various hydroxyl groups present in the 
isoflavone nucleus.
107 
Isoflavones containing A-ring hydroxyl groups usually show bathochromic shift 
of both Band I and Band II in the presence of NaOMe.
107
 NaOAc, being a weaker 
base than NaOMe, tends to ionize only the more phenolic hydroxyl groups. It ionizes 
the more acidic 7-hydroxyl group in isoflavone causing a bathochromic shift of 6-20 
nm in Band II of the UV spectrum. NaOAc/H3BO3 mixture is used for the detection of 
the ortho-dihydroxyl groups in A-ring. However, the ortho-dihydroxyl groups in B-
ring are not detectable by this shift reagent because the B-ring lacks effective 
conjugation with the major chromophore. A bathochromic shift of a 10-15 nm in 
Band I, is detectable in presence of 6,7-dihydroxyl group in the A-ring of isoflavones 
on addition of NaOAc/H3BO3.
107
 A-ring ortho-dihydroxyl groups which do not 
involve the C-5 hydrogen bonded hydroxyl group, are also detectable by the use of 
AlCl3 in UV spectrum, while B-ring ortho-dihydroxyl groups are not detectable 
Chapter-1 
18 
 
because the B-ring has little or no conjugation with the major chromophore. Thus, 
6,7- or 7,8-dihydroxyl isoflavones exhibit bathochromic shift (usually for both Band I 
and Band II) in AlCl3 spectrum with respect to the AlCl3/HCl spectrum. The UV 
spectra of all 5-hydroxyisoflavones undergo a consistent 10-14 nm bathochromic shift 
in Band II in the presence of AlCl3/HC1. However, the spectra of isoflavones lacking 
a free 5-hydroxyl group are unaffected by this reagent.
107
  
Infra-red Spectroscopy 
The infrared spectroscopy is a simple and reliable technique used for the identification 
of the natural and synthesized compounds. It provides valuable information regarding 
the presence of functional groups in a molecule. The IR spectroscopy is based on the 
absorption of the infrared radiation by molecule which causes an excitation of 
molecule from a lower to the higher energy levels. Organic applications on IR 
spectroscopy are almost entirely concerned with the range 600-4000cm
-1
. In case of 
flavonoids, IR measurements are helpful in providing evidence for the presence of (a) 
pyrone ring (b) chelated hydroxyl groups and (c) the gem dimethyl grouping. The IR 
spectrum of isoflavone shows the band for pyrone carbonyl and hydroxyl groups at 
around 1620-1660 and 3200-3500 cm
-1
, respectively.
101,109
 However, the hydrogen 
bonding in the case of 5-hydroxy isoflavones lowers the carbonyl stretching 
frequency. The presence of methylenedioxy group and a gem dimethyl group may be 
inferred from the band at 925 and 1400 cm
-1
, respectively.
110,111
 The glycosidic nature 
of an isoflavone glycosides is reflected by broad bands at 3250 and 1060 cm
-1
.
112 
Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (
1
H and 
13
C NMR) spectroscopy serves as a powerful 
analytical tool for the structure elucidation of organic compounds. NMR spectroscopy 
is a research technique that exploits the magnetic properties of certain atomic nuclei. 
It relies on the phenomenon of nuclear magnetic resonance and can provide detailed 
information about the structure, dynamics, reaction state, and chemical environment 
of molecules. The intramolecular magnetic field around an atom in a molecule 
changes the resonance frequency, thus giving access to details of the electronic 
structure of a molecule. Now days, large numbers of natural compounds as well as 
synthesized compounds have been characterized by employing NMR spectroscopy. 
The application of 
1
H NMR spectroscopy in the structure elucidation of isoflavones 
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helps in defining the pattern of oxygenation in all three rings and for the 
determination of number and positions of methoxy and hydroxyl groups. It also helps 
in distinguishing isoflavones, flavones, flavanones and flavonols.
107
 The proton 
signals of isoflavones generally occur between δ 0-9 ppm (except the hydroxyl proton 
of C-5, which occurs around δ 12-13 ppm).101 The chemical shift of protons of ring A 
and B prove to be independent of each other but are affected by the nature of ring C. 
13
C NMR spectral data furnish key information about the carbon framework of the 
compound. It helps in determining the total number of carbons and the number of 
oxygenated carbons in the skeleton. It also helps in establishing the nature of carbon, 
whether they are primary, secondary, tertiary, aromatic, olefinic or part of a functional 
group. The chemical shift value of 
1
H and 
13
C NMR of some representative 
isoflavones (52 and 53)
113
 have been presented in the following table. 
 
                               
 
Table 6. 
1
H NMR data of representative isoflavone (values in δ) 
Assignment of protons Compound (52) Compound (53) 
H-2 8.17 (s) 7.98 (s) 
H-5 7.95 (d, 8) ------- 
H-6 6.94 (dd, 8, 2) 6.28 (d, 2) 
H-8 6.86 (d; 2) 6.40 (d, 2) 
H-3‟ 6.49 (s) ----- 
H-5‟ ----- 6.76 (s) 
H-6‟ 6.66 (s) 6.76 (s) 
OCH3 3.74 (s) 3.77 (s), 3.87 (s) 
OH-5 ---- 13.0 (s) 
OH-7 10.8 (s) 10.8 (s) 
OH-2‟ 8.70 (s) --- 
OH-3‟ ----- 8.35 (s) 
OH-5‟ 8.28 (s) ----- 
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Table 7. 
13
C NMR data of representative isoflavone (values in δ) 
Assignment of Carbons Compound 52 Compound 53 
2 154.8 155.3 
3 121.4 118.6 
4 175.2 181.6 
5 127.1 163.8 
6 115.1 99.9 
7 162.5 165.0 
8 102.0 94.6 
4a 116.4 106.1 
8a 157.4 159.1 
1‟ 110.4 122.3 
2‟ 148.1 147.2 
3‟ 101.5 140.3 
4‟ 148.1 150.0 
5‟ 138.8 107.4 
6‟ 117.9 121.9 
OCH3 55.5 60.4, 56.6 
 
Mass Spectrometry 
Mass spectrometry (MS) is an analytical technique that ionizes chemical species and 
sorts the ions based on their mass to charge ratio. It proves to be essential tool for the 
identification and quantification of natural products and synthesized compounds, 
primarily because of its speed, sensitivity, selectivity and its versatility in analysing 
solids, liquids and gases.
114,115
 It has become an indispensable apparatus to the 
modern organic chemists by providing investigators with molecular formulae, isotopic 
profiles and fragmentation data that are especially useful for de-replication and 
structure elucidation. The common fragmentation process of isoflavone is shown in 
Scheme 1 using Nervosin (54)
116
 as a typical example. It showed M
+· 
at m/z 360. The 
fragment ions at m/z 345, 330 and 315 were due to the successive loss of three methyl 
groups. The fragment ions at m/z 332 and 329 are due to the loss of CO and OCH3, 
respectively. The Retro-Diels-Alder (RDA) cleavage representing ring-A at m/z 153, 
152 and ring-B at m/z 208, 207 and 178 suggested the presence of two hydroxyl 
group in ring-A and one hydroxyl and three methoxy group in ring-B. 
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Scheme 1. Mass fragmentation pattern of representative isoflavone 
 
Biological Assay Studies 
Acetylcholinesterase inhibition studies 
An acetylcholinesterase inhibitor (AChEI) or anti-cholinesterase is a chemical that 
inhibits the acetylcholinesterase enzyme from breaking down acetylcholine, thereby 
increasing both the level and duration of action of the neurotransmitter acetylcholine. 
Acting at the cholinergic synapses, by quick hydrolysis of acetylcholine to choline 
and acetate, acetylcholinesterase (AChE) is a terminator enzyme of nerve impulse 
transmission. Inhibition of AChE evolves a strategy for the treatment of several 
diseases such as alzheimer‟s disease (AD), senile dementia, ataxia, myasthenia gravis 
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and parkinson‟s disease.117 Acetylcholinesterase, apart from its involvement in 
cholinergic synaptic transmission, is also known to accelerate the aggregation of 
amyloid-beta (Aβ) during the early stages of AD, primarily via interactions through 
its peripheral anionic binding site (PAS).
118,119
 In light of these observations, the 
search for new AChE inhibitors for alzheimer‟s disease now includes the search of 
dual binding molecules, being able to interact simultaneously with both the PAS and 
the catalytic subsite of AChE. The in vitro inhibition of AChE by the newly 
synthesized compounds has been screened spectrophotometrically by modified 
Ellman‟s coupled enzyme assay method using tacrine as reference drug.120 Electric eel 
AChE (Type-VI-S, EC 3.1.1.7) and human recombinant AChE (EC 3.1.1.7) 
lyophilized powder (Sigma-Aldrich) were used as the enzyme sources while 
acetylthiocholine iodide as substrate and 5,5´-dithio-bis (2-nitrobenzoic) acid (DTNB) 
was also used in the anti-cholinesterase activity determination. 
DNA binding studies 
Ligand binding to macromolecules plays a key role in biology and medicine as 
steering mechanism in biological processes. More specifically, the binding of drugs to 
proteins and DNA has been of great interest in recent years leading to enormous 
unfolding of structural studies using both experimental and theoretical methods. 
Owing to the central role of DNA in replication and transcription, DNA has been a 
major target for antibiotic, anticancer and antiviral drugs.
121
 Inspired by nature, 
chemists have now for more than couple of decades developed principles with the 
ultimate goal of being able to design and synthesize compounds that recognize and 
bind to any desired sequence in double stranded DNA.
122,123
 Drug-DNA interactions 
can be classified into two major categories, intercalation and groove binding. 
Intercalation involves the insertion of a planar molecule between DNA base pairs, 
which results in a decrease in the DNA helical twist and lengthening of the DNA.
124
 
Groove binders are typically crescent-shaped molecules that allows a sterically 
favourable fit into the DNA minor groove. In contrast to intercalation, in which DNA 
base pairs are unstacked and the helix unwound to accommodate the intercalation 
ring, groove binding does not require a major alteration of the DNA structure and are 
stabilized by intermolecular interactions. In analogy with enzyme-substrate binding, 
intercalation could be thought to follow an „„induced fit‟‟ mechanism, while groove 
binding is more like the rigid „„lock-and-key‟‟ mechanism.125 In the present study the 
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isolated compounds from Cassia siamea leaves were screened for DNA binding 
studies by carrying out UV-absorption, fluorescence, circular dichroism and viscosity 
measurements. 
Molecular docking studies 
Molecular docking is a powerful tool to design of ligands toward a specific 
biopolymer target and is commonly used in the field of drug design to predict the 
binding of small molecules to biological protein targets. The need for a rapid search 
for small molecules that may bind to targets of biological interest is of crucial 
importance in the drug discovery process. This method gives the possibility to study 
an active site in detail and can be used for hit identification, virtual screening and 
binding mode determination. Docking studies may be predictive in understanding the 
molecular basis of recognition, which would encompass the ability to design ligands 
that bind specific receptors and to predict the change in stability caused by site-
specific substitutions, which is of central idea in developing rational drug design 
strategies. In our experiment, rigid molecular docking (two interacting molecules 
were treated as rigid bodies) studies were performed to predict the binding modes of 
synthesized compounds with DNA. HEX 6.1
126
 and Discovery studio 3.5 software‟s 
have been used to predict the possible binding orientations of synthesized compounds 
with target protein. The target protein used in the study has been downloaded from 
protein data bank (PDB). 
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INTRODUCTION 
Cassia (Family: Fabaceae) is the large genus of flowering plants comprises about 580 
species of herbs, shrubs and trees that are distributed abundantly throughout the world 
and out of them only twenty species are indigenous to India.
1
 The genus Cassia 
contains structurally and biologically diverse active natural compounds viz. alkaloids, 
flavonoids, steroids, terpenoids, coumarins, anthraquinones and phenolic compounds 
etc.
2-6
 This genus has long been used in folk medicine for the treatment of various 
diseases e.g. the leaves of Cassia alata have been used as a laxative for the treatment 
of ringworm infections, and in the treatment of leprosy and syphilis,
7
 roots of Cassia 
sophera used as an antidote for snake bites,
8
 leaves and the bark of Cassia fistula have 
been reported to use as a prominent laxative and in the treatment of black water 
fever.
9
 Moreover, the crude extracts of genus Cassia have been reported to have 
various pharmacological properties like hepatoprotective activity, anti-inflammatory, 
hypolipidemic, antimutagenic, antishigellosis, antibacterial, antiulcer, antifungal, 
antioxidant and antipyretic activity etc.
10-18
 Cassia siamea Lam. (syn. Senna siamea), 
commonly known as the Kassod tree belongs to family Fabaceae is a medium-sized, 
evergreen tree native to the countries of South and Southeast Asia.
19
 Cassia siamea is 
better known in folklore medicine for the treatment of fever, arthritis, skin disease, 
constipation, hypertension and insomnia.
20
 The literature survey revealed that Cassia 
siamea possess promising biological properties such as antiemetic,
21
 antimicrobial,
22
 
antiplasmodial,
23
 antiviral,
24
 antidiabetic,
25
 antioxidant,
26
 antitumor,
27
 anti-
inflammatory and analgesic
28
 properties. Earlier phytochemical studies of Cassia 
siamea exhibited the presence of different phytochemical constituent viz. alkaloids, 
anthraquinones, chromones, chromone-alkaloids, triterpenoids, steroids, flavonoids 
and coumarins.
29-37
 
In view of its biological importance, our interest has been accelerated to carry 
out comprehensive investigation of Cassia siamea leaves. Herein, overall five 
compounds have been isolated from this plant by employing column chromatography, 
thin-layer chromatography (TLC) and preparative thin-layer chromatography (PTLC) 
followed by crystallization. To the best of our knowledge, among the five isolated 
compounds, compound (3) is novel and has neither been isolated from any plant 
source nor has its synthesis been reported so far. Their structures have been elucidated  
Journal of Photochemistry and Photobiology, B: Biology 2016, 159, 218-228 
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on the basis of chemical and physical evidences (elemental analysis, UV, IR, 
1
H 
NMR, 
13
C NMR, MS and X-ray crystallographic studies) and comparison of their 
spectral data with literature compounds. DNA binding study of compound 2 and 3 are 
also carried out to probe the binding mode and extent of interaction of these 
compounds with calf thymus DNA (CT-DNA). Moreover, aqueous and ethanolic 
extracts are screened for in vivo cytotoxicity against brine shrimp nauplii by lethality 
bioassay. 
 
RESULTS AND DISCUSSION 
This chapter deals with the phytochemical investigation of the leaves of Cassia 
siamea i.e. extraction, isolation and characterization of its chemical constituents, 
screening of cytotoxicity potential of aqueous and ethanolic extracts of leaves, and 
DNA binding study of isolated compound 2 and 3. The following five compounds (1-
5) have been isolated from the Cassia siamea leaves. 
1. 2,6-dimethoxy-4-hydroxy acetophenone (Cs-1) 
2. 2ʹ,2ʹ-dimethylpyranocoumarin (Seselin) (Cs-2) 
3. 5,6,7,3ʹ,4ʹ,5ʹ-hexamethoxyisoflavone (Novel) (Cs-3) 
4. 4ʹ-hydroxy-5-methoxy-6,7-methylenedioxyisoflavone (Nigricin) (Cs-4) 
5. Kaempferol (Cs-5) 
Characterization of compound 1 (Cs-1) 
Compound 1 is isolated from the column with benzene-ethyl acetate (9:1) mixture and 
crystallizes with benzene-chloroform as white shinning crystals (120 mg), m.p. 78-79 
o
C.
38
 Elemental analysis and molecular ion peak determined by ESI-MS spectrum at 
m/z 196.07 agrees with its molecular formula C10H12O4. The IR spectrum displays 
characteristic peaks at 3345 cm
-1
 for phenolic OH group, 3080 cm
-1
 for aromatic C-H 
stretching and 1678 cm
-1
 for carbonyl group. The peaks at 1605 and 1468 cm
-1
 
corresponds to the aromatic C=C stretching. The presence of phenolic hydroxyl group 
is further confirmed with the appearance of greenish colour on treatment with 
alcoholic solution of ferric chloride. The 
1
H NMR spectrum displays sharp singlet at δ 
2.35 for three protons corresponding to COCH3. It shows a meta-coupled doublet for 
two aromatic protons at δ 7.03 (J = 2.2 Hz) assign for H-3 and H-5. An independent 
singlet for one proton at δ 9.12 is ascribed to OH proton. The spectrum also shows a 
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sharp singlet for six protons at δ 3.87 indicating the presence of two methoxy groups. 
The 
13
C NMR spectrum shows the peak at δ 32.8 and 203.5 for methyl and carbonyl 
carbons, respectively, confirms the presence of acetophenone group. The methoxy 
substituents of the aromatic ring are observed at δ 55.7. The spectrum displays signals 
corresponding to four quaternary aromatic carbon atoms at δ 170.1, 164.3, 163.5 and 
111.6 and two aromatic methyne at δ 92.4 and 91.2. 
In light of the above results, compound 1 is identified as 2,6-dimethoxy-4-
hydroxy acetophenone.
38
 
 
Characterization of compound 2 (Cs-2) 
Elution of the column with benzene-ethyl acetate (1:1) furnishes fractions which on 
crystallization with chloroform-methanol give yellow coloured crystals (90 mg), m.p. 
122 
o
C.
39
 It shows blue coloured fluorescence, characteristics of coumarin nucleus 
under UV light exposure and spectrum displays the maximum absorption bands at 
280, 295 and 330 nm. It gives negative result with ferric chloride test for phenolic OH 
and also responds negatively to specific colour tests for flavonoids and alkaloids. Its 
elemental analysis and molecular ion peak determine by ESI-MS spectrum at m/z 228 
agrees with its molecular formula C14H12O8. The IR spectrum displays characteristic 
peaks of aromatic and aliphatic C-Hstr, C=C, and C=O vibration frequencies at 3040, 
2970, 1495-1640 and 1715 cm
-1
, respectively. The 
1
H NMR spectrum displays a sharp 
singlet at δ 1.41 for six protons which ascribes to the geminal dimethyl groups of 
pyran ring. It also shows the presence of three pairs of ortho-coupled doublets for one 
proton each. One pair of doublets resonating at δ 6.25 and 7.91 corresponds to the H-3 
and H-4 proton, while other pair of doublet for single proton each resonating at δ 7.43 
and 6.75 are attributed to the H-5 and H-6 proton of coumarin nucleus. However, the 
remaining pair of ortho-coupled doublets at δ 5.87 and 6.68 ascribes to H-3ʹ and H-4ʹ 
protons of pyran ring, respectively. The 
13
C NMR spectrum shows the characteristic 
peaks of pyranocoumarins at δ 162.8, 149.8, 147.6, 143.9 and 112.8 attributed to 
C=O, C-7, C-8a, C-4 and C-4a, respectively. The sharp peak at δ 28.2 corresponds to 
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the methyl carbons and the peak at δ 82.5 corresponds to the carbon (C-2ʹ) substituted 
with two methyl group. However, the peak displays at δ 110.2-130.0 are assigned to 
the aromatic carbons of the compound. 
In light of the above results, compound 2 is identified as 2ʹ,2ʹ-
dimethylpyranocoumarin.
39
 
 
Characterization of compound 3 (Cs-3) 
Compound 3 is isolated through the elution of column with ethyl acetate-methanol 
(9:1), which on crystallization with chloroform-methanol give light yellowish crystals 
(80 mg) m.p. 262-264 
o
C. The compound responds positively to Shinoda test
40
 and 
Wilson-boric acid test
41
 indicating the presence of isoflavone nucleus. Further, on 
treatment with sodium amalgam followed by acidification give a pink colour confirms 
the presence of isoflavone nucleus. The UV spectrum of compound exhibits 
characteristic absorption bands at 263 and 329 nm, suggesting its isoflavone nature 
and further established by the sharp singlet signal at δ 8.52 for H-2. The absorption 
maxima show no shift on addition of any shift reagent indicates that there is no 
hydroxyl group substitution on the isoflavone nucleus. However, negative response 
towards the alcoholic solution of ferric chloride also ruled out the substitution of any 
phenolic group to the isoflavone nucleus. The IR spectrum shows absorption bands at 
1640, 1610 and 1060 cm
-1
, indicating the presence of α,β-unsaturated carbonyl (C=O), 
C=C and C–O functional groups in the molecule, respectively. The 1H NMR spectrum 
displays an independent sharp singlet integrating for one proton at δ 6.65 ascribes to 
H-8 proton, while singlet at δ 8.52 for H-2 is the characteristic for isoflavone nucleus. 
A meta-coupled doublet at δ 7.71 (J = 2.5 Hz) integrating for two protons is assigned 
to H-2ʹ and H-6ʹ protons. The presence of six methoxy groups is established by the 
appearance of six singlets of three protons each at δ 3.87-3.97 (Fig. 1). The 13C NMR 
spectrum of compound shows resonances for 21 carbons, signals at δ 180.3, 152.7 and 
124.6 are attributed to C-4, C-2 and C-3, characteristic of flavone nucleus. B-ring 
carbons display signals at δ 120.4, 106.3, 150.3 and 141.6 for C-1ʹ, C-2ʹ/6ʹ, C-3ʹ/5ʹ 
and C-4ʹ, respectively. However, A-ring of isoflavone displays peaks at δ 105.3 (C-
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4a), 135.2 (C-5), 130.5 (C-6), 138.4 (C-7), 94.5 (C-8) and 158.6 (C-8a). Moreover, six 
different peaks at δ 55.7-60.9 indicate the substitution of six methoxy groups to the 
isoflavone nucleus (Fig. 2). The mass spectrum exhibits a prominent molecular ion 
peak at m/z 403.36 [M+H]
+• 
agreed with the molecular formula C21H22O8 (Fig. 3). The 
fragmentation pattern of compound 3 is presented in scheme 1. Elemental analysis is 
also found to be in good agreement with the proposed molecular formula C21H22O8. 
Further single-crystal X-ray diffraction analysis confirms the molecular structure of 
compound 3. 
 In the light of above discussion it is concluded that compound (3) is 
5,6,7,3ʹ,4ʹ,5ʹ-hexamethoxyisoflavone, which is being reported for the first time from 
natural source and has not been synthesized so far. 
 
 
Fig. 1 
1
H NMR spectrum of compound 3 (Cs-3) 
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Fig. 2 
13
C NMR spectrum of compound 3 (Cs-3) 
 
 
Fig. 3 Mass spectrum of compound 3 (Cs-3) 
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Scheme 1 Fragmentation pattern of compound 3 (Cs-3) 
Characterization of compound 4 (Cs-4) 
Compound 4 is obtained from the column by ethyl acetate-methanol (7:3) mixture. 
Crystallization with chloroform-methanol affords white crystals (85 mg), m.p. 256-
258 °C
42
. Elemental analysis along with the molecular ion peak at m/z 312 agrees with 
the molecular formula C17H12O6. It gives light green colour with ferric chloride 
indicating the presence of phenolic OH group. The compound responds positively to 
Shinoda test
40
 and Wilson-boric acid test
41
 indicating the presence of isoflavone 
nucleus. Further, on treatment with sodium amalgam followed by acidification gives a 
pink colour pointing out the presence of isoflavone nucleus which is later confirmed 
with UV spectrum displaying λmax absorptions at 263 and 328 nm, suggesting an 
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isoflavone skeleton. The absorption maxima shows no shifts on addition of AlCl3 and 
NaOAc indicating the absence of a free OH group at C5 and C7.
43
 The IR spectrum 
exhibits intense absorption bands at 3465, 2982 and 1652 cm
-1
, indicating the 
presence of OH group, aromatic C-H and α,β-unsaturated carbonyl functionality in the 
molecule. However, the absorption band at 1060 and 935 cm
-1
 signifying the C-O and 
O-CH2-O functions present in the molecule. The presence of a methylenedioxy group 
is further confirmed by a positive response showing green colour with Labat test
44 
(development of blue or green colour when alcoholic gallic acid is added to a solution 
of the compound in concentrated sulphuric acid and warmed) and purple colour in 
Hansen test.
45
 The 
1
H NMR of compound 4 displays a pair of singlet for one proton 
each at δ 8.07 and 6.65 are assigned to the H-2 and H-8 proton of isoflavone nucleus. 
A pair of ortho-coupled doublets for two protons each appears at δ 6.82 (J = 8.4 Hz) 
and 7.40 (J = 8.4 Hz) is due to the aromatic protons of B-ring of isoflavone nucleus 
assignable to H-3ʹ/5ʹ and H-2ʹ/6ʹ protons, respectively. A singlet integrating for three 
protons at δ 3.97 is assigned to the C-5 methoxy group of isoflavone. An independent 
sharp singlet at δ 6.08 for two protons reveals the presence of methylenedioxy (O-
CH2-O) group. However, a singlet at δ 9.49 for one proton indicates the presence of 
OH group attached to the B-ring, which is further authenticated with the formation of 
monoacetate on treatment with acetic anhydride in presence of pyridine. The 
13
C 
NMR spectrum of compound shows resonance for 17 carbons, signals at δ 175.7, 
154.1 and 125.0 were attributed to C-4, C-2 and C-3 carbons, characteristics of 
isoflavone nucleus. Signals at δ 60.9 and 101.8 are assigned to methoxy and 
methylenedioxy carbons, respectively. B-ring carbons display signals at δ 123.3, 
130.9, 116.2 and 157.6 for C-1’, C-2’/6’, C-3’/5’ and C-4’, respectively. However, A-
ring of isoflavone displays peaks at 113.5 (C-4a), 145.2 (C-5), 136.4 (C-6), 153.2 (C-
7), 93.5 (C-8) and 151.7 (C-8a). Further single-crystal X-ray diffraction analysis 
confirms the molecular structure of compound 4.  
On the basis of above data, compound 4 is identified as 4ʹ-Hydroxy-5-methoxy-
6,7-methylenedioxyisoflavone (Nigricin).
42
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Characterization of compound 5 (Cs-5) 
Compound 5 is isolated through the elution of column with ethyl acetate-methanol 
(1:1), which on crystallization with chloroform-methanol yields yellow shining 
crystals (60 mg), m.p. 277-279 
o
C. The compound responds positively to Shinoda 
test
40
 and Wilson-boric acid test
41
 indicating the presence of flavonoidic nucleus. The 
compound also give greenish brown colour with alcoholic ferric chloride solution, 
indicating the presence of phenolic hydroxyl group, which is further confirmed with 
the broad peak in the IR spectrum at 3345-3518 cm
-1
. The IR spectrum also displays 
characteristic peaks of C-Harm, C=O, C=C and C-O at 3025-3080, 1674, 1443-1620 
and 1065 cm
-1
, respectively. The UV spectrum of the compound exhibits two maxima 
at 268 and 368 nm with inflexions at 294 and 322 nm. A very large bathochromic 
shift of Band I to 421 nm is observed with the addition of AlCl3, which is unaffected 
on the addition of HCl. This specifies the presence of hydroxyl moiety at 3 and 5 
positions. A bathochromic shift is also observed with the sodium acetate in Band II of 
7 nm at (275 nm), indicating the presence of OH at 7 position. However, there is no 
appreciable shift in Band I on the addition of NaOAc/H3BO3, which rules out the 
presence of ortho-dihydroxyl grouping. This data can be rationalized in terms of 
kaempferol structure for the compound 5. The 
1
H NMR displays singlet peaks at δ 
11.25, 10.05 and 9.85 integrating for one, one and two protons each has been ascribed 
to protons of hydroxyl group. A pair of ortho-coupled doublets is observed at δ 7.95 
(J = 8.8 Hz) and 7.18 (J = 8.8 Hz) integrating for two protons each are assigned to H-
2
ʹ
/6
′
 and H-3
′
/5
′
, respectively. Similarly, a pair of meta-coupled doublets is also 
observed at δ 6.09 (J = 2.0 Hz) and 6.40 (J = 2.0 Hz) attributes to H-6 and H-8 
protons, respectively. The 
13
C NMR spectrum of compound shows resonance for 15 
carbons, signals at δ 177.1, 151.8 and 134.5 are attributed to C-4, C-2 and C-3 
carbons, characteristic of flavone nucleus. B-ring carbons display signals at δ 121.7, 
129.5, 115.4 and 159.7 for C-1ʹ, C-2ʹ/6ʹ, C-3ʹ/5ʹ and C-4ʹ, respectively. However, A-
ring of compound displays peaks at δ 104.5 (C-4a), 161.2 (C-5), 98.2 (C-6), 163.5 (C-
7), 94.3 (C-8) and 157.2 (C-8a). The mass spectrum showed a prominent molecular 
ion peak at m/z 286.05 [M
+•
] agrees with the molecular formula C15H10O6. Elemental 
analysis is also found to be in good agreement with the proposed molecular formula 
C15H10O6. Co-TLC with the authentic sample and finally the comparison of spectral 
data and melting point with the literature compound confirms the structure.
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  In light of the above data, it is subsequently concluded that compound 5 is 
Kaempferol.
46 
 
 
X-ray crystallographic analysis and DFT study of compound 3 and 4 
The asymmetric unit of compound 3 is shown in Fig. 4, crystallizes in the monoclinic 
crystal system with the chiral space group P21/c. Crystallographic data and structure 
refinement is shown in Table 1. The fused ring system is almost planar with the 
dihedral angle between ring A and C of about 2.3
o
. The trimethoxyphenyl group (O6-
O8/C10-C15/C19-C21) attached at C1 position is twisted away from the plane of 
fused rings with dihedral angle between them being 53.9
o
. The methoxy groups at C6 
and C12 are nearly coplanar with its corresponding phenyl rings with the torsion 
angles C18-O5-C6-C7 = 3.5(2)
o
 and C19-O6-C12-C11 = -1.6(2)
o
. However, the 
methoxy groups at C4, C5, C13 and C14 are oriented out of the plane of benzene 
rings (Table 2). 
The molecular packing diagram viewed down the b-axis exhibited hydrogen 
bonds has been depicted in Fig. 5. The molecules are linked by C-H...O hydrogen 
bonds forming zig-zag chains along the b-axis (Table 3) with descriptor C(6) 
according to Etter’s graph-set theory.47 There are also intramolecular C-H...O 
hydrogen bonds occur at C17-H17C...O5 and C20-H20C...O8 (Table 3). The 
isoflavone skeletons are arranged in an antiparallel fashion leading to π-π stacking 
interactions between adjacent rings. The molecular packing is also stabilized by two 
C-H...π interactions between the hydrogen atoms H16B and H19A of methoxy groups 
from one molecule and the phenyl ring of symmetry related molecules. In these 
interactions the hydrogen atoms H19A and H16B are above the centre of the phenyl 
ring, but the C-H bonds point towards the ring edges, corresponding to C-H...π 
(phenyl) interactions of the type III, according to the classification of Malone et al.
48
 
To gain some insight on the influence of the intermolecular interactions on the 
molecular geometry, namely the relative orientation of the rings, DFT calculations of 
the equilibrium geometry of the free molecule starting from the experimental X-ray 
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geometry have been performed. The DFT calculations reproduce well the observed 
experimental bond lengths and valence angles of the molecule (Fig. 6) but some of 
the calculated dihedral angles in the free molecule differ significantly from those of 
the molecule in the crystal as shown in Table 2 and 3. 
 
Fig. 4 Asymmetric unit of compound 3 with the ellipsoids drawn at the 50% 
probability level, with the atomic labelling scheme 
 
 
 
Fig. 5 Packing diagram for compound 3 viewed down the b-axis. Hydrogen bonds are 
shown as dashed lines. 
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Table 1 Crystal data and structure refinements of compound 3 and 4 
 Compound 3 Compound 4 
Empirical formula C21H22O8 C17H12O6 
Formula weight 402.39 312.27 
Temperature (K) 293(2) 293(2) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Monoclinic Monoclinic 
Space group P21/c P21/c 
a (Å) 13.4800(4) 10.9961(3) 
b (Å) 7.5020(2) 10.1785(3) 
c (Å) 19.4525(6) 12.7517(4) 
α (o) 90 90 
β (o) 105.721(2) 107.0265(13) 
γ (o) 90 90 
Volume (Å
3
) 1893.58(10) 1364.66(7) 
Z 4 4 
Calculated density (g/cm
3
) 1.411 1.520 
Absorption coefficient mm
-1
 0.109 0.117 
F(000) 848 648 
Crystal size (mm) 0.48  0.18  0.14 0.57 × 0.44 × 0.40 
θ range for data collection (o) 3.14 - 29.01 2.61 - 27.96 
Index ranges -17 < h < 16, -9 < k < 9, -
26 < l < 24 
-14 < h < 14, -13 < k < 
13, -16 < l < 16 
Reflections collected 18180 27187 
Independent reflections 4547 3286 
Completeness to θ = 25º 99.7 % 100 % 
Refinement method Full-matrix LS on F
2
 Full-matrix LS on F
2
 
Data/restraints/parameters 2690/0/268 3286/0/209 
Goodness-of-fit on F
2
 1.017 1.040 
Final R indices [I> 2σ(I)] R = 0.0441, wR = 0.1284 R = 0.0399, wR = 0.1065 
R indices (all data) R = 0.0548, wR = 0.1420 R = 0.0464, wR = 0.1131 
Largest diff. peak and hole (e 
Å 
-3
) 
0.258 and -0.223 0.240 and -0.220 
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Table 2 Comparison of selected geometrical parameters for compound 3 as 
determined by X-ray diffraction and from DFT calculation (Å,
o
). 
 Experimental DFT 
O1-C8 1.3704(16) 1.3700 
O1-C9 1.3505(16) 1.3513 
C1-C9 1.3381(19) 1.3528 
C1-C10 1.4860(18) 1.4840 
C2-O2 1.2230(17) 1.2318 
C8-O1-C9 118.40(10) 119.28 
C3-C4-O3-C16 82.04(16) 78.83 
C6-C5-O4-C17 -69.20(18) -74.96 
C7-C6-O5-C18 3.5(2) 1.65 
C11-C12-O6-C19 -1.6(2) -1.87 
C14-C13-O7-C20 -81.8(2) -81.41 
C15-C14-O8-C21 -12.8(2) -0.03 
C9-C1-C10-C15 -126.98(15) -140.24 
 
 
 
Fig. 6 Comparison of the molecular conformation of compound 3, as established from 
the X-ray study (red) with the optimized geometry (blue) 
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Table 3 H-bond geometry (Å, º) of compound 3 
 D-H H...A D...A D-H...A 
C16-H16A...O2 0.96 2.48 3.061(2) 118.6 
C17-H17C...O5 (intra) 0.96 2.38 2.965(2) 118.8 
C20-H20B...O8
i
 0.96 2.49 3.291(2) 140.5 
C20-H20C...O8 (intra) 0.96 2.58 3.087(3) 113.3 
(symmetry code i: -x, 1/2+y, -1/2-z) 
The asymmetric unit of compound 4 is shown in Fig. 7, crystallizes in the 
monoclinic crystal system with the chiral space group P21/c. Crystallographic data 
and structure refinement has been shown in Table 1. The single crystal X-ray 
diffraction analysis of compounds 4 is in good agreement with the previous report.
49
 
The fused ring system of compound is almost planar. The hydroxyphenyl ring 
attached at C2 position is twisted with the dihedral angle of 46.95(17)
o
 away from the 
plane of the fused rings. The C4 methoxy group is almost coplanar with the plane of 
the benzene ring, with the C17-O4-C4-C9 torsion angle of 10.9(2)
o
. There are 
intermolecular O-H…O hydrogen bonds in the crystal structure of 4, forming an 
infinite one-dimensional zig-zag like chain along the b axis (Fig. 8). 
 
Fig. 7 Asymmetric unit of compound 4 with the ellipsoids drawn at the 50% 
probability level, with the atomic labelling scheme 
To investigate the influence of the intermolecular interactions on the molecular 
geometries we have performed DFT calculations of the equilibrium geometry of the 
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free molecule starting from the experimental X-ray geometry. The agreement between 
the experimental and calculated geometries is good (Table 4, Fig. 9). There are some 
noticeable differences in some torsion angles that may be explained by intermolecular 
interactions that help in the stabilization of the observed molecular geometries. For 
example, there is a difference of approximately 18.6º between the calculated and the 
experimental torsion angle C5-C4-O4-C17 and this may be due to the participation of 
the O4 atom in a hydrogen bond with O6 atom. 
 
Fig. 8 Packing diagram for compound 4 viewed down the b-axis 
 
 
Fig. 9 Comparison of the molecular conformation of compound 4, as established from 
the X-ray study (red) with the optimized geometry (blue) 
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Table 4 Comparison of selected geometrical parameters for (4) as determined by X-
ray diffraction and from the DFT geometry optimization (Å,°). 
 Experimental DFT 
O1-C1 1.3493(15) 1.3513 
O1-C8 1.3662(15) 1.3659 
O2-C6 1.3585(15) 1.3651 
O2-C16 1.4280(17) 1.4340 
O3-C5 1.3792(15) 1.3913 
O3-C16 1.4258(15) 1.4244 
O4-C4 1.3482(14) 1.3424 
O4-C17 1.4175(15) 1.4304 
O5-C3 1.2308(15) 1.2211 
O6-C13 1.3604(15) 1.3665 
C2-C10 1.4803(16) 1.4815 
C1-O1-C8 118.52(10) 119.66 
C6-O2-C16 106.46(10) 105.21 
O2-C16-O3 107.76(10) 107.13 
C4-O4-C17 121.33(10) 120.68 
C5-O3-C16 105.98(10) 104.77 
C1-C2-C10-C15 46.95(17) 40.94 
C5-C4-O4-C17 10.9(2) -7.74 
 
DNA binding results 
UV-Visible spectroscopy  
UV-Visible studies are often used to study the interaction of small molecules with 
DNA. We have exploited this technique to study the interaction of compound 2 and 3 
with CT-DNA. Appreciable changes in the spectra of compounds 2 and 3 were 
monitored with increasing concentration of CT-DNA as shown in Fig. 10. Compound 
2 exhibits maximum absorption at 290 and 330 nm. With increasing concentration of 
CT-DNA, a hyperchromism is observed at 290 nm while the peak at 330 nm remains 
unchanged (Fig. 10A). Similarly, compound 3 displays maximum absorption near 257 
nm (Fig. 10C). With the increasing concentration of CT-DNA, a hyperchromism is 
observed with no apparent shift in the peak. Hence, UV-Visible studies provide 
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evidence for non-intercalative binding pattern of compounds 2 and 3 with CT-DNA as 
the hyperchromism observed mainly arise due to various non-covalent interactions 
occurring outside DNA-helix.
50
 The value of binding constant for interaction of 
compound 2 and 3 is calculated using the following equation
51
 
  
     
 
  
          
  
  
          
   
 
    
  
where, A0 and A are the absorbance of compound in the absence and presence of calf 
thymus DNA, εD and εD-DNA are the molar extinction coefficient of free compound and 
compound + DNA complex, respectively, Kb is the binding constant and C is the 
concentration of calf thymus DNA. The double reciprocal plot of 1/(A-A0) vs 1/C was 
linear (Fig. 10B and 10D). The binding constant for both compounds is calculated 
from the ratio of the intercept to that of slope. The value of binding constant of 
compound 2 and 3 is found to be 1.84 × 10
4
 M
-1 
and 2.32 × 10
4
 M
-1
, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 UV-Visible absorption spectra of (A) compound 2 (30 μM) and (C) 
compound 3 (30 μM) in the presence of increasing concentrations of CT-DNA. 
(B) and (D) represents the inverse plot of compound 2 and 3 
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Steady State Fluorescence 
Drug-DNA interactions are widely studied with the help of fluorescence 
spectroscopy. Since DNA does not have endogenous fluorescence property, 
fluorescence property of small molecule is exploited. In our experimental conditions, 
compound 3 shows negligible fluorescence behaviour and hence it is not possible to 
calculate the binding constant using steady state fluorescence. Compound 2 is excited 
at 290 nm and emission spectra are recorded in the absence and presence of CT-DNA. 
As seen in Fig. 11, with the increasing concentration of DNA, there is a decrease in 
the fluorescence intensity with no apparent shift in the emission maxima. The 
quenching of fluorescence intensity is possibly due to the interaction of compound 2 
with CT-DNA. To calculate the quenching constant, ratio of peak fluorescence 
intensity in the presence and absence of CT-DNA (F0/F) is plotted as a function of 
DNA concentration (Fig. 12A). Stern-Volmer quenching constant (Ksv) is calculated 
from the slope of the graph and is found to be 0.3 × 10
4
 M
-1
. It is well known that the 
quenching processes are of two types, static quenching and dynamic quenching and 
they follow different mechanism.
52
 To distinguish between the quenching processes 
involved in compound 2-DNA interaction, the bimolecular quenching constant (Kq) is 
calculated from the following equation 
Kq = Ksv / το 
where, τ is the lifetime of the fluorophore. It is known that if the value of Kq is higher 
than the limiting diffusion rate constant (2 × 10
10
 Lmol
-1
s
-1
), the quenching process is 
static.
52
 In case of interaction of compound 2 with CT-DNA, the value of Kq is 
calculated to be 0.3 × 10
12
 by taking the value of τ0 as 10
-8
 s.
52
 Kq value is found to be 
more than the limiting diffusion rate constant suggesting the quenching process to be 
static rather than dynamic.
53
 
The binding stoichiometry (n) and the binding constant (K) of DNA-compound 
2 interaction are calculated using these fluorescence titration data with the help of 
following equation.
54
 
log[(F0 - F) / F = log K + nlog[Q] 
Here, F0 and F are the fluorescence emission intensities of compound 2 in the absence 
and presence of DNA [Q], respectively. Plot of log [(F0 - F) / F] versus log [Q] is 
obtained and the intercept of this plot corresponds to log K (Fig. 12B). The result 
obtained is presented in the Table 5. The binding constant (K) is calculated to be 1.58 
× 10
4
 M
-1
 and the number of binding sites (n) is found to be 1.163. 
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Fig. 11 Fluorescence emission spectra of compound 2 (30 μM) in the presence of 
increasing concentrations of CT-DNA 
 
 
 
 
 
 
 
 
 
 
Fig. 12 (A) Stern-Volmer plot for the compound 2 (B) Plot of log(F0/F)/F versus 
log[CT-DNA] to calculate the binding constant of compound 2 
 
Table 5 Parameters obtained using fluorescence studies 
Compound KSV (L mol
-1
) Kq (L mol
-1
 s
-1
) K (L mol
-1
) n R
2
 
Compound 2 0.3 × 10
4
 0.3 × 10
12
 1.58 × 10
4
 1.163 0.9898 
 
Competitive displacement assay 
Various DNA binding dyes are used in different competitive displacement assay to 
study the binding mode of a drug. Binding mode of these dyes with DNA is well 
established. Ethidium bromide (EB) is a well-known DNA intercalating dye and 
shows enhanced fluorescence intensity in the presence of DNA.
55
 Any other molecule 
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that binds to DNA via intercalation is expected to compete with the EB for the 
binding site. Hence, we employed ethidium bromide displacement assay to study the 
binding mode of compound 2 and 3. As can be seen in Fig. 13A, with increasing 
concentration of compound 2, there is a no change in the fluorescence behaviour of 
EB-DNA system. This indicates that compound 2 is not able to displace EB from the 
DNA helix and hence is suggested to follow non-intercalative mode of binding. 
Similarly, with increasing concentration of compound 3, fluorescence intensity of EB-
DNA system remains unchanged (Fig. 13B). These results suggest that both 
compound 2 and 3 follows the non-intercalative mode of binding. 
To further explore the binding mode of compound 2 and 3, a groove binding 
dye is used in a similar dye displacement assay. Hoechst 33258 is commonly used to 
study the groove binding nature of any molecule. Hoechst 33258 binds to the minor 
groove of DNA and shows enhancement in fluorescence intensity on binding with 
DNA.
56
 As observe in Fig. 14A, with the increasing concentration of compound 2, 
there is significant decrease in the fluorescence intensity of Hoechst-DNA system 
inferring that compound 2 successfully displaces Hoechst 33258 from the minor 
groove of DNA. This suggests that compound 2 binds to the minor groove of DNA 
helix. However, with the increasing concentration of compound 3, no change is 
observed in the fluorescence intensity of Hoechst-DNA system (Fig. 14B), means 
compound 3 is unable to displace Hoechst 33258 from the minor groove of DNA. It is 
possible that compound 3 follows the electrostatic mode of binding since both 
intercalative and groove binding is not observed in our study. 
 
 
 
 
 
 
 
 
Fig. 13 Ethidium bromide (EB) displacement assay; Fluorescence emission spectra of 
DNA-EB complex in presence of increasing concentration of (A) compound 2 and (B) 
compound 3. 
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Fig. 14 Hoechst displacement assay; Fluorescence emission spectra of Hoechst-DNA 
complex in the presence of increasing concentration of (A) compound 2 and (B) 
compound 3. 
Circular Dichroism (CD) studies 
CD spectroscopy is commonly used to detect any changes in the secondary structure 
of DNA in presence of interacting drug molecules.
57
 Various non-covalent drug-DNA 
interactions are known to alter the CD spectral behaviour of DNA. CD spectra of CT-
DNA in Tris-HCl display a positive peak at 277 nm and a negative peak at 244 nm 
(Fig. 15). The positive peak in the CD spectrum of CT-DNA is attributed to the base 
stacking while the negative peak is due to the helicity, both being the characteristics 
of right-handed B form of DNA.
58 
Intercalating molecules are known to perturb the 
CD spectra of DNA significantly while non-intercalative binding has negligible effect 
on the CD spectra of CT-DNA.
54 
Change in secondary structure of CT-DNA in 
presence of compound 2 and 3 are studied using CD spectroscopy. As seen in Fig. 
15A, with increasing concentration of compound 3, there is slight increase in the 
intensity of the peaks at 244 nm and 277 nm. Similarly, with the increasing 
concentration of compound 2 there is an increase in the intensity of both the peaks 
(Fig. 15B). Since all other experiments performed suggests non-intercalative mode of 
binding, changes in the CD spectra of CT-DNA in the presence of compound 2 and 3 
may be due to the conformational changes caused by interacting molecules. Such 
changes in the CD spectra can be linked to conversion of DNA from B-type to a more 
A-type structure.
59
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Fig. 15 CD spectra of CT-DNA in the presence of (A) compound 3 and (B) 
compound 2 
Viscosity measurement 
Studying the change in viscosity of DNA solution in the absence and presence of drug 
provide reliable evidence of the binding mode.
60
 On intercalation of small molecules 
in DNA helix, length of DNA is increased due to base pair separation and hence 
results in increase in the viscosity.
61
 However, in case of electrostatic interaction and 
groove binding, no such increase in the viscosity of DNA is observed.
62 
In case of 
compound 2 and 3, there is negligible change in the viscosity of DNA (Fig. 16). 
Hence, it can be safely deduced that both these molecules interact with DNA via non-
intercalative mode of binding. 
 
Fig. 16 Effect on the viscosity of CT-DNA with an increase in concentration of 
compound 2 and 3 
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Cytotoxicity study of plant extracts 
The in vivo cytotoxicity of ethanolic and aqueous extract of Cassia siamea leaves are 
evaluated to brine shrimp nauplii (Artemia salina) using Vincristine sulfate as 
standard (Fig. 17). It is one of the most convenient diagnostic tests to ascertain the 
cytotoxicity of compound. This bio-screening assay is considered as a useful tool for 
preliminary assessment of toxicity
63
 and it has also been used for the detection of 
fungal toxins.
64
 This method is based on the survival of number of brine shrimps after 
24 h of incubation as described by Meyer et al.
65
 The LD50 value of extracts 
(ethanolic and aqueous) and standard (Vincristine sulfate) is reported in µg/mL. In the 
present study the LD50 value of the ethanolic and aqueous extract of leaves are found 
to be 10.90 µg/mL and 12.88 µg/mL, respectively, as compared to the standard drug 
Vincristine sulfate whose LD50 is 8.70 µg/mL. These data clearly signifies 
considerable cytotoxicity of the crude extracts of Cassia siamea. This significant 
lethality of the crude plant extracts to brine shrimp is indicative of the presence of 
potent cytotoxic and probably insecticidal compounds. 
 
Fig. 17 Determination of LD50 values for ethanolic and aqueous extract of Cassia 
siamea leaves and standard (Vincristine sulfate) from linear correlation between 
logarithms of concentration versus percentage of mortality. 
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EXPERIMENTAL 
Materials and methods 
The melting points of isolated compounds are determined on a Kofler apparatus and 
are uncorrected. The UV measurements are run in methanolic solution with a 
PerkinElmer UV Win Lab spectrophotometer. Elemental analysis (C, H & N) is 
conducted using Thermo Scientific (FLASH 2000) CHN Elemental Analyser. The 
FT-IR spectra are recorded in the 400-4000 cm
-1
 wave-number range using a Perkin-
Elmer (2000 FTIR) Spectrometer by the KBr pellet method. 
1
H-NMR and 
13
C-NMR 
spectra are recorded on a Bruker Avance-II 400 MHz and 100 MHz, instrument, 
respectively, in CDCl3/DMSO-d6 solvent. The chemical shifts (δ) are reported in ppm 
relative to the TMS as an internal standard and J values are reported in Hertz. Mass 
spectra are recorded on a JEOL D-300 mass spectrometer. The silica gel (60-120 
mesh) used for different chromatographic purposes, is purchased from Merck (India) 
and Merck (Germany). Authentic samples are purchased from Sigma Aldrich (India). 
Alcoholic ferric chloride, dil. perchloric acid and iodine vapours are used for 
visualization of spots on TLC. 
Extraction and isolation 
The leaves of Cassia siamea were procured from Aligarh Muslim University campus. 
A voucher specimen bearing number 309/10 has been deposited in the herbarium of 
the Department of Botany, AMU, Aligarh. The fresh leaves of Cassia siamea (2 kg) 
are dried under shade and crushed to make powder. The powdered leaves are defatted 
with light petroleum ether (60-80 
o
C) and then extracted exhaustively with 95% 
ethanol about three times under reflux temperature and filtered to yield a filtrate. The 
filtrate is evaporated under reduced pressure to obtain a crude extract which is dark 
green gummy mass and fractionated successively with benzene, ethyl acetate, acetone 
and methanol. The ethyl acetate and acetone extracts shows similar behaviour on TLC 
examinations in different solvent systems [petroleum ether-benzene (1:1), benzene-
chloroform (9:1, 1:1), benzene-acetone (8:2, 1:1), benzene-pyridine-formic acid 
(PBF-36:9:5), toluene-ethyl formate-formic acid (TEF-5:4:1)], hence they are mixed 
together. The mixed ethyl acetate-acetone extracts are subjected to column 
chromatography on silica gel (60-120 mesh) eluting with a gradient of increasing 
polarity of various solvent systems. The column is eluted first with blank petroleum 
ether then with petroleum ether-benzene mixture in different ratios (9:1-1:1), benzene 
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and benzene-ethyl acetate (9:1-1:1), ethyl acetate and ethyl acetate-methanol (9:1-1:1) 
and finally with blank methanol to obtain different fractions. The fractions showing 
similar behaviour on TLC examination are pooled together. Repeated column 
chromatography of the pooled fractions followed by fractional crystallization affords 
five pure compounds (Cs-1, Cs-2, Cs-3, Cs-4 and Cs-5). 
Spectral characterization of isolated compounds (1-5) 
Compound 1 (Cs-1) 
White shining crystals (120 mg), m.p. 79 
o
C. IR (KBr, νmax, cm
-1
): 3345 (OH), 3080 
(C-H str), 1678 (C=O), 1605 and 1468 (C=C). 
1
H NMR (400 MHz, CDCl3, δ, ppm): 
9.12 (s, 1H, -OH), 7.03 (d, 2H, H-3/5, J = 2.2 Hz), 3.87 (s, 6H, 2 × -OCH3), 2.35 (s, 
3H, -CH3). 
13
C NMR (100 MHz, CDCl3, δ, ppm): 203.5 (C=O), 170.1 (C-4), 164.3 
(C-6), 163.5 (C-2), 111.6 (C-1), 92.4 (C-5), 91.2 (C-3), 55.7 (2 × -OCH3), 32.8 (CH3). 
ESI-MS (m/z): 196.07 [M
+•
] (C10H12O4). Anal. Calc. for C14H12O4: C, 61.22; H, 
6.16. Found: C, 61.12; H, 6.20. 
Compound 2 (Cs-2) 
Yellow coloured crystals (90 mg), m.p. 119-120 
o
C. IR (KBr, νmax, cm
-1
): 3040 (C-
Hstr), 2970 (C-Hstr), 1715 (C=O), 1490-1640 (C=C). UV λmax (MeOH, nm): 280, 295 
and 330. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 7.91 (d, 1H, H-4, J = 9.3 Hz), 7.43 (d, 
1H, H-5, J = 8.4 Hz), 6.75 (d, 1H, H-6, J = 8.4 Hz), 6.68 (d, 1H, H-4ʹ, J = 10.0 Hz), 
6.25 (d, 1H, H-3, J = 9.3 Hz), 5.87 (d, 1H, H-3ʹ, J = 10.0 Hz), 1.41 (s, 6H, 2 × -CH3). 
13
C NMR (100 MHz, CDCl3, δ, ppm): 162.8 (C=O), 149.8 (C-7), 147.6 (C-8a), 143.9 
(C-4), 130.0 (C-5), 127.8 (C-3ʹ), 116.4 (C-4ʹ), 114.3 (C-6), 113.5 (C-3), 112.8 (C-4a), 
110.2 (C-8), 82.5 (C-2ʹ), 28.2 (2 × -CH3). ESI-MS (m/z): 228.08 [M
+•
] (C14H12O3). 
Anal. Calc. for C14H12O3: C, 73.67; H, 5.30. Found: C, 73.71; H, 5.36. 
Compound 3 (Cs-3) 
Light yellowish crystals (80 mg), m.p. 262-264 
o
C. IR (KBr, νmax, cm
-1
): 1640 (C=O), 
1610 (C=Cstr), 1060 (C-O). UV λmax (MeOH, nm): 215, 263, and 329. 
1
H NMR (400 
MHz, CDCl3, δ, ppm): 8.52 (s, 1H, H-2), 7.71 (d, 2H, H-2ʹ/6ʹ, J = 2.5 Hz), 6.65 (s, 
1H, H-8), 3.87-3.97 (s, 18H, 6 × OCH3). 
13
C NMR (100 MHz, CDCl3, δ, ppm): 180.3 
(C-4), 158.6 (C-8a), 152.7 (C-2), 150.3 (C-3ʹ/5ʹ), 141.6 (C-4ʹ), 138.4 (C-7), 135.2 (C-
5), 130.5 (C-6), 124.6 (C-3), 120.4 (C-1ʹ), 106.3 (C-2ʹ/6ʹ), 105.3 (C-4a), 94.5 (C-8), 
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60.9 (4ʹ-OCH3), 59.5 (6-OCH3), 57.3 (5-OCH3), 56.3 (3ʹ/5ʹ-OCH3), 55.7 (7-OCH3). 
ESI-MS (m/z): 402.39 [M+H]
+•
 (C21H22O8). Anal. Calc. for C21H22O8: C, 62.68; H, 
5.51. Found: C, 62.63; H, 5.48. 
Compound 4 (Cs-4) 
White crystals (85 mg), m.p. 256-258 
o
C. IR (KBr, νmax, cm
-1
): 3225 (OH), 1670 
(C=O), 1605, 1482 (C=Carm), 1190 (C-O), 955 (O-CH2-O). UV λmax (MeOH, nm): 
215, 263, and 328. 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 9.49 (s, 1H, -OH), 8.07 
(s, 1H, H-2), 7.40 (d, 2H, H-2ʹ/6ʹ, J = 8.4 Hz), 6.82 (d, 2H, H-3ʹ/5ʹ, J = 8.4 Hz), 6.65 
(s, 1H, H-8), 6.08 (s, 2H, -CH2-), 3.97 (s, 3H, -OCH3). 
13
C NMR (100 MHz, DMSO-
d6, δ, ppm): 175.7 (C-4), 157.6 (C-4ʹ), 154.1 (C-2), 153.2 (C-7), 151.7 (C-8a), 145.2 
(C-5), 136.4 (C-6), 130.9 (C-2ʹ/6ʹ), 125.0 (C-3), 123.3 (C-1ʹ), 116.2 (C-3ʹ/5ʹ), 113.5 
(C-4a), 101.8 (O-CH2-O), 93.5 (C-8), 60.9 (-OCH3). ESI-MS (m/z): 312.27 [M
+•
] 
(C17H12O6). Anal. Calc. for C17H12O6: C, 65.39; H, 3.87. Found: C, 65.42; H, 3.84. 
Compound 5 (Cs-5) 
Yellow shining crystals (60 mg), m.p. 277-279 
o
C. IR (KBr, νmax, cm
-1
): 3345-3518 
(OH), 3042 (C-Hstr), 1674 (C=O), 1443-1620 (C=Carm), 1065 (C-O). UV λmax 
(MeOH, nm): 254, 268 and 368. 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 11.25 (s, 
1H, -OH), 10.05 (s, 1H, -OH), 9.85 (s, 2H, -OH), 7.95 (d, 2H, H-2ʹ/6ʹ, J = 8.8 Hz), 
7.18 (d, 2H, H-3ʹ/5ʹ, J = 8.8 Hz), 6.40 (d, 1H, H-8, J = 2.0 Hz), 6.09 (d, 1H, H-6, J = 
2.0 Hz). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 177.1 (C-4), 163.5 (C-7), 161.2 
(C-5), 159.7 (C-4ʹ), 157.2 (C-8a), 151.8 (C-2), 134.5 (C-3), 129.5 (C-2ʹ/6ʹ), 121.7 (C-
1ʹ), 115.4 (C-3ʹ/5ʹ), 104.5 (C-4a), 98.2 (C-6), 94.3 (C-8). ESI-MS (m/z): 286.05 [M]+• 
(C15H10O6). Anal. Calc. for C15H10O6: C, 62.94; H, 3.52. Found: C, 62.98; H, 3.49. 
 
Crystal structure determination 
The crystal structures of compounds 3 and 4 are determined by X-ray diffraction 
experiments performed on a Bruker Apex II diffractometer. The diffraction data are 
collected at room temperature 293(2) K using graphite monochromated Mo Kα (λ= 
0.71073 Å). Data reduction is performed with APEX II.
66
 Lorentz and polarization 
corrections are applied. Absorption correction is applied using SADABS.
67
 The 
crystallographic structure is solved by direct methods (SHELXS-97).
68
 The structure 
refinements are carried out with SHELXL-97 software.
68 
The refinements are made 
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by full-matrix least-squares on F
2
, with anisotropic displacement parameters for all 
non-hydrogen atoms. All the hydrogen atoms are located in a difference Fourier 
synthesis, placed at calculated positions and then, included in the structure factor 
calculation in a riding model using SHELXL-97 defaults with the exception of the 
hydrogen atoms bonded to hetero atoms, which are refined freely. MERCURY 3.3
69
 
is used for figure plotting. PLATON
70
 is used for data analysis. Supplementary data 
has been deposited at the Cambridge Crystallographic Data Centre (CCDC No. 
936859 and 1451248). 
DFT calculations 
The geometry optimizations are performed using the GAMESS package,
71
 starting 
from the experimental X-ray geometries. The calculations are performed within 
density functional theory (DFT) using B3LYP (Becke three-parameter Lee-Yang-
Parr) for exchange and correlation, which combines the hybrid exchange functional of 
Becke
72, 73
 with the correlation functional of Lee, Yang and Parr.
74
 The calculations 
are performed with an extended 6-311G(d,p) basis set. Tight conditions for 
convergence of both the self-consistent field cycles and the maximum density and 
energy gradient variations are imposed (10
-5
 atomic units). At the end of each 
geometry optimization we conduct a Hessian calculation to guarantee that the final 
structure corresponds to a true minimum, using the same level of theory as in the 
geometry optimization. 
Sample preparation of compound 2 and 3 for DNA binding study 
To make a homogenous solution, calf thymus DNA (CT-DNA) is suspended in 10 
mM Tris-HCl buffer (pH 7.2) at 4 
o
C for 24 h with occasional stirring. Further, to 
check the purity of DNA solution, absorbance ratio (A260/A280) was recorded. No 
further purification is required since the ratio was between 1.8 and 1.9. Concentration 
of DNA is determined spectrophotometrically using average molar extinction 
coefficient value of 6600 M
-1
cm
-1
 of a single nucleotide at 260 nm. Stock solutions of 
compound (2) and (3) are prepared in DMSO. 
UV-Visible spectroscopy 
To study the interaction of CT-DNA with compound 2 and 3, UV-Visible spectra are 
recorded. Shimadzu spectrophotometer (Japan) is used to perform all UV-Visible 
studies using a cuvette of 1 × 1 cm path length. Spectra of compound 2 and 3 are 
Chapter-2 
58 
 
measured in the respective wavelengths in the absence and presence of increasing 
concentration of CT-DNA. A fixed amount of CT-DNA (35 μM) is taken in the blank 
and baseline is corrected. Increasing amount of DNA is added where maximum 
concentration of DNA does not exceed the amount taken for baseline correction.  
Steady State Fluorescence 
Fluorescence emission spectra of compound 2 are recorded on a Shimadzu RF-
5301PC spectroflourophotometer (Japan) equipped with xenon flash lamp using 1.0 
cm quartz cells. Excitation of compound 2 is done at 292 nm and emission spectra are 
recorded from 400 nm to 600 nm after setting the widths of both the excitation and the 
emission slits at 5 nm. Background fluorescence of buffer is subtracted from the final 
readings. Concentration of compound 2 is fixed at 30 μM and increasing 
concentration of DNA (0-90 μM) is added. Since compound 3 does not show any 
fluorescence behaviour in our experimental conditions, we could not study the 
interaction of compound 3 with DNA using fluorescence spectroscopy. 
Competitive Displacement Assays 
To decipher the binding mode, Ethidium bromide (EB) and Hoechst 33258 
displacement assays are performed. A solution containing 2 μM intercalating dye 
(EB) or groove binding dye (Hoechst 33258), 20 μM DNA and increasing 
concentration of small molecule (compound 2 and 3) is added as mentioned in the 
respective figure. EB-DNA complex is excited at 471 nm and emission spectra are 
recorded from 550-700 nm. DNA-Hoechst 33258 complex is excited at 343 nm and 
emission spectra are recorded from 350-600 nm. 
Circular Dichroism (CD) studies 
To further study the binding mode, CD spectra of CT-DNA in presence of increasing 
concentrations of compound 2 and 3 is recorded. CD spectrophotometer (Applied 
Photophysics, model CIRASCAN, U.K.) equipped with a peltier temperature 
controller is used in the study. The temperature of solution is kept constant at 25 
o
C. 
Spectra are recorded from 200-320 nm with a scan speed of 200nm/min and a spectral 
width of 10 nm. Background spectrum of buffer is subtracted from the spectra. 
Concentration of DNA used is 30 μM in 10 mM Tris-HCl (pH 7.2) and the 
concentration of compounds 2 and 3 are kept 30 and 60 μM. 
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Viscosity Measurement 
Viscosity measurements are carried out with an Ubbelohde viscometer (Canon, 
Model-9721-K56, Coleparmer, USA) suspended vertically in a thermostat at 25 
o
C 
(accuracy + 0.1 
o
C). Digital stopwatch is used to measure the flow time where each 
sample is tested three times. The data is presented as (η/η0) versus ratio of 
DNA/compound 2 or DNA/compound 3 concentrations, where η and η0 are the 
viscosity of DNA in the presence and absence of compound 2 or 3. Viscosity 
measurements are carried out by keeping DNA concentration constant (100 μM) 
while varying the concentration of compounds 2 and 3. 
In vivo cytotoxicity assay of plant extracts 
Brine shrimp lethality bioassay is commonly used in the bioassay for the bioactive 
compounds.
75
 The in vivo cytotoxicity assay is performed on brine shrimp nauplii 
(Artemia salina) in accordance with the Meyer method.
65 
The egg of brine shrimp are 
hatched in a tank filled with artificially prepared sea water (brine, 3.8% NaCl) 
exposed to incandescent light. Air is supplied at the bottom of the tank with the help 
of air supplier fitted with tube to keep the shrimps in uniform motion. The assay is 
performed 24 h after hatching and no food supplement has given during the hatching 
and experimental periods. A test sample (50.0 mg) is dissolved in 10 mL DMSO to 
obtain stock solution of 5 mg/mL. Different concentrations of test samples are 
obtained from stock solution and placed in separate vials, and the volume of each vial 
was made up to 5 mL with brine to obtain the desired final concentrations (10, 20, 40, 
60 and 80 µg/mL). The negative control is prepared in the same manner without the 
samples. Vincristine sulphate is used as a standard anti-cancer drug. Thirty brine 
shrimp nauplii are then placed in each vial. After 24 h of incubation, the vials are 
observed using a magnifying glass, and the number of survivors in each vial are 
counted and noted. The LD50 values are calculated using the plot of percentage of 
mortality versus logarithm of concentration. All tests are performed in triplicate and 
expressed as mean. 
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CONCLUSION 
In this chapter, we have reported the isolation of a novel isoflavone, 5,6,7,3ʹ,4ʹ,5ʹ-
hexamethoxyisoflavone (3) from the leaves of Cassia siamea along with four known 
compounds viz. 2,6-dimethoxy-4-hydroxy acetopheneone (1), Seselin (2), Nigricin (4) 
and Kaempferol (5). To the best of our knowledge compound 3 has not been reported 
from any natural sources and also has no report of its chemical synthesis so far. 
Molecular structure of compound 3 and 4 is further authenticated unambiguously by 
X-ray crystallography and density functional theory (DFT) studies. Interaction of 
compounds 2 and 3 with DNA is extensively studied using various biophysical 
techniques. The multi-technique approach employed in the present study reveals that 
both the compounds are found to interact with DNA via non-intercalation mode. 
Groove binding is the major interaction mode in case of compound 2 while compound 
3 probably interacts with DNA through electrostatic interactions. The aqueous and 
ethanolic extract of leaves possess potential cytotoxic activity.  
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CLUTIA LANCEOLATA LEAVES AND 
THEIR BIOLOGICAL STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter-3 
65 
 
INTRODUCTION 
Clutia is a genus of plants belongs to the family Euphorbiaceae and is native to sub-
Saharan Africa and the Arabian Peninsula. Ethnobotanical studies have uncovered 
several Clutia species which are widely used in folk medicine and have potential 
medicinal value.
1
 The chemical constituents of the genus Clutia have not been 
investigated extensively, only few species have been phytochemically explored. 
Waigh et al
2,3
 reported the isolation of ten derivatives of 5-methylcoumarins and three 
new diterpenes with a secolabdane skeleton from the root of Clutia abyssinica. 
Zerihun et al
4
 reported the isolation of two 6-C-glycosylflavones; spinosin and 2″-O-
glycosylisovitexin and a diterpene, ent-16β,17-dihydroxykaurane from the leaves of 
Clutia abyssinica. Muhammad et al
5-7
 reported the isolation of new modified labdane 
diterpenoids cluytene (A-E) and a new modified 6,7-secolabdane diterpenoid 
derivative namely 1β-hydroxysaudinolide from the aerial parts of Clutia richardiana. 
Mossa et al
8-10
 reported the isolation of a novel hypoglycemic diterpene named 
saudin, two novel 6,7-seco-6,11-cyclolabdane diterpenoids, richardianidin-1 and 2, 
and  five new modified 6,7-secolabdane diterpene derivatives; saudinolide, 
dihydrosaudinolide, 5β-hydroxyrichardianidin 1, 5β-hydroxyrichardianidin 2, and 6,7-
seco-6,11-cyclo-20-norlabdane (cluytene F) from the leaves of Clutia richardiana. 
Chepkwony et al
11
 reported alkaloids and terpenoids from the Clutia robusta and their 
uses for treating HIV infection. Tutin and Clewer
12
 also explored the chemical 
constituents of Clutia similis. 
Clutia lanceolata Forssk., a woody herb or shrub or sometime grown up to tree 
belonging to the family Euphorbiaceae, is relatively unexplored. Baka
13
 in 2010 
showed the antifungal property of the aqueous extracts of Clutia lanceolata leaves 
and Mossa et al
14
 reported the hypoglycaemic property of Clutia lanceolata. As part 
of our research work to explore the phytochemical and biological profile of medicinal 
plants, we have carried out the comprehensive phytochemical investigation of the 
leaves of Clutia lanceolata. Herein, overall four compounds (1-4) have been isolated 
from the ethanolic extract of leaves by employing column chromatography, thin-layer 
chromatography (TLC) and preparative thin-layer chromatography (PTLC) followed 
by crystallization. The structures of all the isolated compounds have been elucidated 
on the basis of chemical and physical evidences viz. (elemental analysis, UV, IR, 
1
H  
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NMR, 
13
C NMR, MS and X-ray crystallographic studies) and comparing their spectral 
data with reported literatures. However, all the isolated compounds are known but 
have not been reported so far from this plant source. These isolated compounds are 
subjected to acetylcholinesterase (AChE) enzyme inhibition study in order to get 
some insight about their ability to inhibit AChE enzyme for managing Alzheimer’s 
disease. Molecular docking study of potent AChE inhibitor (compounds 3 and 4) is 
also performed to find the probable binding mode of the compounds into the active 
site of receptor. Moreover, aqueous and ethanolic extracts are screened for in vivo 
cytotoxicity against brine shrimp nauplii by lethality bioassay. 
 
RESULTS AND DISCUSSION 
This chapter deals with the phytochemical investigation of the leaves of Clutia 
lanceolata i.e. extraction, isolation and characterization of chemical constituents, 
anticholinesterase inhibition study of isolated compounds and screening for in vivo 
cytotoxic activity of aqueous and ethanolic extract of leaves. The following four 
compounds (1-4) have been isolated from the leaves of Clutia lanceolata Forssk. 
1. 3,4-dihydroxy-2-methylbenzoic acid (Cl-1) 
2. 2,2ʹ-dihydroxy-1,1ʹ-binaphthyl (Cl-2) 
3. 1,3,8-trihydroxy-6-methylanthracene-9,10-dione (Cl-3) 
4. 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one (Cl-4) 
Characterization of compound 1 (Cl-1) 
Compound 1 is isolated through elution of column with petroleum ether-benzene (6:4) 
which on crystallisation with chloroform-benzene furnishes brick red crystalline solid 
(60 mg), m.p. 233-235 
o
C. Elemental analysis along with the molecular ion peak at 
m/z 168.04 [M
+·
] agrees with the molecular formula C8H8O4. The IR spectrum reveals 
the characteristic absorption bands for hydroxyl group (3336 cm
-1
) and phenyl ring 
(1608-1489 cm
-1
). The presence of phenolic OH group is further confirmed with the 
positive ferric chloride test. The IR spectrum also shows absorption bands at 3463 and 
1685 cm
-1
 corresponding to carboxylic group which was further confirmed by the 
appearance of effervescences with NaHCO3. The 
1
H NMR spectrum exhibits the 
presence of two ortho-coupled doublets at δ 7.74 and 6.75 corresponding to the H-6 
and H-5 aromatic protons, respectively. The downfield shift of proton H-6 is due to 
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the presence of carboxylic group on adjacent carbon. The presence of two singlets at δ 
10.06 and 9.67 integrating for two and one protons are corresponding to two phenolic 
OH and a carboxylic OH, respectively. Moreover, a sharp singlet at δ 2.24 integrating 
for three protons indicates the presence of methyl group (Fig. 1). The 
13
C NMR 
spectrum exhibits peaks at δ 13.7 and 178.4 corresponding to methyl and carbonyl 
carbon, respectively. Further, peaks at δ 148.0 (C-1), 128.3 (C-2), 158.60 (C-3), 
158.69 (C-4), 127.9 (C-5) and 114.9 (C-6) shows the presence of six carbons of 
aromatic ring (Fig. 2). The structure is further confirmed by comparing their spectral 
data and melting points with those reported in the literature.
15
 
In the light of above assignment it is concluded that the compound 1 is 3,4-
dihydroxy-2-methylbenzoic acid. 
 
 
Fig. 1 
1
H NMR spectrum of compound 1 (Cl-1) 
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Fig. 2 
13
C NMR spectrum of compound 1 (Cl-1) 
Characterization of compound 2 (Cl-2) 
Compound 2 is obtained by elution of column with petroleum ether-benzene (1:9) and 
crystallises with chloroform-methanol as white crystals (110 mg), m.p. 207 
o
C. The 
positive ion ESI-mass spectrum exhibits the molecular ion peak at m/z 286.10 [M
+·
]. 
Elemental analysis along with the mass spectrum establishes the molecular formula 
C20H14O2. It responds positively to the ferric chloride test pointing out the presence of 
phenolic group. The UV spectrum of the compound displays characteristic absorption 
band for aromatic nucleus displaying λmax at 227, 278 and 336 nm indicating the 
presence of a phenolic chromophore. The IR spectrum shows absorption bands at 
3425 cm
-1
 for hydroxyl group, 3028 cm
-1
 for aromatic C-H stretching and 1380-1615 
cm
-1
 for C=C stretching of aromatic rings. The 
1
H NMR spectrum displays a singlet at 
δ 11.15 integrating for two protons corresponds to two hydroxyl group. Two 
independent ortho-coupled doublets with J = 9.0 Hz at δ 7.24 and 7.85 integrating for 
two protons each corresponds to the H-3/3ʹ and H-4/4ʹ protons of the A ring of 
naphthalene. The H-5/5ʹ and H-8/8ʹ protons of B ring displays double doublets with J 
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= 1.3 and 8.0 Hz at δ 7.94 and 7.12, respectively. Two multiplets at δ 7.38 and 7.44 
integrating for two protons each are corresponded to H-6/6ʹ and H-7/7ʹ protons, 
respectively, of the naphthyl ring B. The 
13
C NMR spectrum displays characteristic 
peaks of naphthyl ring resonating at δ 118.4-133.9. However, the carbon of the 
connected naphthyl rings shows peak at δ 110.8 and the carbon with hydroxyl group 
substitution displays peak at δ 154.3. The structure is also confirmed by comparing 
their spectral data and melting point with the reported literature.
16
 The structure of 
compound 2 is further authenticated with the X-ray crystallographic analysis. 
In light of the above data, it is significantly concluded that compound 2 is 2,2ʹ-
dihydroxy-1,1ʹ-binaphthyl. 
 
 
Characterization of compound 3 (Cl-3) 
Compound 3 is obtained from the elution of column with benzene-ethyl acetate (8:2) 
which on crystallisation with chloroform-methanol furnishes orange coloured solid 
(80 mg), m.p. 267-269 
o
C. Elemental analysis along with the molecular ion peak at 
m/z 270.05 [M
+·
] agrees with the molecular formula C15H10O5. The compound 
responds positively to the ferric chloride test indicating the presence of phenolic OH 
group, which is further confirmed with the broad peak at 3510 cm
-1
 in the IR 
spectrum. The IR spectrum also displays peaks at 3056 and 2918 cm
-1 
corresponding 
to aromatic and aliphatic C-H stretching vibrations.  However, peaks at 1676 and 
1625 cm
-1
 correspond to C=O and C=C bonds of α,β-unsaturated carbonyl 
functionality. The 
1
H NMR spectrum of compound shows four meta-coupled doublets 
at δ 7.81, 7.65, 7.30 and 7.09 corresponding to aromatic protons H-2, H-4, H-7 and H-
5, respectively. Singlets at δ 12.13 and 12.02 integrating for two and one protons each 
are assigned to hydroxyl protons. Moreover, sharp singlet at δ 2.46 integrating for 
three protons is assigned to methyl protons (Fig. 3). The 
13
C NMR spectrum exhibits 
two independent peaks for carbonyl carbons at δ 182.0 (C-9) and 192.5 (C-10). The 
methyl group is found to resonate at δ 22.2. The signals at δ 162.4, 160.3 and 162.6 
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are assigned to C-1, C-3 and C-8 carbons. The spectrum also shows nine more peaks 
for aromatic carbons at δ 113.7 (C-8a), 121.3 (C-7), 149.3 (C-6), 119.9 (C-5), 133.8 
(C-5a), 124.5 (C-4), 134.0 (C-4a), 136.9 (C-2) and 111.8 (C-1a) (Fig. 4). Moreover, 
the structure is also confirmed by co-TLC with the authentic samples and matching 
the spectral data and melting point with the reported ones.
17
 
In light of the above data, it is significantly concluded that compound 3 is 1,3,8-
trihydroxy-6-methylanthracene-9,10-dione (Emodin). 
 
 
 
Fig. 3 
1
H NMR spectrum of compound 3 (Cl-3) 
Chapter-3 
71 
 
 
Fig. 4 
13
C NMR spectrum of compound 3 (Cl-3) 
Characterization of compound 4 (Cl-4) 
Elution of column with benzene-ethyl acetate (3:7) affords compound 4 which further 
crystallises with chloroform-methanol as shining light orange coloured crystals (120 
mg), m.p. 177 
o
C. Elemental analysis along with the molecular ion peak at m/z 368.13 
[M
+·
] are in good agreement with the molecular formula C21H20O6. The IR spectrum 
shows characteristics peak for OH at 3427 cm
-1
, aromatic and aliphatic C-H vibrations 
at 3065 and 2905 cm
-1
, respectively. The absorption peaks at 1682, 1480-1605 and 
1120 cm
-1 
correspond to C=O, C=C and C-O bands, respectively. The 
1
H NMR 
spectrum exhibits doublets at δ 7.58, 7.22, 6.65 and 6.51 corresponding to H-1, H-2, 
H-6 and H-7, respectively. However, a sharp singlet resonating at 6.72 is assigned to 
H-4 proton. The broad singlet at δ 11.12 and 10.75 are assigned to phenolic and enolic 
hydroxyl groups, respectively. The aromatic protons of compound 4 shows ortho-
coupled doublets at δ 6.92, 6.81 and singlet at δ 7.10 integrating for two protons each 
corresponds to H-5ʹ/5″, H-6ʹ/6″ and H-2ʹ/2″, respectively. The methoxy group showed 
singlet at δ 3.85 integrating for six protons. The 13C NMR spectrum exhibits peaks for 
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aromatic carbons at δ 111.2, 116.5, 121.9, 127.8, 147.3 and 149.6 corresponding to C-
2ʹ/2″, C-5ʹ/5″, C-6ʹ/6″, C-1ʹ/1″, C-3ʹ/3″ and C-4ʹ/4″, respectively. Moreover, the 
straight chain of compound shows peak at δ 142.3, 124.8, 140.7 and 122.2 for C-1, C-
2, C-7 and C-6, respectively. However, C-3, C-4 and C-5 displays peak at δ 182.4, 
100.1 and 180.3, respectively. The structure of compound 4 is also authenticated by 
X-ray crystallographic analysis. 
In light of the above discussion and with comparison of the data to the reported 
literature,
18
 it is concluded that compound 4 is 5-hydroxy-1,7-bis(4-hydroxy-3-
methoxyphenyl)hepta-1,4,6-trien-3-one i.e. Curcumin. 
 
X-ray crystallographic analysis and DFT study of compound 2 and 4 
The asymmetric unit of compound 2 and 4 with the ellipsoids drawn at the 50% 
probability level is shown in Fig. 5 and 6, respectively. The crystal data and structure 
refinement parameters are summarized in Table 1. The single crystal X-ray 
diffraction analysis of compounds 2 and 4 is in good agreement with the previous 
report.
19,20
 Compound 2 crystallizes in the orthorhombic crystal system with the chiral 
space group Iba2, whereas compound 4 crystallizes in the monoclinic crystal system 
with the chiral space group P2/n. 
To examine the influence of the intermolecular interactions on the molecular 
geometries we have performed DFT calculations of the equilibrium geometries of the 
free molecules starting with the experimental X-ray geometries. For the compound 2, 
there is a good agreement between the experimental and calculated geometries (Table 
2 and Fig. 7) with the largest difference occurring in the torsion angle C2-C1-C11-
C12 (7.3º), however this is not unexpected, since the rotation around a C-C single 
bond does not have a high energy cost.
21
 The situation is quite different for compound 
4. In the experimental geometry, there is a high degree of chemical symmetrisation in 
the enol ring, defined as near equality of the C–C and C–O bond lengths compared 
pairwise, according to Herbstein et al.
22
 The theoretical geometry does not display 
this symmetrisation. One possible explanation for this discrepancy may be the O—
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H…O hydrogen bonds involving the oxygen atoms of the enol ring and hydroxyl 
groups, that link different curcumin molecules (Table 3 and Fig. 8). 
 
 
Fig. 5 Asymmetric unit of compound 2 with the ellipsoids drawn at the 50% 
probability level, with the atomic labelling scheme 
 
 
 
 
 
Fig. 6 Asymmetric unit of compound 4 with the ellipsoids drawn at the 50% 
probability level, with the atomic labelling scheme 
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Table 1 Crystal data and structure refinements of compound 2 and 4 
 Compound 2 Compound 4 
Empirical formula C20H14O2 C21H20O6 
Formula weight 286.31 368.37 
Temperature 293(2) K 293(2) K 
Wavelength 0.71073 Å 0.71073 Å 
Crystal system Orthorhombic Monoclinic 
Space group Iba2 P2/n 
a 21.5986(8) Å 12.6851(5) Å 
b 15.6844(6) Å 7.1848(3) Å 
c 8.6243(3) Å 19.8951(8) Å 
α 90º 90.00º 
β 90º 95.223(2)º 
γ 90º 90.00º 
Volume 2921.58(19) Å
3
 1805.71(13) Å
3
 
Z 8 4 
Density (calculated) 1.302 gcm
-3
 1.355 gcm
-3
 
Absorption coefficient 0.083 mm
-1
 0.099 mm
-1
 
Extinction coefficient 0.0052(12) - 
F(000) 1200 776 
Crystal size 0.53×0.48×0.24 mm
3
 0.60×0.46×0.44 mm
3
 
θ range for data collection 3.11 - 25.84º 1.99 - 29.73º 
Index ranges -26 < h < 26; -19 < k < 
19;  -10 < l < 10 
-17 < h < 13; -10 < k < 
10; -27 < l < 27 
Reflections collected 24389 39945 
Independent reflections 2832 5076 
Completeness to 2θ = 50º 99.8 % 98.8 % 
Refinement method Full matrix LS on F
2
 Full matrix LS on F
2
 
Data/restrains/parameters 2832/1/206 5076/0/255 
Goodness-of-fit on F
2
 1.104 1.033 
Final R indices [I>2σ(I)] R = 0.0487; wR = 0.1170 R = 0.0487; wR = 0.1408 
R indices (all data) R = 0.0781; wR = 0.1480 R = 0.0648; wR = 0.1570 
Largest diff. peak and hole 0.163 and -0.204 0.342 and -0.301 
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Fig. 7 Comparison of the molecular conformation of compound 2, as established from 
the X-ray study (red) with the optimized geometry (blue) 
 
Fig. 8 Comparison of the molecular conformation of compound 4, as established from 
the X-ray study (red) with the optimized geometry (blue) 
Table 2 Comparison of selected geometrical parameters for compound 2 as 
determined by X-Ray diffraction and from the DFT geometry optimization (Å,°). 
 Experimental DFT 
O1—C2 1.375(5) 1.358 
O2—C12 1.351(6) 1.358 
C1—C11 1.496(5) 1.496 
C1—C2 1.367(6) 1.390 
C11—C12 1.388(6) 1.390 
C1—C2—C3 122.1(4) 121.4 
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C11—C12—C13 120.4(4) 121.3 
C2—C1—C11 120.2(4) 118.9 
C1—C11—C12 118.8(4) 118.9 
C2—C1—C11—C12 -88.8(5) -96.1 
O1—C2—C3—C4 -180.0(4) -180.0 
O2—C12—C13—C14 -178.4(5) -180.0 
Table 3 Comparison of selected geometrical parameters for compound 4 as 
determined by X-Ray diffraction and from the DFT geometry optimization (Å,°). 
 Experimental DFT 
O1—C2 1.3635(16) 1.3553 
O4—C17 1.3583(16) 1.3552 
O5—C1 1.3626(16) 1.3726 
O6—C18 1.3606(18) 1.3717 
O5—C23 1.4170(19) 1.4227 
O6—C21 1.408(2) 1.4237 
O2—C9 1.2982(17) 1.2554 
O3—C11 1.2867(18) 1.3290 
C8—C9 1.4578(17) 1.4721 
C9—C10 1.3898(18) 1.4403 
C10—C11 1.4052(18) 1.3793 
C11—C12 1.4544(18) 1.4590 
C1—O5—C23 117.42(11) 118.51 
C18—O6—C21 118.19(12) 118.54 
O5—C1—C6 125.72(13) 126.21 
O6—C18—C19 125.18(13) 126.17 
C8—C9—C10 121.39(12) 117.09 
C9—C10—C11 120.62(12) 120.75 
C10—C11—C12 124.30(13) 124.77 
C23—O5—C1—C6 8.0(2) 0.5 
C21—O6—C18—C19 5.3(2) 2.1 
C6—C5—C7—C8 -4.6(2) 0.0 
C12—C13—C14—C19 24.7(2) 13.9 
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AChE inhibition results 
The acetylcholinesterase inhibition effect of the isolated compounds (1-4) is assessed 
by Ellman's spectrophotometric method using human recombinant AChE with tacrine 
as reference compound. The results obtain has been summarized in Table 4. It can be 
inferred from the data shown in table, that compound 3, exhibits the strongest 
inhibition to AChE with an IC50 value of 14.2 µM, followed by compound 4 (IC50 = 
16.4 µM), 2 (IC50 = 21.9 µM) and 1 (IC50 = 23.7 µM). The results indicate that all the 
isolated compounds display moderate inhibitory activity against the 
acetylcholinesterase enzyme. However, compounds 3 and 4 are found to be more 
active in comparison to 1 and 2. This is mainly attributed to the basic skeleton of 
compounds 3 and 4 which provide them more binding prospects with the formation of 
hydrogen bonding interactions to the amino acid residues of the protein. However, the 
π-π stacking may also leads to improve its activity with the formation of additional 
non-bonding interactions to the protein. 
Table 4 In vitro AChE inhibition of compounds 1-4 and reference drug tacrine. 
S. No. Compounds IC50 (µM)
a
 ± SEM for hAChE inhibition 
1 Compound 1 23.7 ± 0.02 
2 Compound 2 21.9 ± 0.05 
3 Compound 3 14.2 ± 0.06 
4 Compound 4 16.4 ± 0.03 
5 Tacrine (standard) 0.20 ± 0.01 
a
IC50 = Concentration of inhibitor required to decrease enzyme activity by 50%. 
Molecular docking studies  
The molecular docking studies are conducted in order to get insight the binding 
pattern and extent of binding of compounds with the target enzymes. In the present 
study, docking study of the two most potent acetylcholinestrerase inhibitor i.e. 
compound 3 and 4 of the isolated compounds have been carried out in order to 
anticipate the binding mode towards target enzyme (PDB: 1EVE) and to give 
justification for the observed in vitro AChE inhibition property of the isolated 
compounds 3 and 4 (Fig. 9). The in silico docking experiment for compounds 3 and 4 
against the X-ray crystal structure of receptor (PDB: 1EVE), is carried out using 
PATCHDOCK and iGEMDOCK software. Docking simulations show comparable 
binding affinity of compounds 3 and 4 with AChE enzyme. Several interactions from 
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the docking pose are observed notably TYR121; SER122; LEU127; TYR130; 
GLU199; SER200; PHE330; PHE331 and HIS440 between the receptor and 
compound 3, SER 122; SER226; CYS231; TRP233; PHE288; VAL323; LEU404 and 
HIS440 between the receptor and compound 4 in proper binding orientations. The 
binding score from iGEMDOCK is found to be -108.18 and -98.91 Kcal/mol for 
compound 3 and 4, respectively. This is due to the cumulative van der waal 
contribution and H-bonding interactions. The docking studies reveal that the aromatic 
ring also plays a major role in stabilizing the ligand-receptor complex by pi- cation 
interactions with amino acid residue of the target protein as shown in Fig. 9. These 
strong interactions help the compounds to bury well inside the cavity of target protein 
and acts as a potent AChE inhibitor. The analysis of enzyme inhibition data obtains 
from the in vitro experiments, shows the comparative inhibitory property of 
compound 3 (IC50 = 14.2 µM) and compound 4 (IC50 = 16.4 µM) and is found to be 
moderately potent as compared to a standard drug tacrine (IC50 = 0.20 µM), as AChE 
inhibitor. 
 
Fig. 9 Interactions profile of (A) compound 3 and (B) compound 4 with receptor 
protein. 
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Cytotoxicity study of plant extracts 
The in vivo cytotoxicity of ethanolic and aqueous extract of Clutia lanceolata leaves 
are evaluated to brine shrimp nauplii (Artemia salina) using Vincristine sulfate as 
standard (Fig. 10). It is one of the most convenient and simple bioassay for testing the 
cytotoxicity of plant extracts. This bio-screening assay is considered as a useful tool 
for preliminary assessment of toxicity
23
 which in most cases correlates reasonably 
well with cytotoxic and anti-tumour properties
24
 and it has also been used for the 
detection of fungal toxins.
25
 This method is based on the survival of number of brine 
shrimps after 24 h of incubation as described by Meyer et al.
26
 The LD50 value of 
extracts (ethanolic and aqueous) and standard (Vincristine sulfate) is reported in 
µg/mL. In the present study, each of the test samples display different mortality rates 
at different concentrations, the percentage mortality increases with an increase in 
concentration. The variation in results may be due to the difference in the amount and 
kind of cytotoxic substances present in the crude extracts. The calculated LD50 value 
of the ethanolic and aqueous extract of leaves are found to be 11.28 µg/mL and 14.34 
µg/mL, respectively, as compared to the standard drug Vincristine sulfate whose LD50 
is 8.70 µg/mL. These data clearly indicates significant cytotoxicity of the crude 
extracts of Clutia lanceolata. This significant lethality of the crude plant extratcts to 
 
Fig. 10 Determination of LD50 values for ethanolic and aqueous extract of Clutia 
lanceolata leaves and standard (Vincristine sulfate) from linear correlation between 
logarithms of concentration versus percentage of mortality. 
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brine shrimp is indicative of the presence of potent cytotoxic and probably insecticidal 
compounds. 
 
EXPERIMENTAL 
Materials and Methods 
All solvents and chemicals are purchased from commercial sources (Sigma-Aldrich, 
Merck, and others) and dried using standard procedures. Melting points of isolated 
compounds are determined on a Kofler apparatus and are uncorrected. Elemental 
analysis (C, H & N) has been conducted using a Thermo Scientific (FLASH 2000) 
CHN Elemental Analyser. Fourier transform-infrared (FT-IR) spectra are recorded 
using a Perkin-Elmer (2000 FTIR) Spectrometer by the KBr pellet method, values are 
given in cm
-1
. The UV spectra are recorded with PerkinElmer UV Win Lab 
spectrophotometer. 
1
H-NMR and 
13
C-NMR spectra are recorded on a Bruker Avance-
II 400 MHz and 100 MHz, instrument, respectively, in CDCl3/DMSO-d6 solvent. The 
chemical shifts (δ) are reported in ppm relative to the TMS as an internal standard and 
J values are reported in Hertz. Mass spectra are recorded on a JEOL D-300 mass 
spectrometer. The silica gel (60-120 mesh) used for different chromatographic 
purposes, is obtained from Merck (India) and Merck (Germany). Authentic samples 
are purchased from sigma aldrich (India). Alcoholic ferric chloride, dil. perchloric 
acid and iodine vapours are used for visualization of spots on TLC. 
Extraction and isolation 
The leaves of Clutia lanceolata are collected from Abha region of South of Saudi 
Arabia, identified by Dr. S. Adeen, Taxonomist of the Medicinal, Aromatic and 
Poisonous Plant Research Centre (MAPPRC), College of Pharmacy, King Saud 
University, Riyadh, Saudi Arabia. A voucher specimen bearing number 14077 has 
been deposited in their herbarium. The leaves of Clutia lanceolata are dried under 
shade and crushes to make powder (1.5 kg). The powdered leaves are defatted with 
petroleum ether (60-80 
o
C) to remove fatty material and then extracted exhaustively 
with 95% ethanol about three times under reflux temperature and filtered to yield a 
filtrate. The filtrate is evaporated under reduced pressure to obtain dark green gummy 
mass of crude extract and fractionated successively with petroleum ether, benzene, 
ethyl acetate, acetone and methanol. The petroleum ether and benzene extracts show 
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similar behaviour on TLC examinations in different solvent systems [petroleum ether-
benzene (1:1), benzene-chloroform (9:1, 1:1), benzene-acetone (8:2, 1:1), benzene-
pyridine-formic acid (PBF-36:9:5), toluene-ethyl formate-formic acid (TEF-5:4:1)], 
hence they are mixed together. The mixed petroleum ether and benzene extract is 
chromatographed on a silica gel column, eluting stepwise with petroleum ether-
benzene (1:0, 9:1 → 1:9) which affords compound 1 and 2. Similarly, the ethyl 
acetate extract is subjected to column chromatography on silica gel, eluting stepwise 
with benzene-ethyl acetate (1:0, 9:1 → 1:9, 0:1) which furnishes two compounds i.e. 
compound 3 and 4. The isolated compounds are purified by repeated column 
chromatography followed by crystallization to get pure compounds (Cl-1, Cl-2, Cl-3 
and Cl-4). 
Spectral characterization of isolated compounds 
Compound 1 (Cl-1) 
Brick red crystalline solid (90 mg), m.p. 233-235 
o
C. IR (KBr, υmax, cm
-1
): 3463, 
3336, 3184, 1685, 1608, 1489, 1431, 1264, 1228, 1173, 1089, 827. 
1
H NMR (400 
MHz, DMSO d6, δ, ppm): 10.06 (2H, s, 2 × -OH), 9.67 (1H, s, -COOH), 7.74 (1H, d, 
H-6, J = 8.0 Hz), 6.75 (1H, d, H-5, J = 8.0 Hz), 2.24 (3H, s, -CH3). 
13
C NMR (100 
MHz, DMSO d6, δ, ppm): 178.4 (C=O), 158.69 (C-4), 158.60 (C-3), 148.0 (C-1), 
128.3 (C-2), 127.9 (C-5), 114.9 (C-6), 13.7 (-CH3). ESI-MS (m/z): 168.04 [M
+·
] 
(C8H8O4). Anal. Calc. for C8H8O4: C, 57.14; H, 4.80; found: C, 58.09; H, 4.95. 
Compound 2 (Cl-2) 
White crystals (110 mg), m.p. 207 
o
C. IR (KBr, υmax, cm
-1
): 3425, 3382, 2971, 2918, 
2840, 1615, 1590, 1461, 1380, 1216, 1175, 1146, 826,750. UV λmax (MeOH, nm): 
227, 278, 336. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 11.15 (2H, s, 2 × OH), 7.94 (2H, 
dd, H-5/5ʹ, J = 1.3 and 8.0 Hz), 7.85 (2H, d, H-4/4ʹ, J = 9.0 Hz), 7.44 (2H, m, H-7/7ʹ), 
7.38 (2H, m, H-6/6ʹ), 7.24 (2H, d, H-3/3ʹ, J = 9.0 Hz), 7.12 (2H, dd, H-8/8ʹ, J = 1.3 
and 8.0 Hz). 
13
C NMR (100 MHz, CDCl3, δ, ppm): 154.3 (C-2/2ʹ), 133.9 (C-8a/8ʹa), 
130.0 (C-4/4ʹ), 129.2 (C-4a/4ʹa), 128.2 (C-5/5ʹ), 126.9 (C-7/7ʹ), 125.7 (C-6/6ʹ), 123.5 
(C-8/8ʹ), 118.4 (C-3/3ʹ), 110.8 (C-1/1ʹ).  ESI-MS (m/z): 286.10 [M+·] (C20H14O2). 
Anal. Calc. for C20H14O2: C, 83.90; H, 4.93; found: C, 84.88; H, 5.05. 
Compound 3 (Cl-3) 
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Orange coloured crystals (120 mg), m.p. 267-269 
o
C. IR (KBr, υmax, cm
-1
): 3510, 
3056, 2918, 1676, 1625, 1565, 1458, 1371, 1272, 1205, 1161, 1082, 1026, 749. 
1
H 
NMR (400 MHz, CDCl3, δ, ppm): 12.13 (2H, s, 2 × OH), 12.02 (1H, s, OH), 7.81 
(1H, d, H-2, J = 1.2 Hz), 7.65 (1H, d, H-4, J = 1.2 Hz), 7.30 (1H, d, H-7, J = 1.2 Hz), 
7.09 (1H, d, H-5, J = 1.2 Hz), 2.46 (3H, s, -CH3). 
13
C NMR (100 MHz, CDCl3, δ, 
ppm): 182.0 (C-9), 192.5 (C-10), 162.6 (C-8), 162.4 (C-1), 160.3 (C-3), 149.3 (C-6), 
136.9 (C-2), 134.0 (C-4a), 133.8 (C-5a), 124.5 (C-4), 121.3 (C-7), 119.9 (C-5), 113.7 
(C-8a), 111.8 (C-1a), 22.2 (CH3). ESI-MS (m/z): 270.05 [M
+·
] (C15H10O5). Anal. 
Calc. for C15H10O5: C, 66.67; H, 3.73; found: C, 67.58; H, 3.85. 
Compound 4 (Cl-4) 
Yellow-orange coloured crystals (190 mg), m.p. 177 
o
C. IR (KBr, υmax, cm
-1
): 3427, 
3065, 2905, 1682, 1605, 1480, 1120. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 11.12 
(2H, s, 2 × -OH), 10.75 (1H, s, -OH), 7.58 (1H, d, H-1), 7.22 (1H, d, H-2), 7.10 (2H, 
s, H-2ʹ/2″), 6.92 (2H, d, H-5ʹ/5″), 6.81 (2H, d, H-6ʹ/6″), 6.72 (1H, s, H-4), 6.65 (1H, d, 
H-6), 6.51 (1H, d, H-7), 3.85 (6H, s, 2 × -OCH3). 
13
C NMR (100 MHz, CDCl3, δ, 
ppm): 182.4 (C-3), 180.3 (C-5), 149.6 (C-4ʹ/4″), 147.3 (C-3ʹ/3″), 142.3 (C-1), 140.7 
(C-7), 127.8 (C-1ʹ/1″), 124.8 (C-2), 122.2 (C-6), 121.9 (C-6ʹ/6″), 116.5 (C-5ʹ/5″), 
111.2 (C-2ʹ/2″), 100.1 (C-4), 55.6 (2 × -OCH3). ESI-MS (m/z): 368.13 [M
+·
] 
(C21H20O6). Anal. Calc. for C21H20O6: C, 68.47; H, 5.47; found: C, 69.81; H, 5.85. 
X-ray crystallographic analysis 
The crystal structures of compounds 2 and 4 are determined by X-ray diffraction 
experiments performed on a Bruker Apex II diffractometer. The diffraction data is 
collected at room temperature 293(2) K using graphite monochromated Mo Kα (λ = 
0.71073 Å). Data reduction is performed with APEX II.
27
 Lorentz and polarization 
corrections are applied. Absorption corrections are applied using SADABS.
28
 An 
extinction correction is applied during the refinement of the crystal structure of 
compound 2.
29
 The crystallographic structures are solved using direct methods 
(SHELXS-97).
29
 The structure refinements are carried out with SHELXL-97 
software.
29
 The refinements are made by full-matrix least-squares on F
2
, with 
anisotropic displacement parameters for all non-hydrogen atoms. All the hydrogen 
atoms are located in a difference Fourier synthesis, placed at calculated positions and 
then, included in the structure factor calculation in a riding model using SHELXL-97 
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defaults with the exception of the hydrogen atoms bonded to hetero atoms, which are 
refined freely. MERCURY 3.3
30
 is used for figure plotting. PLATON
31
 is used for 
data analysis. Atomic coordinates, thermal parameters and bond lengths and angles 
have been deposited at the Cambridge Crystallographic Data Centre (CCDC) with 
reference numbers CCDC 1463766 and 1463767. 
DFT calculations 
The geometry optimizations are performed using the GAMESS package,
32
 starting 
from the experimental X-ray geometries. The calculations are performed within 
density functional theory (DFT) using B3LYP (Becke three-parameter Lee-Yang-
Parr) for exchange and correlation, which combines the hybrid exchange functional of 
Becke
33,34
 with the correlation functional of Lee, Yang and Parr.
35
 The calculations 
are performed with an extended 6-311G(d,p) basis set. Tight conditions for 
convergence of both the self-consistent field cycles and the maximum density and 
energy gradient variations are imposed (10
-5
 atomic units). At the end of each 
geometry optimization we conduct a Hessian calculation to guarantee that the final 
structure corresponds to a true minimum, using the same level of theory as in the 
geometry optimization. 
In vitro AChE inhibition study 
All the isolated compounds (1-4) are assessed for AChE inhibition study by Ellman’s 
method.
36
 AChE stock solution is prepared by dissolving human recombinant AChE 
(EC: 3.1.1.7) lyophilized powder (Sigma-Aldrich) in 0.1 M phosphate buffer (pH = 
8.0) containing Triton X-100 (0.1%). Five increasing concentrations of test 
compounds are assayed to obtain % inhibition of the enzymatic activity in the range 
of 20-80. The assay solution consisted of a 0.1 M phosphate buffer pH 8.0, with the 
addition of 340 µM 5,50-dithio-bis(2-nitrobenzoic acid), 0.02 unit per mL of human 
recombinant AChE from human serum and 550 µM of the substrate (acetylthiocholine 
iodide, ATCh). Increasing concentrations of the tested inhibitor are added to the assay 
solution and pre-incubated for 5 min at 37 
o
C with the enzyme followed by the 
addition of the substrate. Initial rate assays are performed at 37 
o
C using a Jasco V-
530 double beam Spectrophotometer. The absorbance value at 412 nm is recorded for 
5 min and enzyme activity is calculated from the slope of the obtained linear trend. 
Assays are carried out with a blank containing all components except AChE to 
account for the non-enzymatic reaction. The reaction rates are compared and the 
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percent inhibition due to the presence of tested inhibitors is calculated. Each 
concentration is analysed in triplicate, and IC50 values are determined graphically 
from log concentration-inhibition curves (GraphPad Prism 4.03 software, GraphPad 
Software Inc.). Tacrine is used as a standard inhibitor. 
Molecular docking 
Docking simulations of compounds 3 and 4 are carried out according to the method 
described previously.
37
 The energy minimized structure of compounds 3 and 4 is 
sketched with ChemDraw Ultra (2D and 3D). The coordinates of compound 3 and 4 is 
checked using PRODRG program
38
 for generating molecular topologies. The three-
dimensional structures of target protein function as a receptor (PDB: 1EVE) and is 
retrieved from the protein data bank. All the heteroatoms coupled with proteins 
including water molecules, bound ligands and any co-crystallized solvent are 
discarded from the PDB file and the missing assignments like proper bonds, bond 
orders, hybridization and charges were assigned using the Molegro Virtual Viewer.
39
 
PATCHDOCK,
40
 iGEMDOCK
41
 and Acceryl Discovery Studio 4.0 Client
42
 are 
employed to evaluate the molecular docking, energy profile and visualization of 
compounds-receptor interactions, respectively. 
In vivo cytotoxicity assay of plant extracts 
Brine shrimp lethality bioassay is commonly used in the bioassay for the bioactive 
compounds.
43
 The in vivo cytotoxicity assay is performed on brine shrimp nauplii 
(Artemia salina) in accordance with the Meyer method.
26 
The egg of brine shrimp are 
hatched in a tank filled with artificially prepared sea water (brine, 3.8% NaCl) 
exposed to incandescent light. Air is supplied at the bottom of the tank with the help 
of air supplier fitted with tube to keep the shrimps in uniform motion. The assay is 
performed 24 h after hatching and no food supplement is given during the hatching 
and experimental periods. A test sample (5.0 mg) is dissolved in 1 mL DMSO to 
obtain stock solution of 5 mg/mL. Different concentrations of test samples are 
obtained from stock solution and placed in separate vials, and the volume of each vial 
is made up to 5 mL with brine to obtain the desired final concentrations (10, 20, 40, 
60 and 80 µg/mL). The negative control is prepared in the same manner without the 
samples. Vincristine sulphate is used as a standard anti-cancer drug. Thirty brine 
shrimp nauplii are then placed in each vial. After 24 h of incubation, the vials are 
observed using a magnifying glass, and the number of survivors in each vial are 
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counted and noted. The LD50 values are calculated using the plot of percentage of 
mortality versus logarithm of concentration. All tests are performed in triplicate and 
expressed as mean. 
 
CONCLUSION 
The present chapter reports the phytochemical analysis of Clutia lanceolata leaves 
and its biological activity. This is first report of the isolation of these four compounds 
from the ethanolic extract of Clutia lanceolata leaves viz. 3,4-dihydroxy-2-
methylbenzoic acid (1), 2,2'-dihydroxy-1,1'-binaphthyl (2), 1,3,8-trihydroxy-6-
methylanthracene-9,10-dione (3) and 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl) 
hepta-1,4,6-trien-3-one (4). Molecular structure of compound 2 and 4 is authenticated 
unambiguously by X-ray crystallography and DFT studies. All the isolated 
compounds (1-4) show significant activity for acetylcholinesterase enzyme inhibition 
assay, however, compound 3 and 4 show potent enzyme inhibition among the isolated 
compounds. Molecular docking study validates the binding pattern and extent of 
binding of compound 3 and 4 with the target enzymes. The alcoholic and aqueous 
extracts of leaves are screened for in vivo cytotoxicity assay and shows significant 
cytotoxic activity. 
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INTRODUCTION 
Over the years, coumarins have been established as the well-known naturally 
occurring oxygen containing heterocyclic compounds isolated from various plant 
sources as well synthesized chemically.
1
 They are structural subunits in many 
complex natural products and exhibit wide spectrum of pharmacological activities 
such as antitumor,
2
 anti-HIV (NNRTI),
3
 antioxidant,
4
 tumor necrosis factor-α (TNF-
α) inhibition,5 antimicrobial activity,6 anti-inflammatory, antipyretic,7 antibacterial,8 
antifungal,
9
 serine protease inhibition
10
 and anticancer activities.
11
 The studies have 
also shown that naturally occurring as well as the chemically synthesized coumarin 
analogues exhibit potent acetylcholinesterase (AChE) inhibitory activity.
12-14
 
Furthermore, functionalization of the coumarin nucleus has led to the development of 
novel analogues that are capable of inhibiting amyloid-beta (Aβ) aggregation.15 The 
recognition of key structural features within coumarin template has helped in 
designing and synthesizing new analogues with improved AChE inhibitory activity 
and additional pharmacological activities including β secretase (BACE) inhibition 
associated with decreased Aβ deposition,16 monoamine oxidase (MAO) inhibition17 
and 15-lipoxygenase inhibition.
18
 Preliminary studies by employing Torpedo 
californica AChE revealed that coumarin and its derivatives are capable of interacting 
and inhibiting AChE by binding to peripheral anionic binding site (PAS) in a 
reversible manner.
19
 This led the scientists to make modifications in coumarin moiety 
to develop potent AChE inhibitors for managing Alzheimer’s disease (AD).20 
The synthesis of coumarin derivatives has previously been achieved by the use 
of various methods reported in the literature including the Pechmann,
21
 Perkin,
22
 
Knoevenagel,
23
 Claisen,
24
 Reformatsky
25
 and Wittig reactions.
26
 However, quest to 
achieve higher efficiency of reactions in terms of product yield, reaction time and 
mild reaction conditions paved way to design different protocol for the synthesis of 
coumarin derivatives incorporating numerous catalysts under varied reaction 
conditions. 
Ghosh and Das
27
 has developed a green, efficient and facile protocol for the 
synthesis of a series of benzylamino coumarin derivatives by the reaction of 4-
hydroxycoumarin, cyclic secondary amine and aromatic aldehyde in aqueous media in 
the presence of nano crystalline ZnO at room temperature. 
 Catalysis Letters, 2014, 144, 2091-2106
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Ar = (a) C6H5; (b) 3-NO2C6H4; (c) 3-OMeC6H4; (d) 4-pyridyl; (e) 4-NO2C6H4; 
(f) 4-MeC6H4; (g) 4-OMe,3-OHC6H3; (h) 2,3-(OMe)2C6H3 
Khoobi et al.
28
 reported simple and convenient microwave-assisted method for 
the synthesis of 3-substituted coumarin derivatives from the reaction of o-
aminothiophenol derivatives with 3-acetly and 3-cyanocoumarins in the presence of 
catalytic amount of heteropoly acids (HPMo, 5 mol%) and ethanol. 
 
 a b c d e f 
R  = H H 8-OMe 6-Br 6-OH 7-OH 
Rʹ = H Cl H H H H 
 
 
 a b c d e 
R  = H 8-OH H 6-Br 7-OH 
Rʹ = H H Cl H H 
 
Khurana and Kumar
29
 outlined the simple and efficient procedure using 
tetrabutylammonium bromide (TBAB) as catalyst for the synthesis of 
dihydropyrano[c]chromene derivatives in water and solvent-free neat conditions. 
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R = (a) C6H5; (b) 4-ClC6H4; (c) 4-BrC6H4; (d) 3-ClC6H4; (e) 4-NO2C6H4; 
(f) 4-CH3C6H4; (g) 2,4-Cl2C6H3; (h) 4-FC6H4; (i) 4-(CH3)2NC6H4; (j) 4-OHC6H4; 
(k) 4-OCH3C6H4; (l) -CH=CH-C6H5; (m) 4-(CH3)2CHC6H4; (n) 1-naphthyl 
 Rao and co-workers
30
 carried out the synthesis of series of α-benzylamino/ aryl 
indole coumarins by InCl3 catalysed three component reactions of 4-hydroxy 
coumarin, aromatic aldehyde and secondary amine/ indole in the presence of toluene 
and reported to obtained good yields. 
 
R = (a) H; (b) 4-Cl; (c) 4-NO2 (d) 4-CH3; (e) 4-Br; (f) 2-NO2 
Khan et al.
31
 documented the synthesis of a wide variety of substituted 
pyrido[2,3-c] coumarin derivatives accomplished from 3-aminocoumarins, aromatic 
aldehydes, and alkynes in the presence of  molecular iodine (10 mol%) as a catalyst in 
acetonitrile under reflux conditions through one-pot Povarov reactions.  
 
R
1
 = H/ Br/ OMe; R
2
 = H/ Cl/ Br/ F/ Me/ OMe/ CN/ NO2; Ar = -C6H5/ 4-CH3C6H4-/ 
4-tert-Bu-C6H4-/ 3,4-(CH3)2C6H3-/ 3,5-(CH3)2C6H3-/ 1-naphthyl 
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Bagdi and co-workers
32
 carried out efficient synthesis of pyrano[3,2-
c]coumarins by copper(II) triflate catalyzed tandem reaction of 4-hydroxycoumarin 
with α,β-unsaturated carbonyl compounds in high yields. The catalytic reaction 
proceeded very smoothly under solvent free conditions and showed high 
regioselectivity. 
 
R
1 
= C6H5/ 4-MeC6H4/ 4-OMeC6H4/ 2-NO2C6H4/ 4-NO2C6H4/ 4-ClC6H4 
R
2
 = C6H5/ 4-MeC6H4/ 4-ClC6H4 
Karami et al.
33
 outlined the mechanistic steps involved in the simple one pot 
synthesis of new pyrano[2,3-h]coumarin derivatives by the reaction between 5,7-
dihydroxy-4-substituted coumarin, malononitrile, and aromatic aldehydes in the 
presence of a catalytic amount of K2CO3 as a basic catalyst. 
 
Ar = (a) C6H5; (b) 4-ClC6H4; (c) 3-NO2C6H4; (d) 3-BrC6H4; (e) 4-MeC6H4;  
(f) 3,4-Cl2C6H3; (g) 4-OMeC6H4; (h) 3-ClC6H4;  (i) 2-OMeC6H4;  (j) 3-ClC6H4;  
(k) 4-NO2C6H4 
Zhang et al.
34
 described the efficient protocol for the synthesis of bioactive 
coumarin derivatives via palladium-catalysed base-accelerated ortho-selective C-H 
alkenylation of phenols. The reaction condition was mild and the substrate scope was 
broad with both electron-neutral and electron-deficient phenols.  They showed that the 
C-H bond activation occurred through direct metallation pathway rather than the 
Friedel-Crafts pathway in their mechanistic studies. 
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R = (a) H; (b) 4-CH3; (c) 4-Bu
t
; (d) 4-Ph; (e) 4-NO2; (f) 4-OMe; (g) 4-F; (h) 4-Cl;  
(i) 4-Br; (j) 4-Ac; (k) 4-CHO; (l) 4-COOPr
n
; (m) 3-CH3; (n) 3-OMe; (o) 3-CF3;  
(p) 2-CH3; (q) 2-F; (r) 3,4-(CH3)2; (s) 3-CH3,4-Cl; (t) 2-Cl,4-CH3 
Potdar et al.
35
 used 1-Butyl-3-methylimidazolium chloroaluminate, 
[bmim]Cl.2AlCl3 ionic liquid as an alternative to conventional acid catalysts in the 
Pechmann condensation of phenols with ethyl acetoacetate leading to the formation of 
coumarin derivatives. This ionic liquid played the dual role of solvent and Lewis acid 
catalyst providing a quick and efficient route for the synthesis of coumarins. 
 
R = (a) 3-OH; (b) 3-OMe; (c) 3-CH3,5-OH; (d) 2-CH3,3-OH, (e) 3,5-(OH)2; 
(f) 2,3-(OH)2; (g) H; (h) 3-OH,4-COCH3 
Kumar and co-workers
36
 carried out an efficient non-ionic surfactant (Triton X-
100) catalyzed multicomponent synthesis of novel benzylamino coumarin derivatives 
from secondary amines, aromatic aldehyde, and 4-hydroxy coumarin via Mannich 
type reaction in aqueous media. In this reaction, surfactant forms stable colloidal 
medium to stabilize iminium ion which undergoes nucleophilic addition of 4-hydroxy 
coumarin to give benzylamino coumarin in very good yields. 
 
R = (a) H; (b) 4-Cl; (c) 2-Br; (d) 2-NO2; (e) 3,NO2; (f) 4-OMe; (g) 2,4-(Cl)2; 
(h) 2-Cl; (i) 4-F 
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In recent years, the use of silica supported catalysts
37-40
 has received 
considerable attention due to growing environmental concerns as it simplify 
purification processes and also helps in preventing the discharge of toxic reaction 
residues into the environment. In this respect silica supported sulfuric acid (SiO2-
OSO3H) is an attractive candidate as it possesses environmentally benign properties 
such as non-toxicity, biocompatibility, recyclability, physiological inertness, 
inexpensiveness, and thermal stability. It is a well-known catalyst in organic synthesis 
and has been documented in several organic transformations.
41-45
 In light of these 
observations, we have synthesised a series of ester analogues of coumarin-3-
carboxylic acids (7-11) which are typically accessed via a facile esterification reaction 
between propargyl alcohol and appropriately substituted coumarin-3-carboxylic acids 
using silica supported sulfuric acid as the heterogeneous, environmentally benign 
solid acid catalyst. This new eco-friendly synthetic approach result in a noteworthy 
improvement in synthetic efficiency (89-94 % yield) of reaction, high purity, mild 
reaction conditions, cleaner reaction profiles and minimizing the production of 
chemical wastes without using highly toxic reagents for the synthesis. The 
synthesized compounds have been characterized by FT-IR, 
1
H NMR, 
13
C NMR, MS 
and elemental analysis. However, the structure of the compound 6 is also 
authenticated by single crystal X-ray crystallographic analysis. The encouraging 
bioactive score against enzymatic inhibition of the synthesized compounds prompted 
us to carry out acetylcholinesterase inhibition and the promising results are obtained. 
A computer-aided molecular docking study is also carried out to validate the specific 
binding mode of the newly synthesized compounds into the active site of receptor. 
 
RESULTS AND DISCUSSION 
In the present chapter a series of ester derivatives of coumarin (7-11) have been 
synthesized by stirring of coumarin-3-carboxylic acids (1-5) and propargyl alcohol (6) 
in presence of environmentally benign heterogeneous catalyst (SiO2-OSO3H) in 
dichloromethane at room temperature. This protocol offers several advantages over 
other existing synthetic methodologies in terms of yield, purity of products, 
operational procedures, reaction times, catalyst stability and recyclability. This 
synthetic scheme possesses diverse applicability and is compatible to a range of 
functional groups. In the context of the potential applications of heterocyclic 
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compounds against Alzheimer’s disease (AD), we have screened the synthesized 
compounds for the possible AChE inhibition studies which are further validated by 
computer-aided molecular docking studies. 
Characterization of the Catalyst (SiO2-OSO3H) 
The synthetic route for the synthesis of the catalyst (SiO2-OSO3H) employed in the 
present protocol has been shown in Scheme 1. The synthesized catalyst has been 
characterized by FT-IR, SEM-EDX and TEM analysis. The FT-IR spectrum of the 
catalyst is depicted in Fig. 1 and is recorded using the KBr disk technique. The FT-IR 
spectrum displays major peaks for silica (SiO2), as broad anti symmetric Si-O-Si 
stretching band from 1000 to 1200 cm
-1
 and symmetric Si-O-Si stretching at 801 cm
-1
. 
However, for sulphuric acid functional group, the FT-IR absorption range of the 
O=S=O asymmetric and symmetric stretching modes lies in 1120-1200 and 1020-
1090 cm
-1
, respectively and that of the S-O stretching mode appears at 659 cm
-1
. FT-
IR spectrum displays the overlap asymmetric and symmetric stretching bands of SO2 
with Si-O-Si stretching bands in the silica sulfuric acid. The spectrum also shows a 
broad stretching absorption peak at 3440 cm
-1
 for OH group. 
 
Scheme: 1 Synthetic pathway for the synthesis of catalyst 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 FT-IR spectrum of catalyst SiO2-OSO3H 
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SEM analysis of the catalyst is employed to study the surface morphology of the 
catalyst. An examination of SEM images (Fig. 2) shows that catalyst particles were of 
uneven shape and size, well distributed and no conglomeration of catalyst particles is 
found on the surface of the silica gel. The increased reactivity of sulfuric acid 
supported on silica material could be possibly due to the catalyst-support interactions 
and the resultant changes in the surface properties of the reactive sites. TEM image 
(Fig. 3) further shows uniform distribution of catalyst particles as black dots on the 
surface of silica, confirming the formation of the expected catalytic system. EDX 
analysis (Fig. 4) of the catalyst shows the presence of Si, S and O elements suggesting 
the formation of SiO2-OSO3H catalytic system. 
 
 
 
 
 
 
 
 
 
Fig. 2 SEM image of catalyst SiO2-OSO3H 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 TEM image of catalyst SiO2-OSO3H 
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Fig. 4 Energy dispersive X-ray (EDX) analysis of catalyst SiO2-OSO3H 
Chemistry 
The synthetic pathway of a series of ester derivatives of coumarin (7-11) is shown in 
Scheme 2. Herein series of compounds are typically accessed via a facile 
esterification reaction of substituted coumarin-3-carboxylic acids (1-5) and propargyl 
alcohol (6). All the compounds are obtained in excellent yields (89-94 %) with high 
purity. The structural elucidation of the synthesized compounds (7-11) is established 
on the basis of elemental analysis, IR, 
1
H NMR, 
13
C NMR and MS studies. The 
molecular structure of compound (7) is further supported by single crystal X-ray 
analysis. The analytical results for C, H and N are within ± 0.3 % of the theoretical 
values. Mass spectral analysis is also in agreement with the proposed structure of the 
compounds. The FT-IR spectrum of compound 7 (Fig. 5) displays characteristic peaks 
for α-pyrone carbonyl of coumarin nucleus, ester carbonyl and acetylenic group 
(C≡C), resonating at around 1717, 1742 and 2116 cm-1, respectively. The resonating 
peak at 3232 cm
-1
 is attributed to C-H stretching frequency of alkyne group. The 
1
H 
NMR spectrum  of compound 7 (Fig. 6) displays a sharp singlet at δ 8.81 for one 
proton is attributed to vinylic proton (H-4) of coumarin nucleus, this prominent 
downfield shift displays by H-4 protons is attributed to their hydrogen bonding with 
adjacent ester carbonyl oxygen. A sharp singlet and a doublet peak, integrating for 
one and two protons each, resonating at δ 3.31 and 4.93 is ascribed to acetylenic (H-
3ʹ) and methyleneoxy (H-1ʹ) protons, respectively. Besides, the multiplet resonating at 
around δ 7.37-7.92 has been assigned to the aromatic ring protons. 13C NMR 
spectrum (Fig. 7) of the compound displays characteristic absorption bands resonating 
at around δ 155.8, 163.5, 52.6, 78.3 and 78.7 are ascribed to carbonyl moiety of 
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coumarin nucleus, ester carbonyl, methyleneoxy carbon (C-1ʹ) and acetylenic carbons 
(C-2ʹ/C-3ʹ), respectively. In addition to this, a series of signals emerging at around δ 
114.2-134.8 are attributed to coumarin ring carbons. The detailed spectral 
characterization of all the synthesized compounds has been discussed in the 
experimental section. 
In order to develop eco-friendly approach, we have explored efficacy of silica 
supported sulfuric acid (SiO2-OSO3H) by carrying out the reaction of propargyl 
alcohol with a variety of substituted coumarin-3-carboxylic acids in equimolar ratio 
(1:1), at room temperature. The reaction proceeded smoothly and resulted in the 
formation of corresponding products (7-11) in excellent yields (89-94 %) within (1.5-
2 h) as monitored by TLC (Table 1). 
 
R = H (1, 7); OH (2, 8); OCH3 (3, 9); N(C2H5)2 (4, 10); NH2 (5, 11) 
Scheme 2 Synthetic pathway for the synthesis of coumarin ester derivatives (7-11) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 FT-IR spectrum of compound 7 
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Fig. 6 
1
H NMR spectrum of compound 7 
 
Fig. 7 
13
C NMR spectrum of compound 7 
 
 
Chapter-4 
99 
 
Table 1 Silica supported sulfuric acid (SiO2-OSO3H) catalysed synthesis of coumarin 
ester derivatives (7-11) 
S. 
No. 
Reactants Products Time 
(h) 
Yield 
(%) 
 
1 
 
 
 
2 
 
93 
 
2 
  
 
1.5 
 
90 
 
3 
  
 
1.5 
 
94 
 
4 
  
 
2 
 
91 
 
5 
  
 
2 
 
89 
 
X-ray crystallographic study of compound 7  
Compound 7 once isolated found to be air-stable and soluble in all common organic 
solvents but insoluble in water. X-ray crystallographic analysis reveals that compound 
7 crystallizes in the monoclinic structure with space group P21/c. The asymmetric 
unit of compound 7 is shown in Fig. 8, while the crystal data and structure refinement 
parameters are summarized in Table 2. 
Table 2 Crystallographic data and structure refinement of compound (7) 
Compound 7 
Empirical formula C13H8O4 
Formula weight 228.19 
Crystal system Monoclinic 
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Space group P21/c 
a (Å) 6.7877(10) 
b (Å) 17.374(2) 
c (Å) 9.4835(14) 
α (o) 90 
β (o) 110.642(3) 
γ (o) 90 
Volume (Å
3
) 1046.6(3) 
Z 4 
Calculated density, ρcalc. (mg m
-3
) 1.448 
Absorption coefficient , µ (mm
-1
) 0.109 
F(000) 472 
Refl. Collected 6504 
Independent refl. 2067 
GOF 1.092 
Final R indices R1 = 0.0498
a
 
[I > 2σ(I)] wR2 = 0.1398
b
 
R indices R1 = 0.0779 
(all data) wR2 = 0.2166 
a
 R1 = ∑||Fo| - |Fc||/∑|Fo| with Fo
2 
 > 2σ(Fo
2
).  
b
 wR2 = [∑w(|Fo
2
| - |Fc
2
|)
2/ ∑|Fo
2
|
2
 ]
1/2
. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 Asymmetric unit showing thermal ellipsoid (50%) plot of compound 7 
 
 
Chapter-4 
101 
 
Reaction mechanism 
The probable mechanistic pathway for the SiO2-OSO3H catalysed synthesis of ester 
derivatives of coumarin (7-11) has been proposed in Scheme 3. The Lewis acidity of 
the catalyst probably plays a key role in the esterification process of coumarin-3-
carboxylic acids. It is believed that the reaction is initiated with the protonation of 
carboxylic acid by catalyst which activates the carbonyl group and thus generating an 
electrophilic centre. The lone pair of electron present on oxygen of proargyl alcohol 
easily attacks the carbonyl carbon and form the C-O linkage. The next step involves 
the removal of water molecule leading to the formation of target compounds with the 
regeneration of the catalyst. 
 
 
Scheme 3 Plausible mechanistic catalytic loop for the synthesis of compounds (7-11) 
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Optimization of reaction conditions 
In order to probe the best reaction conditions for the present protocol, an optimization 
study including amount of catalyst, effect of solvent and investigating efficiency of 
various catalyst is performed on a selected model reaction using coumarin-3-
carboxylic acid (1, 1 mmol) and propargyl alcohol (6, 1 mmol). To achieve the 
optimum concentration of the (SiO2-OSO3H) catalyst, the model reaction is carried 
out with varying amounts of catalyst stirring at room temperature in dichloromethane 
(Table 3). The model reaction is primarily, tested in absence of catalyst, it is found 
that reaction takes prolonged time for completion with meagre yield. It can be inferred 
from table that 2.5 mol% of the catalyst is sufficient to get optimum yield in shorter 
reaction time (entry 6). Using less than 2.5 mol% catalyst (i.e. 0.5, 1.0, 1.5 and 2.0 
mol%) moderate yield of the product (65-85 %) is obtained with higher reaction time, 
while with excess mol% of catalyst (3.0 mol%) there is no further increment observed 
in the yield of the product probably due to the saturation of the catalyst surface. 
 
Table 3 Effect of catalyst loading on the yield and reaction time of model reaction
a
 
Entry Catalyst (mol %) Time (h)
b
 Yield (%)
c
 
1 0 13 47 
2 0.5 7 65 
3 1.0 6 73 
4 1.5 4 81 
5 2.0 3 85 
6 2.5 2 93 
7 3.0 2 93 
a
Reaction condition: coumarin-3-carboxylic acid (1,1mmol), propargyl alcohol (6,1mmol), 
stirring at room temperature, solvent DCM; 
b
Reaction Progress monitored by TLC; 
c
Isolated 
yield of products 
 
In order to study the solvent effect, the model reaction is carried out in different 
solvent systems (Table 4). The reaction is initially, tested under solvent-free 
condition by grinding method, however only traces of product are obtained (entry 1). 
When the reaction is performed in CH3OH and CH3CH2OH, moderate yield of the 
products are obtained after prolonged reaction time (entry 5, 6). This can be attributed 
to the nucleophilic nature of these solvents, due to presence of lone pair of electrons 
on oxygen atom. Thus, nucleophilic competition between these solvents (MeOH, 
EtOH) and propargyl alcohol for electrophilic carbonyl carbon of acid will eventually 
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resulted in low yield of desired product. Whereas in acetic acid, reaction again takes 
longer time period (entry 4) but there is an improvement in yield, probably 
CH3COOH facilitates the formation of carbocation by activating the carbonyl group 
of coumarin acid, thus enhances the electrophilicity of carbonyl carbon, rendering it 
more feasible for nucleophilic attack. However, there is noteworthy improvement in 
the yield when tetrahydrofuran (THF) is used as a solvent (entry 3). When the 
reaction is carried out in CH2Cl2 (entry 2), the yield of the product improves 
significantly in shorter time period. 
 
Table 4 Effect of various solvents on model reaction
a 
Entry Solvent Time (h)
b
 Yield (%)
c
 
1 Solvent free
d
 - Traces 
2 CH2Cl2 2 93 
3 THF 5.5 73 
4 CH3COOH 7 67 
5 CH3OH 9 63 
6 CH3CH2OH ˃ 10 54 
a
Reaction condition: Coumarin-3-carboxylic acid (1,1mmol), propargyl alcohol (6,1mmol), 
catalyst (2.5 mol%), different solvents (20 mL), stirring at room temperature; 
b
Reaction 
Progress monitored by TLC; 
c
Isolated yield of products; 
d
Solvent free by grinding method 
 
A comparative study of variety of silica supported catalysts is conducted to 
confirm the superiority of silica-sulfuric acid as a heterogeneous acid catalyst (Table 
5). The model reaction is initially conducted in absence of catalyst, the reaction takes 
prolonged time and yield is less than 50 % (entry 1). When the model reaction is 
investigated with different heterogeneous catalysts such as NaHSO4-SiO2, NH4OAc-
SiO2, P2O5-SiO2 and NH2SO3H-SiO2, the reaction takes extended time period and also 
yields are not satisfactory (entry 4-7). It is found that the yield of the product 
increased significantly when HClO4-SiO2 is added to the model reaction, probably 
due to its facile proton release which catalyses the reaction (entry 3). However, there 
is noteworthy improvement in the yield obtained with reduced reaction time when 
SiO2-OSO3H is employed as a catalyst (entry 2). 
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Table 5 Comparison of catalytic activity of different catalysts on the model reaction
a
 
Entry Catalyst Time (h)
b
 Yield (%)
c
 
1 ------- 13 47 
2 SiO2-OSO3H 2 93 
3 SiO2-HClO4 5 70 
4 SiO2-NaHSO4 7 63 
5 SiO2-NH4OAc 6 67 
6 SiO2-P2O5 8.5 59 
7 SiO2-NH2SO3H 8 55 (Impure) 
a
Reaction condition: coumarin-3-carboxylic acid (1,1mmol), propargyl alcohol (6,1mmol), 
stirring at room temperature, different catalysts (2.5 mol%), solvent DCM; 
b
Reaction 
Progress monitored by TLC; 
c
Isolated yield of products. 
 
Reusability of the catalyst 
The reusability of the silica-sulfuric acid catalyst is also examined on model reaction. 
The results demonstrate that catalyst can be reused five more cycles as such without a 
significant loss in yield (Table 6). After the first fresh run with 93 % yield, the 
catalyst is removed by filtration. The recovered catalyst is dried under vacuum at 120 
o
C for 10 h and tested up to five more reaction cycles. Recycling and reuse of the 
catalyst shows minimal decreases in yields. The product is obtained in 90, 88, 85, 81, 
81 % yields after successive cycles (entries 2-6), thus proving the catalyst’s 
reusability. To ascertain the variation in morphological features of the recovered 
catalyst, we carry out its SEM-EDX analysis. It is observed that there is no significant 
changes in the morphology of the catalyst (Fig. 9a) noticed as compared to the fresh 
catalyst and also the composition of the catalytic system is almost consistent with that 
of the fresh catalyst (Fig. 9b). 
Table 6 Reusability of the catalyst for the model reaction
a
 
Entry Reaction Cycle Isolated yield (%)
b
 
1 1
st
 (Fresh run) 93 
2 2
nd
   cycle 90 
3 3
rd
   cycle 88 
4 4
th
   cycle 85 
5 5
th
   cycle 81 
6 6
th
   cycle 81 
a
Reaction condition: coumarin-3-carboxylic acid (1,1mmol), propargyl alcohol (6,1mmol), 
stirring at room temperature, catalyst (2.5 mol%), solvent DCM; 
b
Isolated yield of products. 
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Fig. 9 (a) SEM and (b) EDX spectrum of recovered catalyst 
Molecular Properties Prediction and Drug-Likeness Results 
The prediction of absorption, distribution, metabolism and excretion (ADME) 
properties of the parent coumarin-3-carboxylic acid (1) and synthesized compounds 
(7-11) are calculated to depict molecular properties essential for a drug 
pharmacokinetics in the human body. The physicochemical parameter such as Polar 
surface area (TPSA), MilogP, number of hydrogen bond donor and acceptor atoms, 
number of rotatable bonds, molecular volume and violations of Lipinski’s rule of five 
are premeditated using Molinspiration online property calculation toolkit. Basically, 
Molinspiration is a cheminformatic software tool which computes the molecular 
properties of any chemical structure as well as bioactivity score for the most 
important drug targets such as GPCR ligands, ion channel ligand, kinase inhibitors, 
nuclear receptor ligand, protease inhibitor and enzyme inhibitor. Membrane 
permeability and bioavailability are associated with some basic molecular descriptors 
such as partition coefficient (MiLogP), molecular weight (MW), hydrogen bond 
acceptors (HBA) and hydrogen bond donors (HBD) count in a molecule. Moreover, 
number of rotatable bonds is also important to predict the conformational changes and 
flexibility for binding with receptor or channels. The TPSA is a signifier for the 
anticipation of passive molecular transport through membranes. The combined 
parameters, TPSA and molecular volume are inversely proportional to percentage 
absorption (% ABS) and predict the nature of transport properties of drugs in the 
intestines and blood-brain barrier crossing. All the synthesized compounds (7-11) 
shows zero violations of Lipinski’s ‘‘Rule of Five’’ which indicates their presence for 
bioavailability. The molecular lipophilicity potential (MLP) map and polar surface 
areas (TPSAs) of compounds are shown in Fig. 10 and Table 7. On the close 
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inspection of Table 7, all the synthesized compounds are found in good agreement 
with Lipinski’s rules for new chemical entity to have good oral bioavailability with no 
violations. The MilogP values of all the compounds is found within the range of 
0.986-2.764 (<5), suggesting that these will be soluble in aqueous solution and hence 
will be able to gain access to membrane surfaces. Moreover, the values of TPSA are 
with the limit i.e. 82 Å, indicating a good permeability of the drug in the cellular 
plasma membrane. The upper limit for TPSA for a molecule to penetrate the brain is 
around 90 Å. 
The bioactivity score is also calculated for GPCR ligand, ion channel ligand, 
kinase inhibitor, nuclear receptor ligand, protease inhibitor and enzyme inhibitor. For 
an average drug the probability is, if the bioactivity score is more than 0.00 then it is 
active, if - 0.50 to 0.00 then moderately active and if less than - 0.50 then inactive. On 
comparing the relative bioactivity scores of tacrine with synthesized compounds (7-
11) for various classes, all the compounds display moderate to better results towards 
enzyme inhibition as evident from the Table 8, where compound 11 exhibits 
promising bioactivity score in comparison to other synthesized compounds. The 
standard drug tacrine shows highest bioactivity score 0.43 towards enzyme inhibition 
followed by compounds 11 > 8 > 9 = 7 > 10. We have also compared the bioactivity 
score of the synthesized compounds (7-11) with the parent coumarin acid (1). The 
results obtain suggests that the parent coumarin acid (1) displays lowest bioactivity 
score (-1.21) towards enzyme inhibition. Thus, it is concluded that the appending of 
propargyl group to the coumarin acids enhances their enzyme inhibition potency. 
Table 7 Drug likeness score for synthesized compounds (7-11) 
Compound MW 
(g/mol) 
miLogP
a
 TPSA
b
 HBD
c
 HBA
d
 RB
e
 n 
violation 
1 190.154 1.514 67.51 1 4 1 0 
7 228.203 1.934 56.516 0 4 3 0 
8 224.202 1.43 76.744 1 5 3 0 
9 258.229 1.966 65.75 0 5 4 0 
10 299.326 2.764 59.754 0 5 6 0 
11 243.218 0.986 82.539 2 5 3 0 
(Tacrine) 
Standard 
198.269 3.05 38.915 2 2 0 0 
a
Calculated octanol/water partition coefficient; 
b
Molecular polar surface area; 
c
Number of 
hydrogen-bond donors; 
d
Number of hydrogen-bond acceptors 
e
Number of rotatable bonds 
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Fig. 10 3D sketch of the compounds (7-11) with molecular lipophilicity (Left Side) 
and polar surface pockets (Right Side) showing the most lipophilic area (pink color), 
intermediate lipophilic area (green color), most hydrophobic area (blue color), 
nonpolar area (gray white color) and polar area (red color). 
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Table 8 Bioactivity score of the synthesized compounds (7-11) 
Compound GPCR 
ligand 
Ion 
channel 
ligand 
Kinase 
inhibitor 
Nuclear 
receptor 
ligand 
Protease 
inhibitor 
Enzyme 
inhibitor 
1 -1.03 -0.84 -1.21 -0.42 -0.76 -0.18 
7 -0.73 -0.67 -0.94 -0.24 -0.64 -0.11 
8 -0.61 -0.61 -0.78 0.05 -0.57 0.00 
9 -0.64 -0.73 -0.79 -0.10 -0.58 -0.11 
10 -0.39 -0.57 -0.58 0.10 -0.37 -0.12 
11 -0.62 -0.56 -0.74 -0.24 -0.47 0.02 
(Tacrine) 
Standard 
-0.11 0.36 -0.37 -0.93 -0.59 0.43 
Active = Score more than 0.00; Moderately active = Score between -0.50 to 0.00; Inactive = 
Score less than -0.50. 
In vitro acetylcholinesterase inhibition results 
The parent coumarin-3-carboxylic acid (1) and all the synthesized compounds (7-11) 
substituted with different groups are analysed for AChE inhibition activity. It can be 
inferred from the data shown in Table 9, that compound 11, exhibits the strongest 
inhibition to AChE with an IC50 value of 0.21 µM, followed by compound 8 (IC50 = 
0.24 µM), 9 (IC50 = 0.33 µM), 7 (IC50 = 0.35 µM) and 10 (IC50 = 0.54 µM). The result 
shows that all the tested compounds display significant AChE inhibitory activity 
except compound 10. On close examination of the data reported in Table 9, it can be 
observed that the substituent at C-7 position of the coumarin nucleus inflict prominent 
effect on the AChE inhibition. When the hydrogen atom at C-7 position in compound 
7 (IC50 = 0.35 µM) is replaced by OH group (compound 8), there is significant 
increase in the AChE inhibitory activity by ± 0.11 value. The replacement of 
hydrogen atom at C-7 by methoxy (OCH3) group in compound 9, leads to a slight 
increase in the activity by ± 0.02 value. However when the same hydrogen atom is 
replaced by diethyl amine N(CH3CH2)2 group in compound 10, there is prominent 
decrease in AChE activity by ±0.19 value. This significant dip in activity of 
compound 10 is probably due to the bulky substituent N(CH3CH2)2 at C-7 position of 
coumarin nucleus which restricts it to fit better inside the cavity of AChE. It is 
observed that the substitution of hydrogen atom of compound 7 by amine (NH2) 
group in compound 11, exceptionally enhances the AChE activity by ±0.14 value with 
IC50 value of 0.21 µM almost comparable to standard drug tacrine (IC50 = 0.19 µM). 
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In order to study the effect of appended propargyl group in coumarin esters (7-11) on 
the AChE activity, we have also analysed parent coumarin-3-carboxylic acid (1) for 
AChE inhibition. It can be inferred from the data reported in the Table 9, that there 
has been prominent increase in AChE inhibition of compound 7 by appending 
propargyl group to the parent coumarin-3-carboxylic acid (1) by ±0.24 value. This 
suggests that incorporation of propargyl group inflict a noticeable effect on AChE 
inhibition. Thus, the nature of substituent and appended propargyl group in the 
synthesized coumarin esters (7-11) are believed to inflict effect on AChE activity. The 
results obtained are well supported by the docking studies.  
Table 9 Quantitative estimation of acetylcholinesterase inhibition activity of 
compounds (7-11) 
S. No. Compound Nature of Substituents 
(R) 
IC50 (µM)
a
 ± SEM
b
 for hAChE
c
 
inhibition 
1 1 ---- 0.59±0.01 
2 7 R=H 0.35±0.01 
3 8 R=OH 0.24±0.01 
4 9 R=OCH3 0.33±0.01 
5 10 R=N(CH3CH2)2 0.54±0.01 
6 11 R=NH2 0.21±0.01 
7 (Tacrine) 
Standard 
 0.19±0.01 
a
IC50 = Concentration of inhibitor required to decrease enzyme activity by 50%; 
b
SEM = 
Standard error of the mean; 
c
hAChE = Human recombinant AChE. 
Docking Studies 
Molinspiration calculations and prediction of molecular properties, values are within 
the limits, following Lipinski’s rule, fulfilling the requirements of solubility, low 
polar surface area and total hydrogen bond count are important predictors of good oral 
bioavailability. On the basis of lipophilicity, the synthesized compounds (7-11) are 
considered to be as oral drug/lead. The synthesized compounds are subjected to 
docking studies using Hex6.1, Discovery studio 4.0 Client and iGEMDOCK 
softwares to predict the binding mode of compounds towards target enzyme (PDB: 
4ey4). The docking studies and their scoring functions give crucial information 
regarding the orientation of the compounds and the strength of the non-covalent 
interaction (binding affinity) between molecules (ligand and receptor) in the binding 
pockets. On the basis of docking simulations, the strong binding affinity of compound 
11 with AChE can be explained on the basis of hydrogen bonding as well as 
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orientation and electronic features of the substituents towards the active site of the 
target enzyme Fig. 11f. The hydrogen bonds formed with amino acids of the protein 
shows good agreement with the predicted binding affinities obtained by molecular 
docking studies as verified by AChE inhibition activity data where compound 11 is 
found to be most potent AChE inhibitor (IC50 = 0.21 µM). The improved activity of 
the compound 11 in comparison to compounds 7, 8, 9 and 10 can be explained on the 
basis of its skeleton, that the presence of amine group at C-7 position of coumarin 
nucleus of compound 11, enhances activity due to the formation of additional 
hydrogen bonds with amino acid residues PHE 531 and ALA 377 of the protein and 
easily perform as guest relation with receptor protein (host) Fig. 11f. In addition to 
this, ester carbonyl in compound 11 displays hydrogen bonding interaction with the 
amino acid residue TRP 385. The docking studies reveal that the coumarin nucleus 
plays a major role in stabilizing the ligand-receptor complex by pi-cation interactions 
with amino acid residue of the target protein as shown in Fig. 11. Moreover, 
anticholinesterase activity of the target compounds reveals that inhibition properties 
depend largely on the steric hindrance, orientation and electronic features of the 
substituents towards the active site and the combined effect of these features can 
determine the activity of the compounds. This steric effect can be seen operative in 
case of compound 10 with bulky N(CH2CH3)2 substituent, rendering it less accessible 
to the active site of the target protein. Additionally, the π-π stacking interactions 
between the aromatic rings of coumarin nucleus with amino acid residues of the target 
enzyme further stabilizes the orientation of the molecule into the cavity of receptor as 
shown in Fig. 12. These extra interactions minimize the energy profile of the docked 
ligands and stabilize the position of ligands in the cavity of receptor (Fig. 13). 
Compound 7, 8, 9 and 10 display moderate profile of AChE inhibition. The AChE 
inhibition potency of compounds based on experimental biological assay is seen in the 
order: compound 11 > 8 > 9 > 7 > 10. The empirical scoring function of iGemDOCK 
is the estimated sum total of van der waals and H-bonding energies. From the 
combined table and chart shown in Fig. 13, it is obvious that compound 11 
demonstrates better affinity to receptor and shows maximum docking score as it is 
buried well inside the cavity of target protein. However, docking simulation of parent 
coumarin-3-carboxylic acid (1) displays poor interaction with the target protein thus 
authenticating the weak AChE inhibition properties with respect to its ester analogues.  
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Fig. 11 Available binding sites for parent coumarin acid (1) and compounds (7-11); 
UNK) and target enzyme (PDB: 4ey4) displaying various interactions with amino 
acids residues at active site of target protein (A = 3D active Site and B = 2D ligand- 
receptor interaction diagrams). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12 π-π interaction of compound 11 with amino acid residues PHE535 and 
HIS381 of target enzyme 
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Fig. 13 Estimated binding affinities of parent coumarin acid (1) and compounds (7-
11) based on docked poses within active site of target enzyme (PDB: 4ey4). 
 
EXPERIMENTAL 
Materials and general methods 
All the reagents are purchased from Merck and Sigma-Aldrich as ‘synthesis grade’ 
and used without further puriﬁcation. Human recombinant AChE (EC: 3.1.1.7) 
lyophilized powder is purchased from Sigma-Aldrich. The IR spectra are recorded 
with Shimadzu IR-408 Perkin-Elmer 1800 (FTIR) and its values are given in cm
-1
. 
1
H 
NMR and 
13
C NMR spectra are run in DMSO-d6 on a Bruker Avance-II 400 MHz 
instrument. The chemical shifts (δ) are reported in ppm relative to the TMS as internal 
standard. Mass spectra are recorded on a JEOL D-300 mass spectrometer. Melting 
points are determined on a Kofler apparatus and are uncorrected. Elemental analysis 
(CHN) is conducted using Carlo Erba analyzer model 1108. Thin layer 
chromatography (TLC) glass plates (20×5 cm) are coated with silica gel G (Merck) 
and exposed to iodine vapours to check the homogeneity as well as the progress of 
reaction. The scanning electron microscope (SEM-EDX) analysis is performed using 
a JEOL (JSM-6510) equipped with an energy dispersive X-ray spectrometer at 
different magnification and transmission electron microscope (TEM) results are 
recorded using JEOL (JEM-2100F) model. 
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Preparation of (SiO2-OSO3H) catalyst 
A 500 mL suction flask fitted with a constant pressure dropping funnel and a gas inlet 
tube for conducting HCl gas over an adsorbing solution (i.e. water). It is charged with 
silica gel (60.0 g), and chlorosulphonic acid (23.3 g, 0.2 mol) is added drop wise over 
a period of 30 minutes at room temperature, evolution of profuse amounts of HCl 
occurred instantaneously. After the addition is completed the mixture is stirred for 30 
minutes. A white solid of silica-sulfuric acid is obtained.
42
 The various catalysts i.e. 
HClO4-SiO2,
46a
 NaHSO4-SiO2,
46b
 NH4OAc-SiO2,
46c
 P2O5-SiO2
46d
 and NH2SO3H-
SiO2
46e
 used for the comparative study with respect to silica-sulfuric acid have been 
synthesized according to the previously published standard procedures. 
General method for the synthesis of prop-2-ynyl derivatives of substituted 
coumarin-3-carboxylic acids 
Silica supported sulfuric acid (2.5 mol%) is added to the mixture of substituted 
coumarin-3-carboxylic acids (1-5, 1mmol) and propargyl alcohol (6, 1mmol), in 
dichloromethane (20 mL) and then the reaction mixture is allowed to stir at room 
temperature for 1.5-2 hrs. During stirring, the clear solution of reaction mixture 
begins to turn thick and solid product is precipitated. After completion of the reaction 
as evident from TLC, the solid product is filtered and washed with hot methanol to 
recover the catalyst. The filtrate containing soluble product is evaporated under 
reduce pressure to obtain crude product. The crude product obtained is crystallized 
from chloroform-methanol to afford the pure product. 
Spectral characterization of synthesized compounds (7-11) 
Prop-2-yn-1-yl-2-oxo-2Hchromene-3-carboxylate (7) 
Colourless crystals;
47
 Yield: 93%, mp: 163°C; Anal. Calc. for C13H8O4; C, 68.42; H, 
3.53; found: C, 68.44; H, 3.54. IR (KBr, νmax, cm
-1
): 2116 (C≡C), 1742 (C꞊O, ester), 
1717 (C꞊O, α-pyrone), 1616, 1562 (C꞊C). 1H NMR (400 MHz, DMSO-d6, δ, ppm): 
8.81 (s, 1H, H-4), 7.86-7.92 (m, 1H, H-8), 7.69-7.75 (m, 1H, H-5), 7.37-7.41 (m, 2H, 
H-6, H-7), 4.92-4.93 (d, 2H, H-1ʹ), 3.31 (s, 1H, H-3ʹ). 13C NMR (100 MHz, DMSO-
d6, δ, ppm): 163.5 (C꞊O, ester), 155.8 (C꞊O, α-pyrone), 154.7 (C-8a), 134.8 (C-7), 
130.5 (C-5), 124.9 (C-6), 117.6 (C-4), 116.7 (C-4a), 116.0 (C-8), 114.2 (C-3), 78.7, 
78.3 (C-2ʹ/C-3ʹ), 52.6 (C-1ʹ). MS (ESI) m/z: 228 [M+•]. 
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Prop-2-yn-1-yl-7-hydroxy-2-oxo-2H-chromene-3-carboxylate (8) 
Yellowish solid; Yield: 90%, mp: 245-246°C; Anal. Calc. for C13H8O5; C, 63.94; H, 
3.30; found: C, 63.95; H, 3.34. IR (KBr, νmax, cm
-1
): 3285 (OH), 2123 (C≡C), 1730 
(C꞊O, ester), 1710 (C꞊O, α-pyrone), 1605, 1561 (C꞊C). 1H NMR (400 MHz, DMSO-
d6, δ, ppm): 8.79 (s, 1H, H-4), 8.15 (s, 1H, OH), 7.89 (s, 1H, H-8), 7.52-7.48 (m, 1H, 
H-6), 7.45 (d, 1H, H-5), 4.63-4.64 (d, 2H, H-1ʹ), 3.12 (s, 1H, H-3ʹ). 13C NMR (100 
MHz, DMSO-d6, δ, ppm): 162.3 (C꞊O, ester), 160.9 (C꞊O, α-pyrone), 157.2 (C-7), 
154.4 (C-8a), 140.8 (C-5), 132.5 (C-6), 128.6 (C-8), 118.4 (C-4), 115.2 (C-4a), 114.7 
(C-3), 76.2, 75.5 (C-2ʹ/C-3ʹ), 51.4 (C-1ʹ). MS (ESI) m/z: 244 [M+•]. 
Prop-2-yn-1-yl-7-methoxy-2-oxo-2H-chromene-3-carboxylate (9) 
Colourless crystalline solid; Yield: 94%, mp: 176°C; Anal. Calc. for C14H10O5; C, 
65.12; H, 3.90; found: C, 65.15; H, 3.92. IR (KBr, νmax, cm
-1
): 2110 (C≡C), 1725 
(C꞊O, ester), 1712 (C꞊O, α-pyrone), 1615, 1564 (C꞊C), 1225 (C-O). 1H NMR (400 
MHz, DMSO-d6, δ, ppm): 8.52 (s, 1H, H-4), 7.78 (s, 1H, H-8), 7.51-7.55 (m, 2H, H-
5/6), 4.71 (d, 2H, H-1ʹ), 3.85 (s, 3H, -OCH3), 3.32 (s, 1H, H-3ʹ). 
13
C NMR (100 MHz, 
DMSO-d6, δ, ppm): 165.1 (C꞊O, ester), 160.2 (C꞊O, α-pyrone), 153.2 (C-7), 150.1 
(C-8a), 130.4 (C-5), 125.6 (C-6), 122.3 (C-8), 117.8 (C-4), 116.1 (C-4a), 113.4 (C-3), 
78.4, 76.8 (C-2ʹ/C-3ʹ), 56.1 (-OCH3), 53.3(C-1ʹ). MS (ESI) m/z: 258 [M
+•
]. 
Prop-2-yn-1-yl-7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate (10) 
Yellowish solid; Yield: 91%, mp: 190°C; Anal. Calc. for C17H17NO4; C, 68.21; H, 
5.72; N, 4.68; found: C, 68.22; H, 5.71; N, 4.67. IR (KBr, νmax, cm
-1
): 2120 (C≡C), 
1720 (C꞊O, ester), 1710 (C꞊O, α-pyrone), 1606, 1558 (C꞊C), 1277 (C-N). 1H NMR 
(400 MHz, DMSO-d6, δ, ppm): 8.12 (s, 1H, H-4), 7.43 (s, 1H, H-8), 7.31-7.35 (m, 
2H, H-5/6), 4.59 (d, 2H, H-1ʹ), 3.45 (q, 4H, N-CH2), 3.20 (s, 1H, H-3ʹ), 1.21 (t, 6H, -
CH3). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 164.1 (C꞊O, ester), 162.4 (C꞊O, α-
pyrone), 156.5 (C-8a), 149.3 (C-7), 127.4 (C-5), 124.5 (C-6), 123.0 (C-8), 118.8 (C-
4), 114.8 (C-4a), 113.4 (C-3), 78.7, 76.4 (C-2ʹ/C-3ʹ), 52.5 (C-1ʹ), 45.4 (2 × CH2), 12.3 
(2 × CH3). MS (ESI) m/z: 299 [M
+•
]. 
Prop-2-yn-1-yl-7-amino-2-oxo-2H-chromene-3-carboxylate (11) 
White solid; Yield: 89%, mp: 210°C; Anal. Calc. for C13H9NO4; C, 64.20; H, 3.73; N, 
5.76; found: C, 64.22; H, 3.71; N, 5.77. IR (KBr, νmax, cm
-1
): 3305 (NH2), 2130 
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(C≡C), 1735 (C꞊O, ester), 1715 (C꞊O, α-pyrone), 1598, 1553 (C꞊C), 1267 (C-N). 1H 
NMR (400 MHz, DMSO-d6, δ, ppm): 8.09 (s, 1H, H-4), 7.41 (s, 1H, H-8), 7.33-7.36 
(m, 2H, H-5/6), 5.07 (s, 2H, NH2, D2O exchangeable), 4.55 (d, 2H, H-1ʹ), 3.17 (s, 1H, 
H-3ʹ). 13C NMR (100 MHz, DMSO-d6, δ, ppm): 163.6 (C꞊O, ester), 161.7 (C꞊O, α-
pyrone), 155.2 (C-8a), 147.2 (C-7), 129.3 (C-5), 122.1 (C-6), 121.4 (C-8), 116.2 (C-
4), 114.3 (C-4a), 110.2 (C-3), 77.4, 76.2 (C-2ʹ/C-3ʹ), 50.4 (C-1ʹ). MS (ESI) m/z: 243 
[M
+•
]. 
Single crystal X-ray crystallographic studies of compound (7) 
Single crystal X-ray data of compound 7 is collected at 100 K on a Bruker SMART 
APEX CCD diffractometer using graphite monochromated MoKα radiation (λ = 
0.71073 Å). The linear absorption coefficients, scattering factors for the atoms and the 
anomalous dispersion corrections are taken from the International Tables for X-ray 
Crystallography.
48
 The data integration and reduction are carried out with SAINT 
software.
49
 Empirical absorption correction is applied to the collected reflections with 
SADABS and the space group was determined using XPREP.
50
 The structure is 
solved by the direct methods using SHELXTL-97 and refined on F2 by full-matrix 
least-squares using the SHELXL-97
51
 program package. All non-hydrogen atoms are 
refined anisotropically. Pertinent crystallographic data for compound 7 is summarized 
in Table 2. 
Computational Methods 
Molinspiration online database is used to calculate fourteen descriptors 
(www.molinspiration.com), which are logP, polar surface area, molecular weight, 
number of hydrogen bond donor, number of hydrogen bond acceptor, number of 
violation to Lipinski’s rule, number of rotatable bonds, volume, drug likeness includes 
G protein coupled receptor (GPCR) ligand, ion channel ligand, kinase inhibitor, 
nuclear receptor ligand, protease inhibitor and enzyme inhibitor, for all synthesized 
ligands. The method for calculation of MilogP is developed by Molinspiration 
(miLogP 2.2 - 2005) programme, based on group contributions. Group contributions 
have been obtained by fitting calculated logP with experimental logP for a training set 
of more than twelve thousands of drug-like molecules. Molecular polar surface area 
(TPSA) is calculated relied based on the published methodology,
52
 which is virtually 
a sum of fragment-based contributions. The maps of molecular lipophilicity potential 
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(MLP) and polar surface area (TPSA) are viewed in Molinspiration Galaxy 3D 
Structure Generator. 
In vitro acetylcholinesterase inhibition activity 
The ability of coumarin-3-carboxylic acid (1) and synthesized compounds (7-11) to 
inhibit AChE activity is assessed by Ellman’s method.53 AChE stock solution is 
prepared by dissolving human recombinant AChE (EC: 3.1.1.7) lyophilized powder 
(Sigma-Aldrich) in 0.1 M phosphate buffer (pH = 8.0) containing Triton X-100 
(0.1%). Five increasing concentrations of test compounds are assayed to obtain % 
inhibition of the enzymatic activity in the range of 20-80. The assay solution consisted 
of a 0.1 M phosphate buffer pH 8.0, with the addition of 340 µM 5,5'-dithio-bis(2-
nitrobenzoic acid), 0.02 unit/mL of human recombinant AChE from human serum and 
550 µM of substrate (acetylthiocholine iodide, ATCh). Increasing concentration of 
tested inhibitor were added to the assay solution and pre-incubated for 5 min at 37 °C 
with the enzyme followed by the addition of substrate. Initial rate assays were 
performed at 37 °C with a Jasco V-530 double beam Spectrophotometer. Absorbance 
value at 412 nm is recorded for 5 min and enzyme activity is calculated from the slope 
of the obtained linear trend. Assays are carried out with a blank containing all 
components except AChE to account for the non-enzymatic reaction. The reaction 
rates are compared and the percent inhibition due to the presence of tested inhibitors 
is calculated. Each concentration is analysed in triplicate, and IC50 values are 
determined graphically from log concentration–inhibition curves (GraphPad Prism 
4.03 software, GraphPad Software Inc.). Tacrine is used as a standard inhibitor.   
Molecular Docking  
The retrieved protein (PDB: 4ey4) used for this purpose is improved by using import 
and preparation option of MVD software
54
 and missing bond order, hybridization 
state, angle and flexibility for achieving reliable potential binding site in the receptor. 
All the compounds are designed and structure is analysed using Chem Draw Ultra 3D 
software and then these structures are energetically minimized using MM2 force field 
with RMS gradient set to 0.0001, and coordinates of compounds are checked using 
PRODRG programme.
55
 Hex6.1,
56
 Discovery studio 4.0 Client
57
 and iGEMDOCK
58
 
softwares are used to sort out top ten molecular docking poses of ligand (compound)-
receptor interactions, perform visualization of docked ligands and illustration of basic 
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features of the docked interface and compute energy calculation of docked ligands, 
respectively. 
 
CONCLUSION 
This chapter reports the facile, convenient and eco-friendly silica-sulfuric acid 
assisted synthesis of bioactive ester derivatives of substituted coumarins. The present 
protocol offers attractive features such as excellent yields of the products in short 
times, mild reaction conditions, simple work-up procedure, environmentally benign, 
economic viability and reusability of the catalyst. We believe that this synthetic 
approach provides a better scope for the synthesis of ester derivatives of coumarin and 
will be a more practical alternative to the other existing methods. Moreover, 
information obtained from the results, suggest that these synthesized ester derivatives 
of coumarin can be used as templates for future research, for designing new entities 
through modification and derivatization with an improved AChE inhibition affinities 
for therapeutic purposes. 
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INTRODUCTION 
Tetrazole belongs to a class of 5-membered nitrogen containing heterocyclic 
compounds possessing highest nitrogen content among the known heterocycles. The 
first compound comprising a tetrazole ring is thought to be 2-phenyl-2H-tetrazole-5-
carbonitrile, which was synthesized and characterized in 1885.
1
 In the last few 
decades, the chemistry of  nitrogen containing heterocyclic compounds (tetrazoles), 
have received considerable attention due to their promising biological properties 
especially antiviral,
2
 anticonvulsant,
3
 antiinflammatory,
4
 antimicrobial,
5
 
antinociceptive,
6
 antifungal,
7
 anti-HIV,
8
 antiulcer,
9
 antiallergic,
10
 antiproliferative,
11
 
analgesic
12
 and anticancer.
13
 They have also been shown to be potential P2X7-
antagonists,
14
 TNF alpha inhibitors
15
 and inhibitors of anandamide cellular uptake.
16
 
The importance of tetrazole and its derivatives in medicinal chemistry has augmented 
because of their uses as lipophilic spacers and as metabolically stable surrogate for a 
carboxylic acid group in drug design.
17
 A number of drugs approved by the Food and 
Drug Administration (FDA) which are medicinally important possess tetrazole moiety 
in their structures.
18
 It has been reported, that the lipophilic nature of tetrazole moiety 
in a drug improves its oral bioavailability and cell penetration.
19
 In this regard, 
tetrazole chemistry has gained so much interest due to their potential therapeutic 
profile. Valsartan, Losartan and Irbesartan are well-known antihypertensive drugs 
belonging to the class of nonpeptide angiotensin-II inhibitors and possess biphenyl 
tetrazolyl moiety in their structure. Similarly, TAK-456 a broad-spectrum antifungal 
drug also bears a tetrazole ring in its structure (Fig. 1). 
 Tetrazoles have also found a wide range of applications in materials as specialty 
explosives,
20
 information recording systems,
21
 rocket propellants
22
 and in 
agrochemistry.
23
 They are endowed with befitting coordinating property as nitrogen-
containing heterocyclic ligands are capable to form stable complexes with several 
metal ions and behave as precursors to a variety of nitrogen heterocycles in organic 
synthesis.
24-25
 Moreover, tetrazole ring is a crucial intermediate in the synthesis of 
other more complex heterocycles, through various rearrangements.
26
 It has been 
recently documented that nitrogen containing heterocyclic compounds possess 
inherent acetylcholinesterase inhibition potency and hence, have emerged as one of 
the most promising candidates for the treatment of Alzheimer’s disease (AD).27 As a  
 New Journal of Chemistry, 2015, 39, 2028-2041
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consequence of such immense synthetic utility and inherent pharmacological 
applications of tetrazoles, there is a need for the development of efficient and elegant 
protocols for their synthesis. 
 
                    Valsartan                                Losartan                            Irbesartan 
 
 
TAK-456 
Fig. 1 Drugs available in the market with a tetrazole moiety 
Several sophisticated methodologies have been postulated in the literature for 
the synthesis of a tetrazole nucleus. However, in recent years use of various 
heterogeneous catalysts for chemical transformations led the organic chemists to 
develop new methodologies for the efficient synthesis of tetrazole derivatives with the 
help of heterogeneous catalyst following the principles of green chemistry. 
Lang et al.
28
 exploited mesoporous ZnS nanospheres (MZNSS) as a novel 
heterogeneous catalyst for the synthesis of 5-substituted 1H-tetrazoles from various 
aromatic nitriles and sodium azide (NaN3) with excellent catalytic performance under 
acidic condition in presence of DMF. 
 
[R = (a) H; (b) 2-Cl; (c) 3-Cl; (d) 4-Cl; (e) 4-NO2; (f) 3- NO2; (g) 4-CH3; (h) 2-NH2]; 
(i) PhCH2; (j) 4-Py 
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T. Jin and co-workers
29
 reported the copper catalysed synthesis of 5-substituted 
1H-tetrazoles via [3+2] cycloaddition between numerous nitriles and trimethylsilyl 
azide (TMSN3) at 80 
o
C in the presence DMF/MeOH in good to high yields. The 
reaction most probably proceeds through in situ formation of a copper azide species, 
followed by a successive [3+2] cycloaddition with the nitriles. 
 
[R = (a) 4-OMe; (b) 4-Me; (c) 4-NO2; (d) 3,5-(NO2)2; (e) 4-OH]; (f) 2-naphthyl; 
(g) PhCH2; (h) n-butyl; (i) t-butyl 
Similarly, various other catalysts i.e. Barium tungstate (BaWO4),
30a
 
ZnO/Co3O4,
30b
 ZrOCl2,
30c
 Zn/Al hydrotalcite
30d
 and CuFe2O4 nanoparticles
30e
 have 
also been reported for the synthesis of 5-substituted-1H-tetrazole from differently 
substituted nitriles and TMSN3/ NaN3 under varied reaction conditions. 
Habibi et al.
31
 reported an efficient synthesis of series of 1-substituted 1H-
tetrazoles by the application of Natrolite zeolite as a natural heterogeneous catalyst 
from differently substituted primary amines, triethyl ortho-formate and sodium azide 
(NaN3) under solvent-free conditions. 
 
Ar = (a) C6H5; (b) 3-MeC6H4; (c) 4-MeC6H4; (d) 4-OMeC6H4; (e) 4-ClC6H4;  
(f) 2-ClC6H4; (g) 4-BrC6H4; (h) 3-CF3C6H4; (i) 2,4-Me2C6H3; (j) 2,4-Cl2C6H3;  
(k) 4-CH3OCC6H4; (l) 2-NH2C6H4; (m) 2-MeC6H4; (n) 4-NO2C6H4; (o) C5H4N 
 
Naeimi and Mohamadabadi
32
 reported sulfonic acid-functionalized silica-
coated magnetic nanoparticles as an efficient reusable catalyst for the synthesis of 1-
substituted-1H-tetrazoles under solvent free conditions from an amine, triethyl ortho-
formate and sodium azide. 
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[R = (a) H; (b) 4-Br; (c) 4-Cl; (d) 4-CH3; (e) 3-CH3; (f) 2- CH3; (g) 2,4-(CH3)2; 
(h) 4-COCH3; (i) 3-Cl; (j) 2-Cl; (k) 2-NH2]; (l) 1-naphthyl 
Similarly, some other catalysts such as In(OTf)3,
33a
 Yb(OTf)3,
33b
 SSA,
33c
 and 
[Hbim]BF4
33d 
have also been employed for the synthesis of 1-substituted-1H-tetrazole 
from differently substituted primary amines, triethyl ortho-formate and sodium azide 
under varied reaction conditions. 
Zhu et al.
34 
described the procedure for the synthesis of 5-substituted 1H-
tetrazoles through one-pot three-component reaction between an aryl bromide, 
potassium hexakis(cyano-kC)ferrate(4-)(K4[Fe(CN)6]) and NaN3 catalysed by 
Pd(OAc)2 and ZnBr2 in presence of 1,4-diazabicyclo[2.2.2]octane (dabco) in DMF. 
The reaction occurred under non-acidic conditions and involved a nontoxic cyanide 
source. 
 
[R = (a) H; (b) 3-CF3; (c) 3-CHO; (d) 4-CF3; (e) 4-COCH3; (f) 3-CH3; (g) 4-CH3; 
(h) 4-OCH3; (i) 2-OCH3]; (j) 2-naphthyl 
Penthala and co-workers
35
 developed a novel and efficient route for the 
synthesis of a series of (Z)-5-(2-(heteroaryl-2-yl)-1-(phenyl)vinyl)-1H-tetrazoles from 
cyanostilbene analogs containing benzo[b]thiophene, benzo[b]furan, and indole 
moieties utilizing tributyltin azide as a Lewis acid.  
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 X R
1
 R
2
 R
3
 
a S OCH3 OCH3 OCH3 
b S OCH3 H OCH3 
c S OCH3 OCH3 H 
d S H OCH3 H 
e S OCH3 OH OCH3 
f O OCH3 OCH3 H 
g NH OCH3 OCH3 OCH3 
Gyoung et al.
36 
reported the regiospecific synthesis of 2-allylated-5 substituted 
tetrazoles through palladium [Pd(PPh3)4] catalysed  reaction of different alkyl- and 
arylidenemalononitriles with allyl acetates and d trimethylsilyl azide in 
tetrahydrofuran (THF) as a solvent at 60 
o
C. 
 
Srihari and co-workers
37
 developed a new strategy for the synthesis of series of 
functionalized 1,5-disubstituted tetrazoles by solvent free reaction of Baylis Hillman 
acetate, trimethylsilyl azide and aryl nitriles in presence of tetra-n-butylammonium 
fluoride (TBAF) as a catalyst. Some of the synthesized tetrazoles are found to be 
potential TNF-α inhibitors. 
 
R = CH3, Ph, p-OMeC6H4, MeC6H4, 2-furyl; 
Ar = Ph, m-BrC6H4, 3-pyridyl, 4-pyridyl; E = CO2Et, CN 
Kumar et al.
38
 reported water promoted one pot three component synthesis of a 
library of functionalized tetrazole derivatives from isothiocyanate, amines and sodium 
azide via thiourea. The synthesis involves a chemoselective exocyclic reaction, 
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regioselective electrocyclisation and a preferred conformational orientation of the 
tetrazole side chain. 
 
R = (a) CH3; (b) C2H5; (c) PhCH2; (d) cyclohexyl; (e) C4H9; (f) Ph; (g) p-MePh; (h) 
p-ClPh; (i) p-BrPh; (j) p-OMePh; (k) p-FPh; (l) o-MePh; (m) m-MePh; (n) p-NO2Ph 
 
Li et al.
39
 presented a new protocol that allows the synthesis of 2,5-disubstituted 
tetrazoles via the direct coupling of N-H free tetrazoles and low toxic boronic acids in 
the presence of a catalytic amount of Cu2O (5 mol%) and 1 atm of environmentally 
benign O2 as oxidant. This method represents a simple, green and atom-efficient 
synthesis of 2,5-disubstituted tetrazoles. 
R = (a) 4-CH3; (b) 2-CH3; (c) 2,4,6-(CH3)3; (d) 4-OMe; (e) 4-OH; (f) 2-NH2; 
(g) 4-Cl; (h) 4-COCH3; (i) 2-CHO; (j) 4-CO2Me; (k) 4-CN; (l) 2-NO2 
 
Huang and co-workers
40
 outlined the synthesis of diversely functionalized 
tricyclic tetrazoles using one-pot tandem reaction via intramolecular 1,3-dipolar 
cycloaddition as the key step, employing readily available 9-amino-9-deoxy-
epiquinine as the iminium organocatalysts. 
 
R = (a) H; (b) 5-Cl; (c) 5-Br 
 
Pandey et al.
41
 reported one pot multicomponent reaction system for the 
synthesis of new tetrazole derivatives of 4-aminoquinoline by utilizing highly 
efficient TMSN3-Ugi multicomponent reaction. The majority of these synthesized 
molecules exhibit promising in vitro antimalarial activity. 
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R
1
 = 4-Cl, 3,4-Cl2, 4-OMe, 3,4-(OMe)2, 3,4,5-(OMe)3, 4-F, 4-Br, 4-Me, 4-Et;  
R
2
 = t-butyl, cyclohexyl 
Motivated by these findings, and in continuation of our on-going efforts 
endowed with the finding of new synthetic protocols
42
 under the principles of green 
chemistry, herein, we report for the first time silica-supported boric acid (SiO2-
H3BO3) catalysed synthesis of 1-substituted 1H-tetrazoles under thermal solvent free 
conditions. A silica-supported boric acid (SiO2-H3BO3) catalyst is prepared by 
employing standard procedures depicted in the literature (Scheme 1).
43
 It has emerged 
as a promising heterogeneous solid acid catalyst in many organic transformations
43-45
 
and possesses environmentally benign properties such as nontoxicity, 
biocompatibility, recyclability, physiological inertness, inexpensiveness and thermal 
stability. The structure and morphology of the catalyst is established on the basis of 
FT-IR, powder X-ray diffraction (XRD), scanning electron microscopy (SEM), 
energy-dispersive X-ray spectroscopy (EDX) and transmission electron microscopy 
(TEM). The synthesized compounds have been characterized by FT-IR, 
1
H NMR, 
13
C 
NMR, MS and elemental analysis and are also screened for acetylcholinesterase 
(AChE) inhibition studies. 
 
RESULTS AND DISCUSSION 
In the present chapter, a library of bioactive 1-substituted-1H-tetrazole derivatives 18-
32 have been synthesized using an environmentally benign heterogeneous catalyst 
(SiO2-H3BO3) under solvent free conditions. This protocol offers several advantages 
over other existing synthetic methodologies in terms of yield and purity of products, 
operational procedures, reaction times, catalyst stability and recyclability. This 
synthetic scheme possesses diverse applicability and is compatible to a range of 
functional groups (electron donating/ electron withdrawing). In the context of 
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potential applications of nitrogen containing heterocyclic compounds against 
Alzheimer’s disease (AD),27 we have tested our synthesized compounds for the 
possible AChE inhibition studies.  
Characterization of the silica-supported boric acid catalyst 
The synthetic route for the synthesis of the catalyst (SiO2-H3BO3) employed in the 
present protocol has been presented in Scheme 1. The synthesized catalyst has been 
characterized by FT-IR, powder XRD, SEM-EDX and TEM analysis. The FT-IR 
spectrum of the catalyst (SiO2-H3BO3) is depicted in Fig. 2. The FT-IR spectrum 
displays a stretching band of SiO-H at 3434 cm
-1
, while the stretching band of BO-H 
appears at 3227 cm
-1
. The peak at 2260 cm
-1
 is assigned to the B-OH combination and 
the peak at 1187 cm
-1
 is attributed to the bending vibration of B-OH. The Si-O-Si 
asymmetric stretching vibration band appears at 1091 cm
-1
 and the low frequency 
mode at 800 cm
-1
 is due to the symmetric Si-O-Si stretching vibrations. The peaks at 
927 and 649 cm
-1
 is attributed to the stretching and bending vibration of the 
borosiloxane linkage (Si-O-B), respectively and a B-O stretching band of 
borosiloxane at 1435 cm
-1
 observed in the FT-IR spectrum of the catalytic system 
authenticate the loading of H3BO3 on the SiO2 surface. 
Formation of the catalytic system (SiO2-H3BO3) is further confirmed by powder 
XRD analysis (Fig. 3). The XRD pattern shows a single broad peak at 2θ = 22o 
indicating fine dispersion of boric acid on the silica material and thus confirming the 
formation of an amorphous SiO2-H3BO3 matrix. The absence of reflection at 2θ = 28
o
 
for free boric acid
46,47
 indicated that boron atoms are mainly engaged in the formation 
of borosiloxane bridges in the catalyst. 
SEM analysis is employed to study the surface morphology of the catalytic 
system (Fig. 4). SEM micrographs of the catalyst shows that H3BO3 particles are of 
uneven size and shape, well dispersed and no conglomeration of H3BO3 particles is 
found on the surface of the silica gel. The increased reactivity of boric acid supported 
on the silica material is believed to be due to the catalyst-support interactions and the 
resultant changes in the surface properties of the reactive sites.
43
 The TEM 
micrograph (Fig. 5) of the catalytic system further displays uniform distribution of 
H3BO3 particles as black dots on the surface of silica, approving the formation of the 
expected catalytic system. EDX analysis (Fig. 6) of the catalyst shows the presence of 
Si, B and O elements suggesting the formation of a SiO2-H3BO3 catalytic system. 
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Scheme 1 Synthetic pathway for the synthesis of catalyst 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 FT-IR spectrum of catalyst SiO2-H3BO3 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Powder XRD analysis of catalyst SiO2-H3BO3 
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Fig. 4 SEM image of catalyst SiO2-H3BO3 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 TEM image of catalyst SiO2-H3BO3 
 
 
Fig. 6 Energy dispersive X-ray (EDX) analysis of catalyst SiO2-H3BO3 
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Chemistry 
The synthetic pathway of a series of 1-substituted-1H-tetrazoles 18-32 is presented in 
Scheme 2. Herein, a series of compounds are typically accessed via solvent free, 
facile and environmentally benign cyclization reaction, involving various 
heterocyclic/ aromatic amines with sodium azide and triethyl ortho-formate to yield 
target 1-substituted-1H-tetrazoles in excellent yields (90-97%) with a high degree of 
purity. 
 
Scheme 2 Synthetic pathway for the synthesis of tetrazole derivatives 18-32 
The structural elucidation of all the synthesized compounds (18-32) has been 
established on the basis of elemental analysis, FT-IR, 
1
H NMR, 
13
C NMR and mass 
spectral studies. The analytical results for C, H and N are found to be within ±0.3% of 
the theoretical values. The spectral analysis has been in good corroboration with the 
expected structural framework of the synthesized compounds. The mass spectral 
analysis of all the synthesized tetrazole derivatives has been found to be in good 
conformity with the proposed structures. The FT-IR spectrum of compound 18 (Fig. 
7), displays the resonating peak at 3035 and 2929 cm
-1
 that corresponds to the =C-H 
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(sp
2
) and C-H (sp
3
) stretching vibration, respectively. The characteristic peak for C=N 
is observed at 1626 cm
-1
. However, the resonating vibrations around 1576 and 1536 
cm
-1
 are ascribed to the (C=C) and (N=N) stretching vibrations, respectively. 
Moreover, disappearance of the characteristic -NH2 peak in the IR spectrum has 
confirmed the reaction at the target amine moiety of the substrates, further 
authenticating the formation of tetrazole nucleus. In 
1
H NMR spectrum (Fig. 8) of 
compound 18, a sharp singlet peak resonating at δ 8.07 has been attributed to the H-5 
(-CH=N) proton of the tetrazole nucleus, this prominent downfield shift displays by 
the H-5ʹ proton of the tetrazole nucleus is probably due to its acidic nature imposed by 
adjacent nitrogen atoms of the tetrazole ring. Moreover, the disappearance of -NH2 in 
the spectra further validates the formation of tetrazole nucleus. The singlet appears at 
δ 6.35 and 2.24 has been ascribed to the only proton of isoxazole ring (H-4) and 
methyl protons, respectively. 
13
C NMR spectrum (Fig. 9), shows the absorption band 
resonating at around δ 135.0 that has been assigned to the sp2 hybridized carbon of the 
tetrazole ring. The absorption peak at δ 148.5 and 155.0 has been assigned to the C-3 
and C-5 of the isoxazole ring. However, the peak at δ 102.4 and 15.2 has been 
attributed to the C-4 and CH3 of the isoxazole part. The detailed spectral assignment 
of all the synthesised compounds has been discussed in the spectral characterization 
part of the experimental section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 FT-IR spectrum of compound 18 
 
 
Chapter-5 
135 
 
 
Fig. 8 
1
H NMR spectrum of compound 18 
 
 
Fig. 9 
13
C NMR spectrum of compound 18 
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Optimization of reaction conditions 
In the present study, we probe the optimized reaction conditions including loading of 
the catalyst, the effect of temperature and solvents in terms of time and yield on a 
model reaction using 5-methylisoxazol-3-amine (1) with sodium azide (16) and 
triethyl ortho-formate (17) to establish the best possible reaction conditions for the 
synthesis of tetrazole derivatives. To achieve the optimum concentration of the 
catalyst, the model reaction is investigated at different concentrations of the catalyst 
(SiO2-H3BO3) at 90 
o
C under solvent free conditions (Table 1). The model reaction is 
primarily tested in the absence of catalyst and it is found that reaction takes elongated 
time (8 h) for completion with poor yield (42 %) of the product obtained (entry 1). 
The model reaction is then tested for 0.5 mol% of the catalyst followed by 1.0, 1.5, 
2.0, 2.5 and 3.0 mol% and the results are noted in terms of reaction time and yield. 
The results reveal that at every subsequent increase in concentration of the catalyst by 
0.5%, there has been a noteworthy increase in the yield from 64-95 %, with drop in 
reaction time from 8-0.5 h. It can be inferred from table that 2.5 mol% of the catalyst 
is satisfactory to gain the optimum yield in the shortest reaction time under neat 
conditions at 90 
o
C (entry 6). Using less than 2.5 mol% of the catalyst, moderate yield 
of the product (64-83 %) is obtained with higher reaction time. The use of higher 
concentration of catalyst (>2.5 mol%) does not further enhance the yield, possibly due 
to the saturation of the catalyst surface. 
Table 1 Effect of catalyst loading on the yield and reaction time of model reaction
a
 
Entry Catalyst (mol %) Time (h)
b
 Yield (%)
c
 
1 0 8.0 42 
2 0.5 4.5 64 
3 1.0 4.0 71 
4 1.5 2.0 75 
5 2.0 1.0 83 
6 2.5 0.5 95 
7 3.0 0.5 95 
a
Reaction condition: 5-methylisoxazol-3-amine (1, 2 mmol), NaN3 (16, 2 mmol), triethyl 
ortho-formate (17, 2.4 mmol), solvent free, 90 
o
C; 
b
Reaction Progress monitored by TLC.  
c
Isolated yield of products 
To optimize the reaction temperature, we conduct the model reaction at 
different temperatures under solvent free conditions (Table 2). It is observed that the 
increase in temperature from 25 
o
C to 90 
o
C has a prominent effect on the reaction in 
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terms of yield and reaction time. Initially the model reaction mixture is allowed to stir 
at room temperature (25 
o
C), the results obtained are not satisfactory with a prolonged 
reaction time of 3 h and a moderate yield of 54 %. The increase in temperature 
coupled with stirring produces a profound effect on the yield of the product from 54-
95 % during the course of reaction (entries 1-5). However, further increase in the 
temperature up to 110 
o
C does not show any further increase in the yield of the 
product. Thus, keeping in view the above optimized reaction conditions, 90 
o
C is 
chosen as the optimal temperature for all the reactions. 
Table 2 Effect of temperature on model reaction
a
 
Entry Temperature (
o
C) Time (h)
b
 Yield (%)
c
 
1 25 3.0 54 
2 50 2.5 77 
3 70 2.0 82 
4 80 1.0 86 
5 90 0.5 95 
6 110 0.5 95 
a
Reaction condition: 5-methylisoxazol-3-amine (1, 2 mmol), NaN3 (16, 2 mmol), triethyl 
ortho-formate (17, 2.4 mmol), catalyst (2.5 mol%), solvent free, refluxing at different 
temperatures; 
b
Reaction Progress monitored by TLC; 
c
Isolated yield of products. 
 
To evaluate the efficiency of the solvent free reaction conditions in comparison 
with solvent conditions, the model reaction is examined in different solvent systems 
in the presence of 2.5 mol% of the SiO2-H3BO3 catalyst (Table 3). The model 
reaction is initially performed in common organic solvents like MeOH and EtOH, a 
moderate yield of the product (18) is obtained after a stretched time period (entries 
2,3). This moderate yield can be attributed to the nucleophilic nature of these solvents, 
due to the presence of the lone pair of electrons on the oxygen atom. Thus, 
nucleophilic competition between these solvents (MeOH and EtOH) and the primary 
amine group of the substrate for electrophilic carbon of triethyl ortho-formate will 
eventually result in lower yield of the desired product. Moreover, low yield in these 
solvents (MeOH and EtOH) can be ascribed to the accessibility of the acidic Lewis 
sites of B(OH)2 in these solvents. However, in acetic acid the yield of the desired 
product increases significantly with reduced reaction time (entry 4). This 
improvement of yield in CH3COOH solvent is probably due to its ability to facilitate 
the elimination of the ethoxy group (OEt) from triethyl ortho-formate, thereby 
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enhancing the electrophilicity of carbon, rendering it more feasible for nucleophilic 
attack by the amines. However, when the reaction is carried out in THF and DMF, no 
further significant increase in the yield of the product is observed in comparison to 
CH3COOH, after a stretched reaction time (entries 5,6). Moreover, when the reaction 
is explored under solvent-free conditions, it is noted that the yield of the product 
enhances sharply with significant drop in reaction time. Thus, nature (nucleophlicity/ 
protocity) of the solvent has a considerable effect on the yield and reaction time. 
These results suggest that, solvent free reaction conditions coupled with 2.5 mol% of 
SiO2-H3BO3 at 90 
o
C is the best synthetic approach for the synthesis of 1-substituted 
tetrazole derivatives in terms of reduced reaction times and excellent yields of the 
products. 
Table 3 Effect of various solvents on model reaction
a
 
Entry Solvent Time (h)
b
 Yield (%)
c
 
1 Solvent free 0.5 95 
2 MeOH 7 59 
3 EtOH 8 54 
4 CH3COOH 5 79 
5 THF 9 73 
6 DMF 8 76 
a
Reaction condition: 5-methylisoxazol-3-amine (1, 2 mmol), NaN3 (16, 2 mmol), triethyl 
ortho-formate (17, 2.4 mmol), catalyst (2.5 mol%), different solvents, refluxing at 90 
o
C; 
b
Reaction Progress monitored by TLC; 
c
Isolated yield of products. 
 
Comparison of efficiency of silica-boric acid for the synthesis of compound 
A comparative study of a variety of heterogeneous catalysts is conducted to confirm 
the superiority of silica-boric acid over other heterogeneous acid catalysts (Table 4). 
When the model reaction is investigated with silica-supported catalysts such as 
HClO4-SiO2, NaHSO4-SiO2, NH4OAc-SiO2 and P2O5-SiO2 the reaction takes 
prolonged time period, and also the yields are not satisfactory (entries 2-5). However, 
relatively good yield of the product 18 (77-81 %) is obtained by using Yb(OTf)3 and 
In(OTf)3 as heterogeneous catalysts but again reaction took a protracted time period 
for completion (entries 6,7). When the model reaction is coupled with the silica-boric 
acid catalyst, the yield of product 18 (95 %) increased exponentially with a prominent 
drop in reaction time. These results suggest that silica-boric acid is the catalyst of 
choice for the present synthetic protocol. 
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Table 4 Comparison of catalytic activity of different catalysts on the model reaction
a
 
Entry Catalyst Time (hrs)
b
 Yield (%)
c
 
1 SiO2-H3BO3 0.5 95 
2 SiO2-HClO4 5 50 
3 SiO2-NaHSO4 7 55 
4 SiO2-NH4OAc 6 59 
5 SiO2-P2O5 6.5 62 
6 Yb(OTf)3 5 77 
7 In(OTf)3 3 81 
a
Reaction condition: 5-methylisoxazol-3-amine (1, 2 mmol), NaN3 (16, 2 mmol), triethyl 
ortho-formate (17, 2.4 mmol), different catalyst (2.5 mol%), solvent free, refluxing at 90 
o
C; 
b
Reaction Progress monitored by TLC; 
c
Isolated yield of products. 
 
Under these optimized reaction conditions, the scope and generality of the 
present protocol is further demonstrated by carrying out the reaction of different 
heterocyclic/ aromatic amines with sodium azide and triethyl ortho-formate under 
solvent free conditions (Table 5). All the reactions proceed smoothly to afford the 
desired products 18-32 in excellent yields (90-97%) within 30-55 min. The result 
reveals that employing silica-boric acid as catalyst in the present protocol enhances 
selectivity and product conversion, thus, proves beneficial for the synthesis of 
tetrazoles in terms of yield and reaction times. 
Table 5 Silica-supported boric acid catalyzed synthesis of 1-substituted-1H-tetrazole 
derivatives 18-32 
S. No. Reactants (1-15) Products (18-32) Time 
(min) 
Yield 
(%) 
 
1 
 
 
 
 
30 
 
95 
 
2 
 
 
 
 
40 
 
91 
 
3 
 
 
 
45 
 
93 
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4 
 
 
 
35 
 
96 
 
5 
 
 
 
50 
 
97 
 
6 
 
 
 
42 
 
95 
 
7 
  
 
46 
 
90 
 
8 
 
 
 
35 
 
 
96 
 
9 
 
 
 
40 
 
 
92 
 
10 
 
 
 
55 
 
91 
 
11 
 
 
 
48 
 
97 
 
12 
 
 
 
43 
 
93 
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13 
 
 
 
35 
 
95 
 
14  
 
 
40 
 
94 
 
15 
  
 
42 
 
96 
 
Reaction mechanism 
The probable silica-boric acid catalyzed mechanistic pathway for the synthesis of 
tetrazole derivatives is shown in Scheme 3, in which the Lewis acid character of the 
catalyst probably has an important role in the promotion of the cyclization process. It 
is believed that silica-boric acid activates the ethoxy group of triethyl ortho-formate 
and facilitates its elimination by cleaving the C-O bond of triethyl ortho-formate to 
generate carbenium ion (I), which is resonance stabilized by the oxygen atom of 
another ethoxy group followed by nucleophilic attack of amine. The next step 
involves the expulsion of the second ethoxy group generating carbenium ion (II), 
which can be stabilized by the neighbouring O or the N atom to form either the 
oxonium (A) or iminium (B) cation, respectively. It is believed that the formation of 
an iminium cation is preferential over an oxonium cation due to the greater basicity of 
nitrogen with respect to oxygen. The next step involves the sequential attack of the 
azide anion leading to the formation of proposed imidoylazide intermediate (III).
48,49
 
As the three nitrogens bend away from the linear arrangement the fourth nitrogen 
atom comes within the bonding distance eventually leading to the formation of 
cyclized tetrazoles 18-32. 
Reusability of the catalyst 
The reusability of the silica-boric acid catalyst is also examined on the model reaction 
in order to satisfy the green chemistry criteria. The recycling of the catalyst is an 
important step as it reduces the cost of the process. The catalyst is reused five times 
and the results demonstrate that the catalyst can be reused as such without a 
significant loss in yield (Fig. 10). After completion of the reaction, the catalyst is 
removed by simple filtration. The recovered catalyst is dried under vacuum at 100 
o
C 
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for 6 h and tested up to five more reaction cycles. Recycling and reuse of the catalyst 
shows a minimal decrease in yields. The product is obtained in 93%, 91%, 88%, 85%, 
80% yields after successive cycles (Fig. 10), thus proving the catalyst’s reusability. 
To ascertain the variation in morphological features of the recovered catalyst, we 
carry out its SEM-EDX analysis. It is observed that there is no significant changes 
occur in the morphology of the catalyst (Fig. 11) and also the composition of the 
catalytic system is almost consistent with that of the fresh catalyst (Fig. 12). 
 
 
Scheme 3 Plausible mechanistic pathway for the synthesis of compounds 18-32 
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Fig. 10 Recycling data of the catalyst (SiO2-H3BO3) for the model reaction 
 
 
 
 
 
 
 
 
 
 
    
 
Fig. 11 SEM micrograph of recovered catalyst 
 
 
Fig. 12 EDX spectrum of the recovered catalyst 
 
Chapter-5 
144 
 
AChE inhibition results 
All the synthesized tetrazole derivatives 18-32 are analyzed for AChE inhibition 
studies. The IC50 values for AChE inhibitions are summarized in Table 6. It can be 
inferred from the data reported in table that compounds bearing nicotinic acid nucleus 
i.e. 22, 23 and 24 exhibits strongest inhibition to AChE with IC50 values of 0.43 µM, 
0.21 µM and 0.26 µM, respectively, followed by compound 20 (IC50 = 1.03 µM), 21 
(IC50 = 1.25 µM), 19 (IC50 = 1.46 µM), 18 (IC50 = 1.52 µM), 30 (IC50 = 2.08 µM), 31 
(IC50 = 2.13 µM), 32 (IC50 = 2.17 µM), 29 (IC50 = 2.71 µM), 28 (IC50 = 2.89 µM), 27 
(IC50 = 3.01 µM), 25 (IC50 = 3.29 µM) and 26 (IC50 = 3.32 µM). Of these nicotinic 
acid analogues 4f is found to be the most potent AChE inhibitor. Among the isoxazole 
nucleated tetrazole analogues 18-21, compound 20 with methyl and bromine 
substituted isoxazole rings displays encouraging activity against AChE, the methoxy 
substituted isoxazole ring (21) shows lower activity than 20 by a value of 0.22 but 
higher than methyl substituted isoxazole analogues (18 and 19) by a value of 0.27 and 
0.21, respectively. These results suggest that the nature of the substituent inflicts a 
prominent effect on AChE activity. Compound 30, 31 and 32 comprising a pyridine 
nucleus exhibits nearly similar results for AChE inhibition. Among benzothiazole 
nucleated tetrazole derivatives, compound 29 with a methoxy substituent attached to 
the benzothiazole nucleus at the 6 position exhibits better AChE inhibition. It is 
noticed that when the methoxy group at the 6 position in compound 29 is replaced by 
chlorine (28), the activity decreases significantly by 0.18. However, when the same 
methoxy group is replaced by the nitro group in compound 27, there is further dip in 
AChE inhibition by a value of 0.30. Thus, the nature of the substituent at the 6 
position in benzothiazole based tetrazole derivatives plays an essential role in AChE 
inhibition activity. It can be seen that compounds 25 and 26 exhibit moderate activity 
among all the synthesized tetrazole derivatives. In view of the above results it can be 
concluded that in general electron pumping groups enhance AChE activity while 
electron withdrawing groups reduce it. 
Table 6 In vitro AChE inhibition results of tetrazole derivatives  
Product IC50 (μM)
a 
± SEM Product IC50 (μM)
a 
± SEM  
18 1.52 ± 0.02 26 3.32 ± 0.02 
19 1.46 ± 0.01 27 3.01 ± 0.02 
20 1.03 ± 0.01 28 2.89 ± 0.01 
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21 1.25 ± 0.01 29 2.71 ± 0.01 
22 0.43 ± 0.02 30 2.08 ± 0.02 
23 0.21 ± 0.02 31 2.13 ± 0.02 
24 0.26 ± 0.01 32 2.17 ±0 .01 
25 3.29 ± 0.02 Tacrine 
(Standard) 
0.19 ± 0.02 
a
IC50 values represent the concentration of inhibitor required to decrease the enzyme activity 
by 50%; SEM = Standard error of the mean. 
 
EXPERIMENTAL 
Materials and general methods 
All reagents are purchased from Sigma-Aldrich (India) and Merck as ‘synthesis 
grade’ and used without further purification. The purity of all the compounds is 
checked by thin layer chromatography (TLC) on glass plates coated with silica gel 
G254 (E-Merck). Human AChE (EC: 3.1.1.7) and BuChE (EC: 3.1.1.8) lyophilized 
powder are purchased from Sigma-Aldrich. Melting points of all synthesized 
compounds are determined on a Kofler apparatus and are uncorrected. The FT-IR 
spectra are recorded in the 400-4000 cm
-1
 wave-number range with a Perkin-Elmer 
(2000 FTIR) Spectrometer by KBr pellet method. 1H NMR and 13C NMR spectra are 
recorded on a Bruker Avance-II 400 MHz instrument in pure DMSO-d6 solvent. The 
chemical shifts (δ) are reported in ppm relative to the TMS as an internal standard. 
Mass spectra are recorded on a JEOL D-300 mass spectrometer. Elemental analysis 
(C, H and N) is conducted using Thermo Scientific (FLASH 2000) CHN Elemental 
Analyser. X-ray diffractograms (XRD) of the catalyst is recorded in the 2θ range of 
20-80° with scan rate of 4°/min on a Shimadzu-6100 X-ray diffractometer with Ni-
filtered Cu Kα radiation at a wavelength of 1.54060 Å. The scanning electron 
microscope (SEM-EDX) analysis is performed using a JEOL (JSM-6510) equipped 
with an energy dispersive X-ray spectrometer at different magnification and 
transmission electron microscope (TEM) results are recorded using JEOL (JEM-
2100F) model. 
Synthesis of silica-supported boric acid (SiO2-H3BO3) catalyst 
Boric acid (3.0 g) and 60 mL of water are taken in a 250 ml round bottom flask and 
heated at 60-80 
o
C. Silica gel (60-120 mesh, 27.0 g) is added gradually with constant 
stirring and refluxed for 5 hrs. After the completion of reaction water is evaporated 
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under reduce pressure and the residue is stirred at 100 
o
C for 6-7 hrs under vacuum to 
give free flowing white powder of silica-boric acid (Scheme 1). It is kept under 
vacuum at room temperature.
43
 The various catalysts i.e. SiO2-HClO4,
50a
 SiO2-
NaHSO4,
50b
 SiO2-NH4OAc
50c
 and SiO2-P2O5
50d
 used for the comparative study with 
respect to silica-boric acid have been synthesized according to the previously 
published standard procedures. 
General procedure for the synthesis of 1-substituted-1H-tetrazoles 
To a mixture of amine (1, 2.0 mmol), NaN3 (16, 2.0 mmol) and triethyl ortho-formate 
(17, 2.4 mmol), 2.5 mol% of silica-supported boric acid is added and the reaction 
mixture is allowed to stir at 90 
o
C for 30-55 min. The progress of the reaction is 
monitored by TLC examination. After completion of reaction, the reaction mixture is 
allowed to cool at room temperature and diluted with cold water. The catalyst is 
separated by filtration and washed with water. The filtrate thus obtained is extracted 
with ethyl acetate (3 × 10 mL) for the extraction of compound from water. The ethyl 
acetate layers are then dried over anhydrous sodium sulphate (Na2SO4) and 
evaporated under reduced pressure to get the product. The crude product obtained is 
crystallized with chloroform-methanol to afford the pure compounds. 
Spectral characterization of synthesized compounds 
5-methyl-3-(1H-tetrazol-1-yl) isoxazole (18) 
Yellow crystalline solid; Yield: 95%, m.p. 160 
o
C; Anal. calc. for C5H5N5O: C, 39.74; 
H, 3.33; N, 46.34; found: C, 39.75; H, 3.34; N, 46.36. IR (KBr, νmax, cm
-1
): 1625 
(C=N), 1535 (N=N), 1186 (C-N), 1088 (C-O). 
1
H NMR (400 MHz, DMSO-d6, δ, 
ppm): 8.07 (s, 1H, H-5’), 6.35 (s, 1H, H-4), 2.24 (s, 3H, CH3). 
13
C NMR (100 MHz, 
DMSO-d6, δ, ppm): 155.03 (C-5), 148.54 (C-3), 135.05 (C-5ʹ), 102.44 (C-4), 15.25 
(CH3). MS (ESI) m/z: 151.05 [M
+•
]. 
5-methoxy-3-(1H-tetrazol-1-yl) isoxazole (19) 
Yellowish crystals; Yield: 92%, m.p. 196 
o
C; Anal. calc. for C5H5N5O2: C, 35.93; H, 
3.02; N, 41.90; found: C, 35.94; H, 3.01; N, 41.93. IR (KBr, νmax, cm
-1
): 1582 (C=N), 
1512 (N=N), 1140 (C-N), 1078 (C-O). 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 8.23 
(s, 1H, H-5ʹ), 5.78 (s, 1H, H-4), 2.94 (s, 3H, OCH3). 
13
C NMR (100 MHz, DMSO-d6, 
δ, ppm): 157.80 (C-5), 145.27 (C-3), 142.20 (C-5ʹ), 107.28 (C-4), 53.65 (OCH3). MS 
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(ESI) m/z: 167.04 [M
+•
]. 
3-methyl-5-(1H-tetrazol-1-yl) isoxazole (20) 
Brownish solid; Yield: 94%, m.p. 189-191 
o
C; Anal. calc. for C5H5N5O: C, 39.74; H, 
3.33; N, 46.34; found: C, 39.76; H, 3.32; N, 46.37. IR (KBr, νmax, cm
-1
): 1578 (C=N), 
1511 (N=N), 1135 (C-N), 1058 (C-O). 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 8.15 
(s, 1H, H-5ʹ), 6.38 (s, 1H, H-4), 2.15 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6, δ, 
ppm): 152.31 (C-3), 143.25 (C-5), 137.18 (C-5ʹ), 104.20 (C-4), 17.24 (CH3). MS 
(ESI) m/z: 151.05 [M
+•
]. 
4-bromo-3-methyl-5-(1H-tetrazol-1-yl) isoxazole (21) 
Light brown solid; Yield: 96%, m.p. 174 
o
C; Anal. calc. for C5H4BrN5O: C, 26.11; H, 
1.75; N, 30.45; found: C, 26.13; H, 1.77; N, 30.43. IR (KBr, νmax, cm
-1
): 1587 (C=N), 
1509 (N=N), 1142 (C-N), 1082 (C-O), 574 (C-Br). 
1
H NMR (400 MHz, DMSO-d6, δ, 
ppm): 8.26 (s, 1H, H-5ʹ), 2.17 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 
156.24 (C-3), 147.28 (C-5), 140.25 (C-5ʹ), 102.38 (C-4), 16.32 (CH3).  MS (ESI) m/z: 
228.96 [M
+•
]. 
2-(1H-tetrazol-1-yl) nicotinic acid (22) 
White crystalline solid; Yield: 97%, m.p. 231-233 
o
C; Anal. calc. for C7H5N5O2: C, 
43.98; H, 2.64; N, 36.64; found: C, 43.97; H, 2.66; N, 36.65. IR (KBr, νmax, cm
-1
): 
3212 (-OH), 1712 (C=O), 1592 (C=N), 1510 (N=N), 1132 (C-N). 
1
H NMR (400 
MHz, DMSO-d6, δ, ppm): 9.84 (brs, 1H, OH), 8.59 (s, 1H, H-5ʹ), 8.02 (d, 1H, H-4), 
7.85 (d, 1H, H-6), 7.23 (t, 1H, H-5). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 171.35 
(C=O), 148.13 (C-2), 144.21 (C-5ʹ), 142.24 (C-6), 132.18 (C-3), 129.25 (C-4), 123.59 
(C-5). MS (ESI) m/z: 191.04 [M
+•
]. 
6-(1H-tetrazol-1-yl) nicotinic acid (23) 
Creamish yellow solid; Yield: 93%, m.p. 211 
o
C; Anal. calc. for C7H5N5O2: C, 43.98; 
H, 2.64; N, 36.64; found: C, 43.99; H, 2.63; N, 36.67. IR (KBr, νmax, cm
-1
): 3225 (-
OH), 1723 (C=O), 1602 (C=N), 1514 (N=N), 1135 (C-N). 
1
H NMR (400 MHz, 
DMSO-d6, δ, ppm): 9.79 (brs, 1H, OH), 8.58 (s, 1H, H-5ʹ), 7.84 (s, 1H, H-2), 7.62 
(dd, 2H, H-4/H-5). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 169.25 (C=O), 151.25 
(C-2), 146.10 (C-6), 145.21 (C-5ʹ), 134.28 (C-3), 130.25 (C-4), 124.20 (C-5). MS 
(ESI) m/z: 191.04 [M
+•
]. 
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5-(1H-tetrazol-1-yl) nicotinic acid (24) 
Cream coloured solid; Yield: 94%, m.p. 203 
o
C; Anal. calc. for C7H5N5O2: C, 43.98; 
H, 2.64; N, 36.64; found: C, 43.96; H, 2.65; N, 36.66. IR (KBr, νmax, cm
-1
): 3221 (-
OH), 1708 (C=O), 1594 (C=N), 1510 (N=N), 1141 (C-N). 
1
H NMR (400 MHz, 
DMSO-d6, δ, ppm): 9.73 (brs, 1H, OH), 8.48 (s, 1H, H-5ʹ), 7.92 (s, 1H, H-4), 7.80 (s, 
1H, H-2), 7.72 (s, 1H, H-6). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 168.25 (C=O), 
150.24 (C-2), 142.12 (C-5ʹ), 140.20 (C-6), 138.82 (C-5), 131.42 (C-3), 128.51 (C-4). 
MS (ESI) m/z: 191.04 [M
+•
]. 
1-(naphthalen-1-yl)-1H-tetrazole (25) 
Violet crystals; Yield: 97%, m.p. 98 
o
C, reported 95-96 
o
C;
51
 Anal. calc. for C11H8N4: 
C, 67.34; H, 4.11; N, 28.55; found: C, 67.36; H, 4.12; N, 28.57. IR (KBr, νmax, cm
-1
): 
1597 (C=N), 1572, 1462 (C=Caromatic), 1505 (N=N), 1141 (C-N). 
1
H NMR (400 MHz, 
DMSO-d6, δ, ppm): 8.78 (s, 1H, H-5ʹ), 7.88 (m, 1H, H-8), 7.85 (m, 2H, H-4/H-5), 
7.64 (m, 1H, H-2), 7.58 (m, 1H, H-7), 7.53 (m, 2H, H-3/H-6). 
13
C NMR (100 MHz, 
DMSO-d6, δ, ppm): 148.25 (C-5ʹ), 132.82 (C-2), 132.33 (C-9), 130.25 (C-10), 128.05 
(C-1), 125.13 (C-7), 127.28 (C-8), 127.15 (C-4/C-5), 126.20 (C-3/C-6). MS (ESI) 
m/z: 196.07 [M+•]. 
1-(naphthalen-2-yl)-1H-tetrazole (26) 
Light pink colour solid; Yield: 95%, m.p. 116 
o
C, reported 114-115 
o
C.
52
 Anal. calc. 
for C11H8N4: C, 67.34; H, 4.11; N, 28.55; found: C, 67.33; H, 4.14; N, 28.56. IR 
(KBr, νmax, cm
-1
): 1593 (C=N), 1575, 1456 (C=Caromatic), 1503 (N=N), 1146 (C-N). 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 8.89 (s, 1H, H-5ʹ), 8.04 (d, 1H, H-1), 7.92 
(m, 1H, H-8), 7.86 (d, 1H, H-4), 7.79 (m, 1H, H-5), 7.68 (m, 1H, H-3), 7.45 (m, 2H, 
H-6/H-7). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 144.25 (C-5ʹ), 133.25 (C-9), 
132.43 (C-4), 130.79 (C-10), 129.33 (C-1), 128.21 (C-5), 128.05 (C-8), 127.38 (C-2), 
126.24 (C-6/C-7), 125.54 (C-3). MS (ESI) m/z: 196.07 [M
+•
].  
6-nitro-2-(1H-tetrazol-1-yl)benzo[d]thiazole (27) 
Yellowish solid; Yield: 92%, m.p. 263 
o
C; Anal. calc. for C8H4N6O2S: C, 38.71; H, 
1.62; N, 33.86; found: C, 38.73; H, 1.61; N, 33.89. IR (KBr, νmax, cm
-1
): 1591 (C=N), 
1520, 1325 (NO2), 1507 (N=N), 1147 (C-N), 625 (C-S). 
1
H NMR (400 MHz, DMSO-
d6, δ, ppm): 8.57 (s, 1H, H-5ʹ), 7.95 (s, 1H, H-7), 7.67 (d, 1H, H-5), 7.58 (d, 1H, H-4). 
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13
C NMR (100 MHz, DMSO-d6, δ, ppm): 152.31 (C-2), 147.28 (C-9), 144.21 (C-5ʹ), 
142.26 (C-6), 138.24 (C-8), 125.29 (C-7), 124.47 (C-4), 122.38 (C-5). MS (ESI) m/z: 
248.01 [M
+•
].  
6-chloro-2-(1H-tetrazol-1-yl)benzo[d]thiazole (28) 
White solid; Yield: 94%, m.p. 174 
o
C; Anal. calc. for C8H4ClN5S: C, 40.43; H, 1.70; 
N, 29.47; found: C, 40.45; H, 1.68; N, 29.48. IR (KBr, νmax, cm
-1
): 1596 (C=N), 1503 
(N=N), 1137 (C-N), 710 (C-Cl), 632 (C-S). 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 
8.47 (s, 1H, H-5ʹ), 7.85 (s, 1H H-7), 7.59 (d, 1H, H-5), 7.54 (d, 1H, H-4). 13C NMR 
(100 MHz, DMSO-d6, δ, ppm): 155.18 (C-2), 144.20 (C-9), 141.24 (C-5ʹ), 134.27 (C-
8), 130.51 (C-6), 125.34 (C-4), 123.21 (C-5), 120.12 (C-7). MS (ESI) m/z: 236.99 
[M
+•
]. 
6-methoxy-2-(1H-tetrazol-1-yl)benzo[d]thiazole (29) 
White creamy solid; Yield: 96%, m.p. 181-183 
o
C; Anal. calc. for C9H7N5OS: C, 
46.34; H, 3.02; N, 30.03; found: C, 46.32; H, 3.03; N, 30.05. IR (KBr, νmax, cm
-1
): 
1603 (C=N), 1508 (N=N), 1143 (C-N), 1128 (C-O), 638 (C-S). 
1
H NMR (400 MHz, 
DMSO-d6, δ, ppm): 8.42 (s, 1H, H-5ʹ), 7.71 (s, 1H, H-7), 7.51 (d, 1H, H-4), 7.43 (d, 
1H, H-5), 2.34 (s, 3H, OCH3). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 152.20 (C-
2), 150.28 (C-6), 142.15 (C-9), 140.29 (C-5ʹ), 136.18 (C-8), 126.13 (C-4), 121.35 (C-
5), 115.21 (C-7), 51.21 (OCH3). MS (ESI) m/z: 233.04 [M
+•
]. 
2-(1H-tetrazol-1-yl)pyridine (30) 
Colourless crystalline solid; Yield: 95%, m.p. 127 
o
C, reported 128 
o
C;
53
 Anal. calc. 
for C6H5N5: C, 48.98; H, 3.43; N, 47.60; found: C, 48.92; H, 3.38; N, 47.62. IR (KBr, 
νmax, cm
-1
): 1588 (C=N), 1512 (N=N), 1135 (C-N). 
1
H NMR (400 MHz, DMSO-d6, δ, 
ppm): 8.95 (s, 1H, H-5ʹ), 8.36 (m, 1H, H-6), 8.12 (m, 1H, H-4), 7.94 (m, 1H, H-3), 
7.38 (m, 1H, H-5). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 144.72 (C-5ʹ), 142.44 
(C-6), 138.54 (C-2), 130.36 (C-4), 121.05 (C-3), 118.14 (C-5). MS (ESI) m/z: 147.05 
[M
+•
]. 
3-(1H-tetrazol-1-yl)pyridine (31) 
White solid; Yield: 93%, m.p. 79 
o
C, reported 77 
o
C;
53
 Anal. calc. for C6H5N5: C, 
48.98; H, 3.43; N, 47.60; found: C, 49.08; H, 3.39; N, 47.56. IR (KBr, νmax, cm
-1
): 
1593 (C=N), 1507 (N=N), 1138 (C-N). 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 8.85 
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(s, 1H, H-5ʹ), 8.11 (d, 1H, H-6), 7.96 (s, 1H, H-2), 7.42 (d, 1H, H-4), 7.14 (m, 1H, H-
5). 
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 143.72 (C-2), 141.44 (C-5ʹ), 138.24 (C-
6), 132. 63 (C-4), 122.81 (C-5), 119.05 (C-3). MS (ESI) m/z: 147.05 [M
+•
]. 
4-(1H-tetrazol-1-yl)pyridine (32) 
Colourless crystals; Yield: 96%, m.p. 171 
o
C; Anal. calc. for C6H5N5: C, 48.98; H, 
3.43; N, 47.60; found: C, 48.93; H, 3.41; N, 47.68. IR (KBr, νmax, cm
-1
): 1598 (C=N), 
1503 (N=N), 1141 (C-N). 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 8.78 (s, 1H, H-
5ʹ), 8.07 (d, 2H, H-3/H-5), 7.28 (d, 2H, H-2/H-6),. 13C NMR (100 MHz, DMSO-d6, δ, 
ppm): 145.83 (C-4), 142.26 (C-5ʹ), 139.41 (C-2/C-6), 121.08 (C-3/C-5). MS (ESI) 
m/z: 147.05 [M
+•
]. 
 
In vitro inhibition studies on AChE 
The ability of all the synthesized tetrazole derivatives 18-32 to inhibit AChE activity 
is assessed by Ellman’s method.54 AChE stock solution is prepared by dissolving 
human recombinant AChE (EC: 3.1.1.7) lyophilized powder (Sigma-Aldrich) in 0.1 
M phosphate buffer (pH = 8.0) containing Triton X-100 (0.1%). Five increasing 
concentrations of test compounds are assayed to obtain % inhibition of the enzymatic 
activity in the range of 20-80. The assay solution consisted of a 0.1 M phosphate 
buffer pH 8.0, with the addition of 340 μM 5,5'-dithio-bis(2-nitrobenzoic acid), 0.02 
unit/mL of human recombinant AChE from human serum and 550 μM of substrate 
(acetylthiocholine iodide, ATCh). Increasing concentration of tested inhibitor are 
added to the assay solution and pre-incubated for 5 min at 37 °C with the enzyme 
followed by the addition of substrate. Initial rate assays are performed at 37 
o
C with a 
Jasco V-530 double beam Spectrophotometer. Absorbance value at 412 nm is 
recorded for 5 min and enzyme activity is calculated from the slope of the obtained 
linear trend. Assays are carried out with a blank containing all components except 
AChE to account for the non-enzymatic reaction. The reaction rates are compared and 
the percent inhibition due to the presence of tested inhibitors is calculated. Each 
concentration is analysed in triplicate, and IC50 values are determined graphically 
from log concentration-inhibition curves (GraphPad Prism 4.03 software, GraphPad 
Software Inc.). Tacrine is used as a standard inhibitor. 
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CONCLUSION 
This chapter reports a convenient, eco-friendly and scalable protocol approach for the 
synthesis of tetrazole derivatives 18-32 in excellent yields (90-97%) by employing 
silica-supported boric acid as a catalyst. This solvent-free, green synthetic procedure 
eliminates the use of toxic solvents and thus makes it attractive one in organic 
synthesis. The noteworthy features of this protocol are shorter reaction time, high 
purity, mild reaction conditions, operational simplicity, a cleaner reaction profile, 
enhanced reaction rates and easy workup. The present protocol demonstrates that 
optimization conditions, i.e. 2.5 mol% of the catalyst under solvent-free condition at 
90 
o
C, are the best parameters for the synthesis of tetrazole analogues in excellent 
yields for scalable purposes. All the compounds display moderate to good AChE 
inhibition potency. The results validate that the nature of substituents attached to the 
heterocyclic moieties is crucial for biological activity. We believe that this synthetic 
approach provides a better scope for the synthesis of tetrazole analogues and will be a 
more practical alternative to the other existing methods. 
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INTRODUCTION 
Erlenmeyer azlactones, 4-arylidene-2-phenyl-5(4H)-oxazolones was first reported by 
Friedrich Gustav Carl Emil Erlenmeyer way back in 1893,
1
 representing an important 
class of five-membered heterocyclic motifs possessing nitrogen and oxygen as 
heteroatoms in their structural framework. The literature reveals that the C-2 and C-4 
positions of the azlactones are significant for their various biological activities.
2
 
Azlactones have been found to be promising intermediates for the synthesis of a 
variety of organic motifs, including N-substituted pyrroles,
3
 amino acids,
4
 α-
acylaminoalcohols,
5
 thiamine,
6
 amides,
7
 peptides
8
 and other heterocyclic precursors.
9
 
They have also been used as synthons for the construction of various alkaloid 
skeletons,
10
 immunomodulators
11
 and biosensor coupling and/or photosensitive 
composition devices for proteins.
12
 Recently, Zimmermann et al.
13
 reported the 
application of azlactones for the synthesis of (meth)acrylamidopeptide 
macromonomers, employed in the synthesis of hydrogel supports for in vitro cell 
growth. Moreover, a plethora of medicinally important compounds bearing azlactones 
in their structural framework have been reported possessing antimicrobial,
14
 
antitumor,
15
 antioxidant,
16
 antiinflammatory,
17
 anti-HIV,
18
 anticonvulsant,
19
 
antihypertensive
20
 and tyrosinase inhibiting
21
 properties useful for the treatment of 
skin diseases associated with melanin hyperpigmentation (Fig. 1). They have also 
been used in active site titrations of enzymes.
22
 Such immense synthetic utility and 
inherent pharmacological applications of azlactones have inspired organic chemists to 
develop various efficient and elegant protocols for their synthesis. 
The most well-known method for the synthesis of azlactone is Erlenmeyer 
method, which involves the direct condensation of aryl aldehydes with hippuric acid 
in the presence of acetic anhydride as dehydrating agent and anhydrous sodium 
acetate as a homogeneous basic catalyst.
23
 The reaction proceeds via the formation of 
2-phenyl-5-oxazolones which undergo Perkin condensation with aromatic aldehydes 
to give the corresponding arylidene oxazolones. However, with the growing 
environmental concern and need of efficient and sustainable reaction protocol, 
motivated a great deal of interest for organic chemists towards the design of new 
reaction systems satisfying the green chemistry principles. In this perspective, organic 
chemists have developed several sophisticated synthetic methodologies for synthesis 
RSC Advances, 2015, 5, 52330-52346 
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of azlactones in presence of different catalysts under varied reaction conditions. 
 
Fig. 1 Biologically active molecules bearing oxazolone moiety in their structural 
framework 
Siddaiah and co-workers
24
 developed a simple and efficient method for the 
synthesis of 4-benzylidene-2-phenyl-5(4H)-oxazolones via reactions of hippuric acid 
with various aldehydes catalysed by 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT)/ 
N-methylmorpholine (NMM) in presence of tetrahydrofuran (THF) at 75 
o
C. 
 
R = (a) Ph; (b) 4-MeC6H4; (c) 4-OMeC6H4; (d) 3,4-(OMe)2C6H3; 
(e) 5-Cl-2,3-(OMe)2C6H2; (f) 4-ClC6H4; (g) 4-FC6H4; (h) 4-N(Me)2C6H4; 
(i) 4-NO2C6H4; (j) 3-NO2C6H4; (k) 2-C10H7; (l) 2-C4H3O; (m) 3-C6H9; (n) C2H5 
Ahmadi et al.
25
 employed Fe2O3 nanoparticles as a catalyst for the synthesis of 
azlactones via Erlenmeyer synthesis from aromatic aldehydes and hippuric acid under 
ultrasonic irradiation. The main advantages of this protocol are short reaction times, 
easy and quick isolation of the products with excellent yields. 
X = (a) H; (b) 4-Br; (c) 4-NO2; (d) 2-NO2; (e) 4-OMe 
Chapter-6 
158 
 
Tikdari et al.
26
 reported the synthesis of azlactones under microwave 
irradiation by employing three different catalysts dodecatungstophosphoric acid 
(H3PW12O40), samarium or ruthenium (III) chloride under solvent free condition and 
contemplated its comparative study in terms of yield and reaction time. It was found 
that the reaction proceeds faster in the case of dodecatungstophosphoric acid, but the 
products were obtained in high yields in the case of samarium. 
 
Ar = (a) Ph; (b) 4-ClC6H4; (c) 2,4-(Cl)2C6H3; (d) 3-NO2C6H4; (e) 4-OMeC6H4;  
(f) 4-N(Me)2C6H4; (g) 4-CH3C6H4; (h) 2-furyl; (i) 2-thiophenyl. 
Karade and co-workers
27
 outlined the synthesis of azlactones via classical 
Erlenmeyer synthesis from aromatic aldehydes and hippuric acid in acetic anhydride 
in the presence of catalytic amount of Montmorillonite K-10 by using ethyl acetate as 
a solvent at reflux temperature. 
 
Ar = (a) Ph; (b) p-OMeC6H4; (c) p-N(Me)2C6H4; (d) p-MeC6H4; (e) p-ClC6H4; 
(f) p-OHC6H4; (g) o-OHC6H4; (h) m-NO2C6H4; (i) p-NO2C6H4; (j) PhCH=CH                
Ozturk et al.
28
 reported novel 5-oxazolone derivatives containing an N-phenyl-
aza-15-crown-5 moiety synthesized via Erlenmeyer synthesis. 
 
Ar = (a) C6H5; (b) 3,5-(NO2)2C6H3; (c) 4-NO2C6H4; (d) 4-CH3C6H4. 
Puterova et al.
29
 reported the synthesis of novel 4-heteroarylidene-2-phenyl-
1,3-oxazol-5(4H)-ones by reactions of hippuric acid with substituted furo[b]pyrrole 
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type aldehydes in acetic anhydride using potassium acetate as a base under microwave 
irradiation. The effect of microwave irradiation was also compared with classical 
conditions and found that microwave irradiation shortens the reaction times with 
comparable yields. 
 
                        a (R
1
 = H, R
2
 = CH3)                b (R
1
 = H, R
2
 = C2H5) 
                        c (R
1
 = CH3, R
2
 = C2H5)          d (R
1
 = benzyl, R
2
 = C2H5) 
Patil and co-workers
30
 developed a mild, efficient and environmental friendly 
protocol for Erlenmeyer Plochl reaction using reusable basic ionic liquid 1-n-butyl-3-
methylimidazolium hydroxide ([bmIm]OH) as a catalyst as well as reaction medium, 
in low reaction time and affording comparatively high yields. 
 
R = (a) Ph; (b) p-CH3Ph; (c)  p-FPh; (d)  p-BrPh; (e) ) p-ClPh; (f)  p-NO2Ph; 
(g) p-OMePh; (h) 4-pyridyl; (i) 2-thiophenyl; (j) 2-furyl; (k) 2-naphthyl; (l) n-C3H7; 
(m) C2H5 
Heravi
31
 outlined the synthesis of a series of 4-arylidene-2-phenyl-5(4H)-
oxazolones from cyclodehydration-condensation of hippuric acid and aromatic 
aldehydes in acetic anhydride by sonochemical reaction in presence of imidazolium 
ionic liquid [bmIm][PF6] and methanol as a co-solvent at room temperature. This 
work evidenced that Erlenmeyer synthesis of azlactones conducted at relatively low 
temperature can efficiently be activated by ultrasound radiation. 
 
Ar = (a) C6H5; (b) 4-CH3C6H4; (c) 4-OMeC6H4; (d) 4-BrC6H4; (e) 2,4-Br2C6H3; 
(f) 3-NO2C6H4; (g) 4-NO2C6H4; (h) 4-ClC6H4. 
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Rostami and co-workers
32
 developed novel organic-inorganic hybrid 
polyoxometalates catalysts, consist of 1-butyl-3-methylimidazolium salts of 
(W10O32)
4-
 and (PW12O40)
3-
 polyanions ([bmim]4W10O32 and [bmim]3PW12O40) for the 
synthesis of azlactones under solvent free conditions. These heterogeneous catalysts 
can be reused for several times without loss of their catalytic properties. 
 
Ar = (a) Ph; (b) p-BrPh; (c)  p-OMePh; (d)  p-N(Me)2Ph; (e)  p-BnOPh; (f) p-NO2Ph; 
(g) p-FPh; (h) o-BrPh; (i) m-BrPh; (j) o-ClPh; (k) m-NO2Ph; (l) 2,4-Cl2Ph;  
(m) 1-naphthyl; (n) 3-indolyl. 
Yu et al.
33
 exploited Ytterbium (III) triflate as a catalyst for the synthesis of 4-
arylidene-2-phenyl-5(4)-oxazolones from hippuric acid, aromatic aldehydes and 
acetic anhydride under mild reaction conditions in excellent yields. 
 
Ar = (a) C6H5; (b) 4-MeC6H4; (c) 4-OMeC6H4; (d) 2-ClC6H4; (e) 4-ClC6H4; 
(f) 2,4-Cl2C6H3; (g) 3-NO2C6H4; (h) 4-NO2C6H4; (i) 3-indolyl. 
Chandrasekhar and Karri
34
 reported the synthesis of azlactone derivatives 
by the condensation reaction of 2-Phenyl-5(4H)-oxazolone with aliphatic aldehydes 
upon adsorption on neutral alumina and irradiation with microwaves. The 
corresponding condensation products are obtained in good yields, indicating the 
satisfactory resolution of a long-standing problem plaguing the classical Erlenmeyer 
synthesis with aliphatic aldehydes. 
 
R = (a) Et; (b) n-Pr; (c) iso-Pr; (d) iso-Bu; (e) n-C6H13 
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Motivated by these findings, and in search of novel synthetic protocols under 
the principles of green chemistry, herein, we report a convenient and expeditious 
protocol for the synthesis of Erlenmeyer azlactones from hippuric acid and aldehydes 
in the presence of Bronsted acid ionic liquid [Et3NH][HSO4] as an efficient, cheap 
and recyclable catalyst as well as solvent. The ionic liquid [Et3NH][HSO4] has been 
prepared by employing standard procedures depicted in the literature (Scheme 1).
35
 It 
has emerged as a promising catalyst in many organic transformations
36
 and possesses 
environmentally benign properties such as nontoxicity, biocompatibility, recyclability, 
inexpensiveness and thermal stability. The proficiency of this ionic liquid as both 
catalyst and medium made this protocol more practical than the already reported 
procedures as it eliminates the use of toxic and expensive acetic anhydride. Besides 
this, our present approach also displays some specific advantages as it gives excellent 
yield (%) within a minimum reaction time and can tolerate a wide range of functional 
groups. The structure of the synthesized compounds has been elucidated by FT-IR, 
1
H 
NMR, 
13
C NMR, MS and elemental analysis. Further, the structure of the model 
compound 16 has been authenticated on the basis of single-crystal X-ray analysis and 
density functional theory (DFT) calculations. 
 
RESULTS AND DISCUSSION 
In the present chapter a library of 4-arylidene-2-phenyl-5(4H)-oxazolones 
(Erlenmeyer azlactones) derivatives 16-29 have been synthesized by using 
environmentally benign ionic liquid [Et3NH][HSO4] possessing both catalytic as well 
as medium engineering capability. This protocol offers several advantages over other 
existing synthetic methodologies in terms of yield (94-97%), purity of products, 
reaction times, operational procedure, catalyst stability and recyclability. This 
synthetic scheme possesses diverse applicability and is compatible to a range of 
functional groups (electron donating/ electron withdrawing). 
Characterization of [Et3NH][HSO4] ionic liquid 
The synthetic route for the preparation of the catalyst (IL) employed in the present 
protocol has been shown in Scheme 1. The ionic liquid [Et3NH][HSO4] obtained has 
been characterized on the basis of 
1
H NMR and 
13
C NMR spectral analysis. In the 
1
H 
NMR spectrum, a triplet resonating at around δ 1.32 integrating for nine protons 
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signifies the presence of three methyl (3 × CH3) group. Similarly, a multiplet 
resonating at δ 3.25 has been attributed to six protons of methylene (3 × CH2) group. 
A sharp singlet at δ 9.08 for one proton has been assigned to -NH (D2O-
exchangeable) proton. In 
13
C NMR spectral study, a pair of strong absorption band 
resonating at around δ 16.27 and 59.35 has been assigned to methyl (CH3) and 
methylene (CH2) carbons, respectively. The spectral data is found to be in good 
agreement with the literature,
35
 thus confirms the formation of desired ionic liquid 
[Et3NH][HSO4]. 
 
Scheme 1 Pathway for the synthesis of ionic liquid 
Chemistry 
The synthetic pathway for the preparation of series of azlactones/oxazolone 16-29 has 
been depicted in Scheme 2. Herein, a series of compounds are typically accessed via a 
solvent free, efficient and environmentally benevolent cyclodehydration-condensation 
reaction process, involving various heterocyclic/ aromatic aldehydes with hippuric 
acid in the presence of IL [Et3NH][HSO4] to yield target 4-arylidene-2-phenyl-5(4H)-
oxazolones in excellent yields (94-97%) with high degree of purity. The structural 
elucidation of all the synthesized compounds 16-29 has been established on the basis 
of elemental analysis, IR, 
1
H NMR, 
13
C NMR and mass spectral studies. The 
analytical results for C, H and N are found to be within ±0.3% of the theoretical 
values. The mass spectral analysis of all the synthesized azlactone derivatives has 
been found to be in good conformity with the proposed structures. The spectral 
analysis has been in good corroboration with the expected structural framework of the 
synthesized compounds. The FT-IR spectrum (Fig. 2) of compound 16 shows strong 
absorption band at 1764 cm
-1 
which corresponds to the carbonyl group (C=O) of 
lactone ring. The absorption band at 1642 and 1531 cm
-1 
is due to the (C=N) and 
(C=C)aromatic stretching frequencies. Moreover, C-O displayed absorption band 
resonating at 1161 cm
-1
. The exocyclic double bond attached to the oxazolone ring 
displays the absorption band resonating at 1598 cm
-1
. The 
1
H NMR spectrum (Fig. 3) 
of compound 16 exhibits a characteristic sharp down field singlet resonating at around 
δ 7.36, attributed to the olefinic (=C-H) proton which is in agreement with the Z-
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configuration as reported in the literature.
37
 The aromatic protons of the phenyl ring 
attached at the position 2 of azlactones ring exhibits a multiplet resonating at δ 7.60-
8.10. The double doublet resonating at δ 7.18 and 6.64 corresponds to aromatic 
protons H-3ʹ/5ʹ and H-2ʹ/6ʹ. Moreover, singlet observed at δ 2.98 for six protons 
corresponds to the two methyl group. The 
13
C NMR spectrum (Fig. 4) of the 
compound 16 shows the absorption band resonating at δ 175.3 has assigned to the 
carbonyl group of the azlactone ring. Similarly, the signals at δ 134.8, 141.6, 151.7 
and 163.8 have been attributed to vinylic, C-4, C-4ʹ and C-2 carbons, respectively. 
Moreover, signals from δ 113.2-132.4 have been assigned to the aromatic carbons of 
the compound. The two methyl carbons show the absorption band at δ 44.1. The 
molecular structure of compound 16 is further supported by single crystal X-ray 
crystallographic analysis (Fig. 5). 
 
 
Scheme 2 Synthetic scheme for the synthesis of azlactone derivatives 16-29 
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Fig. 2 FT-IR spectrum of compound 16 
 
 
 
Fig. 3 
1
H NMR spectrum of compound 16 
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Fig. 4 
13
C NMR spectrum of compound 16 
 
 
X-ray crystallographic study of compound 16 
X-ray crystallographic analysis of the compound (16) reveals that it crystallizes in the 
monoclinic crystal system with the non-centrosymmetric and chiral space group P21 
and the whole molecule is almost planar. The crystal structure is stabilised with the 
intermolecular (C-H…O2) hydrogen bonds and intra molecular (C5-H…N2/ C18-
H…O1) hydrogen bond interactions along with the Vander Waals interactions. 
Asymmetric unit of compound 16 with the ellipsoids drawn at the 50% probability 
level is shown in Fig. 5 while the crystal data and structure refinement parameters are 
summarized in Table 1. 
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Fig. 5 Asymmetric unit of compound 16 with the ellipsoids drawn at the 50% 
probability level, with atomic labelling scheme. The intra-molecular interactions are 
drawn as dashed lines 
Table 1 Crystallographic data and structure refinement of compound 16 
 Compound 16 
Empirical formula C18H16N2O2 
Formula weight 292.33 
Temperature (K) 293(2) 
Wavelength (Å) 0.71073 
Crystal system Monoclinic 
Space group P21 
a (Å) 12.0978(3) 
b (Å) 3.97900(10) 
c (Å) 15.5788(4) 
α (o) 90 
β (o) 100.0550(10) 
λ (o) 90 
Volume (Å
3
) 738.40(3) 
Z 2 
Calculated density (g/cm
3
) 1.315 
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Absorption coefficient (mm
–1
) 0.097 
F(000) 308 
Crystal size (mm) 0.60  0.13  0.11 
θ range for data collection (o) 3.41-26.05 
Index ranges -14 < h < 14, -4 < k < 4, -19 < l < 18 
Reflections collected/unique 13647/2873  [R(int) = 0.0208] 
Completeness to θ = 25.00o 99.6 % 
Refinement method Full-matrix least-squares on F
2 
Data/restraints/parameters 2873/1/201 
Goodness-of-fit on F
2 
1.040 
Final R indices [I > 2σ(I)] R1 = 0.0352 wR2 = 0.0877 
R indices (all data) R1 = 0.0422 wR2 = 0.0924 
Largest diff. peak and hole (e Å
-3
) 0.135 and -0.180 
 
DFT calculations 
The stereochemistry around C=C is authenticated by single crystal X-ray 
crystallographic analysis of compound 16, where C=C is found to have Z-geometry. 
Among the two possible geometrical isomers (E/Z), Z-isomer has been obtained as the 
exclusive products (Fig. 5), which has been well established further on the basis of 
density functional theory (DFT) calculations. This Z-selectivity can be interpreted as a 
way to minimise steric interactions among various substituents. To compare the 
relative stability of the E and Z-isomers of the compound 16, we have performed the 
calculation of the vacuum single-point energies of the optimized geometries to obtain 
the energy differences. It is found that the Z-isomer is stabilised by 2.32 kcal mol
-1
 
more than the E-isomer. This difference in energy is the reason that during 
crystallization process, Z-isomer gets exclusively crystallised out. Moreover, the 
intramolecular hydrogen bonding between H5 of N,N-dimethyl phenyl ring and N2 of 
the azlactone ring enhances its stability which promotes its selectivity than the 
corresponding E-isomer (Fig. 5). The rotations about single bonds (intramolecular 
torsions) are worth 1-3 kcal mol
-1
 but can be as high as 10 kcal mol
-1
 due to steric 
factors or restricted rotation,
38
 so this can easily explain the calculated energy 
differences. The agreement between the experimental and calculated geometry has 
been found to be good (Table 2) and our data suggests that the supramolecular 
Chapter-6 
168 
 
aggregation has little importance in the stabilization of the observed molecular 
geometry. On the basis of these results, all the synthesized compounds were believed 
to possess Z-configuration across C=C. 
Table 2 Comparison of selected geometrical parameters for compound 16 as 
determined by X-ray diffraction and from DFT calculation 
Torsion angle (
o
) Experimental DFT 
C6-C9-C10-N2 -0.2(4) -0.09 
C7-C6-C9-C10 -175.1(2) 179.94 
N1-C3-C8-C7 -178.9(2) -179.52 
C12-O1-C11-O2 -178.3(2) 179.97 
N2-C12-C13-C14 1.8(4) -0.13 
Note: In a chain of atoms A-B-C-D, a positive torsion angle correspond to a 
clockwise rotation of the bond A-B in order that it may eclipse the bond C-D and a 
negative torsion angle requires a rotation in the opposite sense. So, the absolute 
differences between the torsion angles presented are relatively small. 
 
Reaction mechanism 
The probable mechanistic pathway for the IL [Et3NH][HSO4] catalysed synthesis of 
azlactone derivatives has been proposed in Scheme 3. The reaction is initiated with 
the protonation of carboxylic group of the hippuric acid by protic ionic liquid 
[Et3NH][HSO4] catalyst which is believed to facilitate the cyclodehydration of the 
substrate to form intermediate (I) which is resonance stabilised as intermediate (II). 
The further protonation of the carbonyl group of the aldehydes by the catalyst 
generates active electrophilic site for the attack of intermediate (II) which facilitates 
the formation of C-C bond to yield intermediate (III). The subsequent elimination of 
water molecule from intermediate (III) promoted by the ionic liquid eventually leads 
to the formation of target azlactone with the regeneration of the catalyst 
[Et3NH][HSO4]. 
Optimization of reaction condition 
Initially, I focused my study to probe the optimized reaction conditions for the present 
protocol including amount of catalyst, reaction temperature and investigating 
efficiency of various catalyst on a selected model reaction using p-(N,N-
dimethylamino)benzaldehyde 1 and hippuric acid 15 to establish the best possible 
reaction conditions for the synthesis of azlactone 16. In order to optimize the reaction 
conditions we first probe the effect of the catalyst loading by carrying out the model 
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reaction with different concentration of the catalyst viz. 3, 5, 10, 15, 20 and 25 mol% 
at 100 
o
C under solvent free condition and the results are noted in terms of reaction 
time and yield (Table 3). The results reveal that with every subsequent increase in 
concentration of catalyst from 3 mol% to 20 mol%, there has been a significant 
improvement in the yield from 55-97 %, with prominent drop in reaction time from 
140-15 min (entries 1-5). However, further increase in the concentration of the 
catalyst (>20 mol%) does not have any significant effect on the reaction. It can be 
inferred from the above results that 20 mol% of the catalyst is satisfactory to gain the 
optimum yield in the shortest reaction time under neat conditions at 100 
o
C, therefore 
20 mol% of the catalyst is selected for further studies. 
 
Scheme 3 Plausible mechanistic catalytic cycle for the synthesis of target azlactone 
derivatives 16-29 
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Table 3 Effect of catalyst loading on the model reaction
a 
Entry Catalyst (mol%) Time (min)
b
 Yield (%)
c
 
1 3 140 55 
2 5 95 63 
3 10 70 73 
4 15 45 82 
5 20 15 97 
6 25 15 97 
a
Reaction conditions: p-(N,N-dimethylamino)benzaldehyde (1, 2 mmol), hippuric acid (15, 2 
mmol), [Et3NH][HSO4] (3-25 mol%), 100 
o
C; 
b
Reaction Progress monitored by TLC; 
c
Isolated yield of products. 
 
In order to optimize the reaction temperature for the present study we have 
carried out the model reaction at different temperatures (Table 4). It is noticed that 
the reaction is strongly influenced by the temperature in terms of yield and reaction 
time. Initially the reaction is allowed to stir at room temperature it takes almost 5 h to 
complete the reaction with poor yield of the product 16. With increase in temperature 
from 25 to 100 
o
C, the yield of the desired product 16 increases significantly from 35-
97 % within the minimum period of reaction time (entries 1–5). However, no further 
enhancement in the yield of product 16 is witnessed when the reaction temperature is 
raised from 100 to 120 
o
C. Thus, keeping in view the above optimized reaction 
conditions, 100 
o
C is chosen as the optimum temperature for all the reactions. 
Table 4 Effect of temperature on the model reaction
a
 
Entry Temp. (
o
C) Time (min)
b
 Yield (%)
c
 
1 Room Temp. 5 h 35 
2 50 2 h 54 
3 70 1.5 h 67 
4 90 40 73 
5 100 15 97 
6 110 15 97 
a
Reaction conditions: p-(N,N-dimethylamino)benzaldehyde (1, 2 mmol), hippuric acid (15, 2 
mmol), [Et3NH][HSO4] (20 mol%), 25-110 
o
C; 
b
Reaction Progress monitored by TLC; 
c
Isolated yield of products.
 
 
In order to establish the superiority of our synthesized ionic liquid 
[Et3NH][HSO4] for the present protocol we have screened different ionic liquids on 
the model reaction. Table 5 lists the effect of different ionic liquids on the model 
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reaction without using any volatile organic solvents. It is clear from table that the 
catalytic activity is potentially influenced by the anionic part of the ionic liquids. The 
higher yield of the product is obtained when the strongly acidic HSO4ˉ anion is 
explored (Table 5). However, the reaction is slow and less efficient when the ionic 
liquids with [H2PO4ˉ] and [CH3COOˉ] anions are probed, which may be due to the 
weaker acidity of the phosphate and acetate anions as compared to [HSO4ˉ] anion. 
The above results demonstrate that the reaction is strongly influenced by the acidity of 
the ionic liquids. This can be presumably attributed to the pKa values (acid 
dissociation constant) of their respective anions (HSO4ˉ, H2PO4ˉ and CH3COOˉ) 
which offer a quantitative measurement of the strength of an acid, smaller the pKa 
value, stronger is the acid. The results obtain in terms of products yield and reaction 
time are in good agreement with acidity/ pKa values of their respective anions which 
follow the order as: HSO4ˉ (pKa =-3) > H2PO4ˉ (pKa = 2.15) > CH3COOˉ (pKa = 4). 
In order to probe the effect of cationic part of the ionic liquid on the azlacones 
synthesis, the reaction is performed in quaternary ammonium cationic bisulfate ionic 
liquids with different alkyl chain length. It is found that the cations with shorter alkyl 
chains gives better yield and the efficiency of the ionic liquids decrease sequentially 
with the increase in the cation chain length of the ionic liquid (entries 1-3). The 
reason may be that the longer alkyl groups of the ammonium cations lead to bigger 
aggregations.
39
 The cationic ILs with short alkyl chains does not form definite 
aggregations but those with longer alkyl chains gradually form well-defined 
aggregations.
40
 These aggregations may lead to non-uniform and co-adjacent structure 
of ILs systems, which causes complication for the transfer of electrons and protons in 
the molecular interior, thus hindering the reaction which leads to decrease in the yield 
of the products with stretched reaction times. The similar results are obtained in the 
case of [HPO4ˉ] and [CH3COOˉ] that increasing the cationic chain length decreases 
the yield of the product (entries 4-7). These results suggest that the cation part of the 
ionic liquid influences the reactivity of ionic liquid to a greater extent. Thus, it is 
obvious that tuning of triethyl ammonium cation by HSO4ˉ anion in the present study 
provides excellent yields (94-97 %) of the desired products 16. These results imply 
that [Et3NH][HSO4] is the best ionic liquid catalyst/promoter for the synthesis of 
present azlactone derivatives. 
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Table 5 Effect of ionic liquids on the model reaction
a 
Entry Catalyst Time (min)
b
 Yield (%)
c
 
1 [Et3NH][HSO4] 15 97 
2 [Pr3NH][HSO4] 30 90 
3 [Bu3NH][HSO4] 45 84 
4 [Et3NH][H2PO4] 40 86 
5 [Bu3NH][H2PO4] 55 68 
6 [Et3NH][CH3COO] 48 78 
7 [Bu3NH][CH3COO] 60 60 
a
Reaction conditions: p-(N,N-dimethylamino)benzaldehyde (1, 2 mmol), hippuric acid (15, 2 
mmol), different ionic liquids (20 mol%), 100 
o
C; 
b
Reaction Progress monitored by TLC; 
c
Isolated yield of products. 
 
After optimization of the reaction conditions, the substrate scope of 
[Et3NH][HSO4] catalysed system is inspected under the optimized reaction 
conditions. As shown in Table 6, a wide variety of heterocyclic/ aromatic aldehydes 
possessing electron-withdrawing and electron-donating groups react with hippuric 
acid to afford the corresponding azlactones in excellent yields (94-97%). The results 
reveal that employing ionic liquids [Et3NH][HSO4] in the present protocol enhances 
selectivity and product conversion, thus, proves beneficial for the synthesis of 
azlactones in terms of yield and reaction times. An important feature of these 
reactions in ionic liquids is that there is no evidence for significant formation of a side 
reaction and the efficient conversion is noticed in the sulfate acid ionic liquids. 
Table 6 Synthesis of azlactone derivatives 16-29 
S. 
No. 
Reactants (1-14) Products (16-29) Time 
(min)
a
 
Yield 
(%)
b
 
 
 
1 
 
  
 
 
15 
 
 
97 
 
 
2 
 
 
 
 
 
18 
 
 
95 
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3 
 
 
 
 
 
22 
 
 
94 
 
 
4 
 
 
 
 
 
20 
 
 
96 
 
5 
 
 
 
23 
 
95 
 
6 
 
 
 
18 
 
96 
 
7 
 
 
 
17 
 
97 
 
8 
 
 
 
15 
 
96 
 
9 
 
 
 
24 
 
95 
 
10 
 
 
 
25 
 
96 
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11 
 
 
 
22 
 
94 
 
 
12 
 
 
 
 
 
 
20 
 
 
97 
 
13 
 
 
 
19 
 
94 
 
14 
 
 
 
20 
 
95 
a
Reaction progress monitored by TLC; 
b
Isolated yield of products 
 
Recyclability of the catalyst (IL) 
The recycling of catalyst is an important step, so as to satisfy the criteria of green 
chemistry principles and also to manage the cost of the process. In order to explore 
the extent of recyclability of our catalyst system, the model reaction has been 
conducted six consecutive times on the same recycled catalyst. After first fresh run 
with 97 % yield, water is added to the reaction mixture and the product is isolated by 
filtration. The ionic liquid is recovered from the filtrate by removing the water under 
reduced pressure. The recovered catalyst is then reused for five more subsequent 
cycles and found to retain its catalytic activity and shows minimal decreases in yield. 
The product is obtained in 94 %, 91 %, 88 %, 85 %, and 83 % yield after successive 
cycles (Fig. 5) thus, proving the catalyst's reusability with high catalytic 
performances. The results demonstrate that our catalytic system is almost stable 
towards moisture and can be recycled without a significant loss in yield. 
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Fig. 6 Recyclability of the catalyst 
 
EXPERIMENTAL 
Materials and general methods 
All the reagents are purchased from Merck and Sigma-Aldrich (India) as ‘synthesis 
grade’ and used without further purification. Melting points of all synthesized 
compounds are determined on a Kofler apparatus and are uncorrected. Fourier 
Transform-Infrared (FT-IR) spectra are recorded in the 400-4000 cm
-1
 wave-number 
range using a Perkin-Elmer (2000 FTIR) Spectrometer by the KBr pellet method. 
1
H 
NMR and 
13
C NMR spectra are recorded on a Bruker Avance-II 400 MHz instrument 
in CDCl3 solvent. The chemical shifts (δ) are reported in ppm relative to the TMS as 
an internal standard. Mass spectra are recorded on a JEOL D-300 mass spectrometer. 
Elemental analysis (C, H and N) is conducted using a Thermo Scientific (FLASH 
2000) CHN Elemental Analyser. Thin layer chromatography (TLC) glass plates 
coated with silica gel G254 (E-Merck) are used to check the purity of the reagent as 
well as the progress of the reaction. 
Synthesis of ionic liquids (Triethylammonium sulfate [Et3NH][HSO4]) 
The [Et3NH][HSO4] ionic liquid is synthesized by the standard procedure as reported 
earlier in the literature.
35
 The synthesis of ionic liquid is carried out in a 500 ml 
round-bottomed flask, which is immersed in a recirculating heated water-bath and 
fitted with a reflux condenser. Sulfuric acid (98 g, 1.0 mol) 98 % solution in water is 
added drop wise into the triethylamine (101 g, 1.0 mol) at 60 
o
C in 1 h. After 
0
20
40
60
80
100
1 2
3
4
5
6
15 15 16 18 20 
20 
97 
94 
91 
88 
85 
83 
Time (min)
Yield (%)
No. of Cycles 
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complete addition, the reaction mixture is stirred for another 1 h at 70 
o
C to ensure the 
reaction had proceeded to completion. The traces of water are removed by heating the 
residue at 80 
o
C in high vacuum (5 mm Hg) until the weight of the residue remained 
constant. 
1
H NMR (400 MHz, DMSO-d6, δ, ppm): 1.32 (t, 9H), 3.25 (m, 6H), 9.08 (s, 1H, D2O 
exchangeable).  
13
C NMR (100 MHz, DMSO-d6, δ, ppm): 16.27 (CH3), 59.35 (CH2). 
The other ionic liquids i.e. [Pr3NH][HSO4], [Bu3NH][HSO4], [Et3NH][H2PO4], 
[Bu3NH][H2PO4], [Et3NH][CH3COO] and [Bu3NH][CH3COO] used for the 
comparative study with respect to [Et3NH][HSO4] are synthesized with the similar 
standard procedures as depicted in literature.
35 
General procedure for the synthesis of azlactones under solvent free conditions 
The solution of hippuric acid 15 (2 mmol) and 20 mol% of the ionic liquids 
[Et3NH][HSO4] is allowed to stir at 80 
o
C for 5 min. After 5 min, aldehyde (1-14) (2 
mmol) is added to the reaction mixture and is further heated at 100 
o
C with constant 
stirring. After completion of the reaction as evident from thin layer chromatography 
(TLC), the reaction mixture is allowed to cool at room temperature and the reaction 
mixture solidifies spontaneously. Then water is added to the reaction mixture and is 
further stirred for 5 min. The precipitate is isolated by simple filtration, washed with 
appropriate solvents. The water is removed from filtrate under reduced pressure to 
recover the ionic liquid, which is then reused in subsequent cycles. The crude product 
obtained is recrystallized with chloroform-methanol to afford the pure product (16-
29). 
 
Spectral characterization 
(Z)-4-(4-(dimethylamino)benzylidene)-2-phenyloxazol-5(4H)-one (16) 
Red needle shaped crystal; Yield: 97%, m.p. 215 
o
C, reported 212-214 
o
C;
24
 Anal. 
calc. for C18H16N2O2: C, 73.95; H, 5.52; N, 9.58; found: C, 73.75; H, 5.69; N, 9.46. 
IR (KBr, νmax, cm
-1
): 1764 (C=O), 1642 (C=N), 1598 (C=C), 1161 (C-O)lactone. 
1
H 
NMR (400 MHz, CDCl3, δ, ppm): 7.60-8.10 (m, 5H, ArH), 7.36 (s, 1H, =C-H), 7.18 
(dd, 2H, H-3ʹ/H-5ʹ), 6.64 (dd, 2H, H-2ʹ/H-6ʹ), 2.98 (s, 6H, 2 × CH3). 
13
C NMR (100 
MHz, CDCl3, δ, ppm): 175.3 (C-5), 163.8 (C-2), 151.7 (C-4ʹ), 141.6 (C-4), 134.8 (H-
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C=C), 132.4 (C-2ʹ/C-6ʹ), 131.2 (C-4″), 129.8 (C-1ʹ), 128.9 (C-3″/C-5″), 128.1 (C-
2″/C-6″), 126.8 (C-1″), 113.2 (C-3ʹ/C-5ʹ), 44.1 (2 × CH3). MS (ESI) m/z: 292.12 
[M
+•
]. 
(Z)-4-(4-fluorobenzylidene)-2-phenyloxazol-5(4H)-one (17) 
Yellow crystalline solid; Yield: 95%, m.p. 181 
o
C, reported 183-185 
o
C;
24
 Anal. calc. 
for C16H10FNO2: C, 71.91; H, 3.77; N, 5.24; found: C, 71.88; H, 3.73; N, 5.27. IR 
(KBr, νmax, cm
-1
): 1778 (C=O), 1656 (C=N), 1594 (C=C), 1195 (C-O)lactone. 
1
H NMR 
(400 MHz, CDCl3, δ, ppm): 7.56-8.05 (m, 5H, ArH), 7.98 (dd, 2H, H-2ʹ/H-6ʹ), 7.54 
(dd, 2H, H-3ʹ/H-5ʹ), 7.32 (s, 1H, =C-H). 13C NMR (100 MHz, CDCl3, δ, ppm): 173.8 
(C-5), 163.4 (C-4ʹ), 162.7 (C-2), 143.2 (C-4), 135.3 (H-C=C), 133.8 (C-2ʹ/C-6ʹ), 
132.8 (C-4″), 130.3 (C-1ʹ), 129.6 (C-3″/C-5″), 128.1 (C-2″/C-6″), 127.3 (C-1″), 116.8 
(C-3ʹ/C-5ʹ),. MS (ESI) m/z: 267.07 [M+•]. 
(Z)-4-(4-hydroxy-3-methoxybenzylidene)-2-phenyloxazol-5(4H)-one (18) 
Yellowish solid; Yield: 94%, m.p. 122-125 
o
C; Anal. calc. for C17H13NO4: C, 69.15; 
H, 4.44; N, 4.74; found: C, 69.18; H, 4.41; N, 4.69. IR (KBr, νmax, cm
-1
): 3211 (O-H), 
1767 (C=O), 1640 (C=N), 1597 (C=C), 1202 (C-O)lactone. 
1
H NMR (400 MHz, CDCl3, 
δ, ppm): 7.52-8.06 (m, 5H, ArH), 7.43 (s, 1H, =C-H), 7.32 (d, 1H, H-6ʹ), 7.21 (d, 1H, 
H-5ʹ), 7.17 (s, 1H, H-2ʹ), 5.28 (s, 1H, -OH), 3.52 (s, 3H, -OCH3). 
13
C NMR (100 
MHz, CDCl3, δ, ppm): 171.6 (C-5), 162.4 (C-2), 152.5 (C-3ʹ), 143.4 (C-4ʹ), 141.8 (C-
4), 135.4 (H-C=C), 132.8 (C-4″), 132.4 (C-1ʹ), 129.3 (C-3″/C-5″), 128.7 (C-2″/C-6″), 
127.5 (C-1″), 121.3 (C-6ʹ), 115.8 (C-5ʹ), 112.2 (C-2ʹ), 55.4 (-OCH3). MS (ESI) m/z: 
295.08 [M
+•
]. 
(Z)-4-(4-nitrobenzylidene)-2-phenyloxazol-5(4H)-one (19) 
Yellowish solid; Yield: 96%, m.p. 243 
o
C, reported 240-241 
o
C;
24
 Anal. calc. for 
C16H10N2O4: C, 65.31; H, 3.43; N, 9.52; found: C, 65.35; H, 3.39; N, 9.57. IR (KBr, 
νmax, cm
-1
): 1771 (C=O), 1648 (C=N), 1602 (C=C), 1528, 1342 (NO2), 1208 (C-
O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 8.20 (dd, 2H, H-3ʹ/H-5ʹ), 7.62-8.05 (m, 
5H, ArH), 7.96 (dd, 2H, H-2ʹ/H-6ʹ), 7.36 (s, 1H, =C-H). 13C NMR (100 MHz, CDCl3, 
δ, ppm): 173.2 (C-5), 161.7 (C-2), 147.5 (C-4ʹ), 142.6 (C-4), 138.2 (C-1ʹ),134.8 (H-
C=C), 132.4 (C-2ʹ/C-6ʹ), 131.1 (C-4″), 129.2 (C-3″/C-5″), 128.3 (C-2″/C-6″), 126.9 
(C-1″), 118.5 (C-3ʹ/C-5ʹ). MS (ESI) m/z: 294.06 [M+•]. 
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(Z)-4-(3-nitrobenzylidene)-2-phenyloxazol-5(4H)-one (20) 
Yellow crystalline solid. Yield: 92%, m.p. 164 
o
C, reported 166-167 
o
C;
24
 Anal. calc. 
for C16H10N2O4: C, 65.31; H, 3.43; N, 9.52; found: C, 65.27; H, 3.48; N, 9.48. IR 
(KBr, νmax, cm
-1
): 1769 (C=O), 1652 (C=N), 1605 (C=C), 1526, 1344 (NO2), 1205 
(C-O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 8.54 (s, 1H, H-2ʹ), 8.19 (dd, 1H, H-
4ʹ), 7.50-7.95 (m, 5H, ArH), 7.84 (dd, 1H, H-6ʹ), 7.62 (t, 1H, H-5ʹ), 7.41 (s, 1H, =C-
H). 
13
C NMR (100 MHz, CDCl3, δ, ppm): 171.5 (C-5), 160.9 (C-2), 148.5 (C-3ʹ), 
141.8 (C-4), 135.1 (H-C=C), 134.3 (C-1ʹ), 132.8 (C-6ʹ), 131.8 (C-4″), 129.9 (C-5ʹ), 
129.1 (C-3″/C-5″), 128.8 (C-2″/C-6″), 127.6 (C-1″), 125.4 (C-4ʹ), 121.7 (C-2ʹ). MS 
(ESI) m/z: 294.06 [M
+•
]. 
(Z)-4-((4-oxo-4H-chromen-3-yl)methylene)-2-phenyloxazol-5(4H)-one (21) 
Cream coloured crystalline solid; Yield: 93%, m.p. 205-207 
o
C; Anal. calc. for 
C19H11NO4: C, 71.92; H, 3.49; N, 4.41; found: C, 71.96; H, 3.45; N, 4.43. IR (KBr, 
νmax, cm
-1
): 1745 (C=O)lactone, 1654 (C=O)γ-pyrone, 1646 (C=N), 1613 (C=C)γ-pyrone, 
1603 (C=C), 1201 (C-O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 7.90-8.09 (m, 
5H, ArH), 7.95 (dd, 2H, H-5 ʹ/H-8 ʹ), 7.50 (dd, 2H, H-6 ʹ/H-7ʹ), 7.40 (s, 1H, =C-H), 
7.28 (s, 1H, H-2ʹ). 13C NMR (100 MHz, CDCl3, δ, ppm): 178.5 (C-4ʹ), 170.8 (C-5), 
162.5 (C-2ʹ), 161.4 (C-2), 154.5 (C-8ʹa), 140.9 (C-4), 134.7 (H-C=C), 134.2 (C-7ʹ), 
131.9 (C-4″), 129.9 (C-3″/C-5″), 129.1 (C-2″/C-6″), 126.7 (C-1″), 125.7 (C-6ʹ), 124.2 
(C-5ʹ), 122.6 (C-4ʹa), 118.4 (C-8ʹ), 115.4 (C-3ʹ). MS (ESI) m/z: 317.07 [M+•]. 
(Z)-4-((6-methyl-4-oxo-4H-chromen-3-yl)methylene)-2-phenyloxazol-5(4H)-one 
(22) 
Orange coloured solid; Yield: 94%, m.p. 210 
o
C; Anal. calc. for C20H13NO4: C, 72.50; 
H, 3.95; N, 4.23; found: C, 72.86; H, 3.98; N, 4.21. IR (KBr, νmax, cm
-1
): 1748 
(C=O)lactone, 1651 (C=O)γ-pyrone, 1639 (C=N), 1622 (C=C)γ-pyrone, 1608 (C=C), 1206 
(C-O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 7.85-8.05 (m, 5H, ArH), 7.80 (s, 
1H, H-5ʹ), 7.42 (dd, 1H, H-7ʹ), 7.32 (d, 1H, H-8ʹ), 7.35 (s, 1H, =C-H), 6.96 (s, 1H, H-
2ʹ), 2.48 (s, 3H, -CH3). 
13
C NMR (100 MHz, CDCl3, δ, ppm): 176.9 (C-4ʹ), 173.5 (C-
5), 164.1 (C-2), 162.1 (C-2ʹ), 154.0 (C-8ʹa), 141.8 (C-4), 138.3 (C-7ʹ), 135.8 (C-6ʹ), 
133.2 (H-C=C), 131.3 (C-4″), 128.6 (C-3″/C-5″), 127.9 (C-2″/C-6″), 125.8 (C-1″), 
123.4 (C-5ʹ), 122.0 (C-4ʹa), 117.8 (C-3ʹ), 115.4 (C-8ʹ), 21.0 (-CH3). MS (ESI) m/z: 
331.08 [M
+•
]. 
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(Z)-4-((6-bromo-4-oxo-4H-chromen-3-yl)methylene)-2-phenyloxazol-5(4H)-one 
(23) 
Yellow powder; Yield: 93%, m.p. 197-199 
o
C; Anal. calc. for C19H10BrNO4: C, 
57.60; H, 2.54; N, 3.54; found: C, 57.63; H, 2.51; N, 3.57. IR (KBr, νmax, cm
-1
): 1752 
(C=O)lactone, 1658 (C=O)γ-pyrone, 1643 (C=N), 1617 (C=C)γ-pyrone, 1606 (C=C), 1204 
(C-O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 7.81-8.02 (m, 5H, ArH), 7.82 (s, 
1H, H-5ʹ), 7.50 (dd, 1H, H-7ʹ), 7.42 (s, 1H, =C-H), 7.32 (d, 1H, H-8ʹ), 7.23 (s, 1H, H-
2ʹ). 13C NMR (100 MHz, CDCl3, δ, ppm): 177.9 (C-4ʹ), 173.6 (C-5), 161.7 (C-2), 
160.3 (C-2ʹ), 153.6 (C-8ʹa), 140.3 (C-4), 135.1 (H-C=C), 134.3 (C-7ʹ), 131.7 (C-4″), 
129.8 (C-3″/C-5″), 129.2 (C-6ʹ), 128.9 (C-2″/C-6″), 127.0 (C-1″), 123.8 (C-5ʹ), 122.9 
(C-4ʹa), 119.5 (C-8ʹ), 119.2 (C-3ʹ). MS (ESI) m/z: 394.98 [M+•]. 
(Z)-4-((6-fluoro-4-oxo-4H-chromen-3-yl)methylene)-2-phenyloxazol-5(4H)-one 
(24) 
Yellow solid; Yield: 95%, m.p. 216 
o
C; Anal. calc. for C19H10FNO4: C, 68.06; H, 
3.01; N, 4.18; found: C, 68.03; H, 3.04; N, 4.20. IR (KBr, νmax, cm
-1
): 1756 
(C=O)lactone, 1665 (C=O)γ-pyrone, 1647 (C=N), 1619 (C=C)γ-pyrone, 1610 (C=C), 1209 
(C-O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 7.99-8.15 (m, 5H, ArH), 7.82 (s, 
1H, H-5ʹ), 7.54 (dd, 1H, H-7ʹ), 7.36 (s, 1H, =C-H), 7.29 (d, 1H, H-8ʹ), 7.21 (s, 1H, H-
2ʹ). 13C NMR (100 MHz, CDCl3, δ, ppm): 176.5 (C-4ʹ), 172.1 (C-5), 162.8 (C-2ʹ), 
160.3 (C-2), 150.9 (C-8ʹa), 141.4 (C-4), 138.7 (C-6ʹ), 133.8 (H-C=C), 131.9 (C-4″), 
129.4 (C-3″/C-5″), 128.2 (C-2″/C-6″), 126.4 (C-1″), 125.2 (C-4ʹa), 124.1 (C-7ʹ), 122.3 
(C-8ʹ), 121.8 (C-5ʹ), 118.3 (C-3ʹ). MS (ESI) m/z: 335.06 [M+•]. 
(Z)-4-((6-chloro-4-oxo-4H-chromen-3-yl)methylene)-2-phenyloxazol-5(4H)-one 
(25) 
Yellow crystalline solid; Yield: 96%, m.p. 204-206 
o
C; Anal. calc. for C19H10ClNO4: 
C, 64.88; H, 2.87; N, 3.98; found: C, 64.91; H, 2.89; N, 3.95. IR (KBr, νmax, cm
-1
): 
1753 (C=O)lactone, 1661 (C=O)γ-pyrone, 1645 (C=N), 1617 (C=C) γ-pyrone, 1609 (C=C), 
1207 (C-O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 7.83-8.04 (m, 5H, ArH), 7.89 
(s, 1H, H-5ʹ), 7.63 (dd, 1H, H-7ʹ), 7.38 (s, 1H, =C-H), 7.28 (s, 1H, H-2ʹ), 7.25 (d, 1H, 
H-8ʹ). 13C NMR (100 MHz, CDCl3, δ, ppm): 177.4 (C-4ʹ), 171.8 (C-5), 161.3 (C-2ʹ), 
159.7 (C-2), 152.8 (C-8ʹa), 140.6 (C-4), 135.8 (C-7ʹ), 133.9 (H-C=C), 132.8 (C-6ʹ), 
132.0 (C-4″), 129.2 (C-3″/C-5″), 128.7 (C-2″/C-6″), 126.8 (C-1″), 123.5 (C-5ʹ), 122.9 
(C-4ʹa), 118.4 (C-8ʹ), 117.9 (C-3ʹ),. MS (ESI) m/z: 351.03 [M+•]. 
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(Z)-4-((1H-indol-3-yl)methylene)-2-phenyloxazol-5(4H)-one (26) 
Yellow crystalline solid; Yield: 94%, m.p. 210 
o
C, reported 207-208 
o
C;
32
 Anal. calc. 
for C18H12N2O2: C, 74.99; H, 4.20; N, 9.72; found: C, 74.96; H, 4.23; N, 9.70. IR 
(KBr, νmax, cm
-1
): 3442 (N-H), 1753 (C=O), 1641 (C=N)lactone, 1609 (C=C), 1215 (C-
O)lactone. 
1
H NMR (400 MHz, CDCl3, δ, ppm): 12.35 (s, 1H, -NH), 8.45 (dd, 1H, H-
7ʹ), 8.35 (d, 1H, H-4ʹ), 8.29 (m, 2H, H-5ʹ/H-6ʹ), 7.75-7.99 (m, 5H, ArH), 7.53 (s,1H, 
H-2ʹ), 7.40 (s, 1H, =C-H). 13C NMR (100 MHz, CDCl3, δ, ppm): 171.7 (C-5), 162.9 
(C-2), 137.6 (C-4), 133.4 (C-7ʹa), 132.5 (H-C=C), 131.2 (C-4″), 130.1 (C-2ʹ), 129.5 
(C-3ʹa), 128.9 (C-3″/C-5″), 128.1 (C-2″/C-6″), 126.2 (C-1″), 123.4 (C-6ʹ), 121.8 (C-
5ʹ), 120.8 (C-4ʹ), 116.4 (C-3ʹ), 112.1 (C-7ʹ). MS (ESI) m/z: 288.09 [M+•]. 
(Z)-4-((1H-pyrrol-3-yl)methylene)-2-phenyloxazol-5(4H)-one (27) 
Yellow crystalline solid; Yield: 97%, m.p. 182-184 
o
C; Anal. calc. for C14H10N2O2: C, 
70.58; H, 4.23; N, 11.76; found: C, 70.60; H, 4.21; N, 11.72. IR (KBr, νmax, cm
-1
): 
3439 (N-H), 1756 (C=O), 1638 (C=N)lactone, 1611 (C=C), 1198 (C-O)lactone. 
1
H NMR 
(400 MHz, CDCl3, δ, ppm): 11.96 (s, 1H, -NH), 7.71-7.93 (m, 5H, ArH), 7.78 (d, 1H, 
H-5ʹ), 7.65 (s, 1H, H-2ʹ), 7.41 (s, 1H, =C-H), 7.35 (d, 1H, H-4ʹ). 13C NMR (100 MHz, 
CDCl3, δ, ppm): 170.1 (C-5), 161.3 (C-2), 136.4 (C-4), 133.6 (C-5ʹ), 132.7 (H-C=C), 
131.7 (C-4″), 129.2 (C-3″/C-5″), 128.4 (C-2″/C-6″), 127.3 (C-2ʹ), 126.8 (C-1″),     
122.4 (C-3ʹ), 115.9 (C-4ʹ),. MS (ESI) m/z: 238.07 [M+•]. 
(Z)-4-(furan-3-ylmethylene)-2-phenyloxazol-5(4H)-one (28) 
Pale yellow powder; Yield: 94%, m.p. 198 
o
C, reported 195-197 
o
C;
26
 Anal. calc. for 
C14H9NO3: C, 70.29; H, 3.79; N, 5.86; found: C, 70.31; H, 3.77; N, 5.85. IR (KBr, 
νmax, cm
-1
): 1765 (C=O), 1641 (C=N)lactone, 1624 (C=C), 1203 (C-O)lactone. 
1
H NMR 
(400 MHz, CDCl3, δ, ppm): 8.11 (s, 1H, H-2ʹ), 7.92 (d, 1H, H-5ʹ), 7.73-7.97 (m, 5H, 
ArH), 7.55 (d, 1H, H-4ʹ), 7.35 (s, 1H, =C-H). 13C NMR (100 MHz, CDCl3, δ, ppm): 
172.5 (C-5), 160.7 (C-2), 141.2 (C-5ʹ), 134.3 (C-2ʹ), 137.4 (C-4), 132.7 (H-C=C), 
131.4 (C-4″), 129.9 (C-3″/C-5″), 128.8 (C-2″/C-6″), 127.3 (C-1″), 122.8 (C-3ʹ), 110.8 
(C-4ʹ),. MS (ESI) m/z: 239.06 [M+•]. 
(Z)-4-(thiophen-3-ylmethylene)-2-phenyloxazol-5(4H)-one (29) 
Bright yellow solid; Yield: 95%, m.p. 177 
o
C, reported 178-179 
o
C;
26
 Anal. calc. for 
C14H9NO2S: C, 65.87; H, 3.55; N, 5.49; found: C, 65.85; H, 3.58; N, 5.52. IR (KBr, 
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νmax, cm
-1
): 1763 (C=O), 1639 (C=N)lactone, 1612 (C=C), 1207 (C-O)lactone. 
1
H NMR 
(400 MHz, CDCl3, δ, ppm): 7.84-7.98 (m, 5H, ArH), 7.97 (s, 1H, H-2ʹ), 7.80 (d, 1H, 
H-5ʹ), 7.45 (d, 1H, H-4ʹ), 7.35 (s, 1H, =C-H). 13C NMR (100 MHz, CDCl3, δ, ppm): 
171.3 (C-5), 161.2 (C-2), 137.2 (C-5ʹ), 136.2 (C-4), 132.8 (H-C=C), 131.9 (C-2ʹ), 
131.3 (C-4″), 129.2 (C-3″/C-5″), 128.5 (C-2″/C-6″), 128.2 (C-3ʹ), 127.1 (C-1″),    
117.4 (C-4ʹ). MS (ESI) m/z: 255.04 [M+•]. 
 
Crystal structure determination 
A crystal of the model compound 16 suitable for an X-ray diffraction study, with 
needle habit and having approximate dimensions of 0.60 mm × 0.13mm × 0.11 mm, 
is glued on a glass fibre and mounted on a Bruker Apex II diffractometer. The 
diffraction data was collected at room temperature 293(2) K using graphite 
monochromated Mo Kα (λ = 0.71073 Å). Data reduction is performed with APEX 
II.
41
 Lorentz and polarization corrections are applied. Absorption correction is applied 
using SADABS.
42
 The crystallographic structure is solved using direct methods 
(SHELXS-97).
43
 The structure refinement is carried out with SHELXL-97 software.
43
 
The refinement is made by full-matrix least-squares on F
2
, with anisotropic 
displacement parameters for all non-hydrogen atoms. All the hydrogen atoms are 
located in a difference Fourier synthesis, placed at calculated positions and then, 
included in the structure factor calculation in a riding model using SHELXL-97 
defaults. MERCURY 3.3
44
 is used for figure plotting. PLATON
45
 is used for 
hydrogen bond interactions. 
DFT calculations 
The geometry optimization is performed using the PC GAMESS/Fireflyy QC 
package,
46
 which is partially based on the GAMESS (US) source code,
47
 starting from 
the experimental X-ray geometry (Z-isomer). The calculation is performed within 
Density Functional Theory (DFT) using B3LYP (Becke three-parameter Lee-Yang-
Parr) for exchange and correlation, which combines the hybrid exchange functional of 
Becke
48,49
 with the correlation functional of Lee, Yang and Parr.
50
 The calculation is 
performed with an extended 6-311G(d,p) basis set. Tight conditions for convergence 
of both the self-consistent field cycles and the maximum density and energy gradient 
variations are imposed (10
-5
 atomic units). At the end of this geometry optimization, 
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we conduct a Hessian calculation to guarantee that the final structure corresponds to a 
true minimum, using the same level of theory as in the geometry optimization. 
The geometry of the E-isomer is also optimized with the same level of theory. 
The starting geometry of the E-isomer uses for the optimization is obtained from the 
optimized geometry of the Z-isomer, performing the necessary rotation of torsion 
angle using the UCSF Chimera software package version 1.8.
51
 For the optimized 
geometries of the Z and E-isomers we perform single-point energy calculations with 
the conditions mentioned above (DFT: B3LYP functional and 6-311G(d,p) basis set). 
 
CONCLUSION 
This chapter reports convenient and eco-friendly approach for the synthesis of 4-
arylidene-2-phenyl-5(4H)-oxazolones in excellent yields in the presence of ionic 
liquid [Et3NH][HSO4]. This solvent-free, green synthetic procedure eliminates the use 
of toxic acetic anhydride and promotes selectivity towards Z-azlactones/ oxazolone. 
The noteworthy feature of this synthetic strategy is that, the ionic liquid possesses 
both catalytic as well as medium engineering potential in this protocol. The ionic 
liquid [Et3NH][HSO4] employed in the present study exhibits stability towards 
moisture and air and is easy to prepare from cheap acid and amine. The scheme not 
only offers substantial yield of products and shorter reaction time but also affords 
mild reaction conditions, high purity, cleaner reaction profile, operational simplicity, 
enhanced reaction rates and easy workup procedure. The present protocol possesses 
wide substrate tolerance. I believe that this synthetic approach provides a better scope 
for the synthesis of Z-azlactones/ oxazolone and will be a more practical alternative to 
the other existing methods. 
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